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ABSTRACT 
 
 
 
Tetraspanins are a superfamily of glycoproteins that function as ‘organisers’ of 
membranes by clustering with each other to form tetraspanin-enriched microdomains, 
into which certain other receptors and signalling proteins are recruited and regulated. 
Tetraspanin microdomains have been implicated in a range of biological processes 
including cell signalling, adhesion, intracellular trafficking, cell-cell fusion and viral 
entry. The tetraspanin CD37 was recently shown to negatively regulate the C-type 
lectin-like receptor dectin-1, which is essential for innate immune responses to fungal 
pathogens. The aim of this thesis was to firstly develop a cell line model system to 
investigate the mechanism by which tetraspanins inhibit dectin-1, and to secondly 
extend this work to the dectin-1-related CLEC-2, which is essential for platelet 
thrombus formation and stability. Using a nuclear factor of activated T-cells (NFAT) 
transcriptional reporter assay in the Jurkat T-cell line, transient over-expression of 
CD37 was found to powerfully inhibit dectin-1 signalling following stimulation with 
its ligand, β-glucan. Over-expression of other tetraspanins also inhibited dectin-1 
signalling, but did not globally inhibit receptor signalling because the platelet collagen 
receptor, GPVI, was unaffected. Similar to dectin-1, CLEC-2 signalling in response to 
its ligand, the snake venom toxin rhodocytin, was also abrogated following 
tetraspanin over-expression. However, stable tetraspanin over-expression only 
partially reduced signalling. Moreover, knockdown of the major Jurkat cell 
tetraspanin, CD81, and deletion of the major platelet tetraspanin, CD9, did not affect 
dectin-1 and CLEC-2 signalling, respectively. In summary, the importance of 
transient tetraspanin over-expression for dectin-1 and CLEC-2 inhibition, and the fact 
that any tetraspanin can inhibit, suggests that tetraspanin microdomains are disrupted 
by the presence of one over-expressed tetraspanin. This leads to a failure of dectin-1 
and CLEC-2 signalling by a mechanism that is not clear, but suggests that tetraspanin 
microdomains are important for signalling by these C-type lectin-like receptors. 
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RNAi - RNA interference 
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CHAPTER 1 – 
 
GENERAL INTRODUCTION 
 
            
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1
 1.1 The tetraspanin family of proteins 
 
1.1.1 Overview 
 
Tetraspanins are widely expressed membrane glycoproteins of 20-50 kilo Daltons 
involved in a number of biological processes, for example, cell signalling, adhesion, 
migration, proliferation, tumour metastasis and cell-cell fusion (Charrin et al., 2009; 
Hemler, 2005; Levy and Shoham, 2005). Their expression in a diverse range of 
organisms including mammals (33 family members), Caenorhabditis elegans (20 
members), Drosophila melanogaster (36 members), schistosomes (>25 members) and 
some fungi (Garcia-Espana et al., 2008), suggests a fundamental biological role. A 
phylogenetic tree of human tetraspanins illustrates their large number and the 
existence of sub-groups that share relatively high sequence similarity, such as the 
CD9/CD81/Tspan2 sub-group that are approximately 50% identical to each other at 
the protein level (Figure 1.1). Tetraspanins have proposed roles in interacting with 
specific partner proteins and regulating their plasma membrane organization, 
biosynthetic maturation and trafficking (Berditchevski and Odintsova, 2007) (Figure 
1.2). For example, the tetraspanin CD37 negatively regulates dectin-1 signalling 
(Meyer-Wentrup et al., 2007). Attention is now being directed towards their 
interaction with proteins such as the C-type lectins, integrins, G-protein coupled 
receptors (GPCRs) and the immunoglobulin superfamily (IgSF). This is of particular 
relevance as tetraspanins are thought to interact laterally with receptors and other 
tetraspanins forming distinct tetraspanin-enriched microdomains to organise the cell 
membrane (Charrin et al., 2009; Hemler, 2005; Le Naour et al., 2006b). 
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Figure 1.1 A phylogenetic tree of human tetraspanins 
 
Human tetraspanin amino-acid sequences were aligned and a phyologram was 
prepared using the Clustalw alignment programme (www.ebi.ac.uk/custalw) to 
determine similarity between superfamily members.  
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Figure 1.2 A hypothetical model for tetraspanin function 
 
Diagrammatic representation of the proposed roles for the tetraspanin superfamily of 
proteins. It is thought that tetraspanins interact with specific partner proteins 
modulating their biosynthetic maturation and trafficking, as well as their organisation 
at the plasma membrane which may facilitate the regulation of signalling and 
clustering. 
 4
 1.1.2 Structural features of a tetraspanin 
 
1.1.2.1 Overview 
 
Tetraspanins are characterised by the presence of four transmembrane domains, a 
small extracellular loop (EC1), a large extracellular loop (EC2) and intracellular 
amino- (NH2) and carboxy-termini (COOH) (Figure 1.3A). In addition, these 
transmembrane proteins have a CCG motif and at least two other cysteine residues 
that contribute to disulphide bond formation in the large extracellular loop that 
characterise this particular superfamily of proteins (Kitadokoro et al., 2001b; 
Seigneuret et al., 2001). The crystal structures of the tetraspanin uroplakins (UP) Ia 
and Ib, along with their respective non-tetraspanin partner proteins, have been solved 
and a schematic is shown in Figure 1.3B (Min et al., 2006). They are small and 
compact, projecting only 4-5 nm from the plasma membrane (Kitadokoro et al., 
2001b; Min et al., 2006). The crystal structure has also revealed that tetraspanins are 
rod-shaped and that the large extracellular loop is folded over the small extracellular 
loop (Min et al., 2006).  
 
1.1.2.2 Transmembrane regions 
 
The first, third and fourth transmembrane domains often contain a polar amino-acid 
residue. These include a conserved asparagine residue in the first transmembrane, and 
conserved glutamic acid or glutamine in the third and fourth. The function of these 
residues is not known (Hemler, 2005). In addition, tetraspanins have membrane-
proximal cysteine residues that undergo palmitoylation which is necessary for 
tetraspanin-tetraspanin interactions. Palmitoylation is the post-translational S-
acylation of proteins with palmitate and is thought to be important for protein 
stability, localization, trafficking and protein-protein interactions (Berditchevski et al., 
2002). Indeed, palmitoylation is necessary for tetraspanin-tetraspanin secondary 
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 interactions, as mutation of intracellular juxtamembrane cysteine residues proximal to 
all four transmembrane domains of CD9, CD81 and CD151 decreases lateral 
associations with other tetraspanins (Berditchevski et al., 2002; Charrin et al., 2002; 
Delandre et al., 2009; Yang et al., 2002). Conversely, the strong and direct primary 
interaction between CD151 and integrin α3β1 is not affected by mutation of 
palmitoylation sites (Berditchevski et al., 2002; Yang et al., 2002). Metabolic 
labelling with 3H-palmitate has been shown to be a useful tool in studying tetraspanin-
enriched microdomains (Yang et al., 2004; Yang et al., 2008). Indeed, it has been 
identified that the palmitate transferase, DHHC2, is the likely candidate to be 
involved in palmitoylation of tetraspanins, as it promotes the palmitoylation, stability 
and function of both CD9 and CD151, and localizes to tetraspanin microdomains 
(Sharma et al., 2008). Inactive mutants of DHHC2 failed to promote tetraspanin 
palmitoylation, and RNA interference (RNAi) knockdown of DHHC2, but not six 
other DHHC family members, substantially impaired tetraspanin stability, as detected 
by western blotting (Sharma et al., 2008). In summary, palmitoylation appears 
fundamental to the formation of tetraspanin-tetraspanin interactions and the integrity 
of tetraspanin-enriched microdomains.  
 
1.1.2.3 The small extracellular loop 
 
Relatively little is known about the small extracellular loop, but it has been proposed 
that it is required for stabilisation of the large extracellular loop (Hemler, 2005). This 
may be particularly relevant in light of the group that crystallized the bladder-specific 
tetraspanins, the uroplakins, where the large extracellular loop appears to cover the 
small loop as shown in Figure 1.3B (Min et al., 2006).  
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 1.1.2.4 The large extracellular loop 
 
The large extracellular loop has been shown to be necessary for protein-protein 
interactions, with a relatively high degree of variability between individual family 
members, and so may be important for specific tetraspanin functions within a 
particular cell type (Stipp et al., 2003). It is subdivided into a constant region that 
contains three α-helices denoted A, B and E and a variable region (Figure 1.4), where 
most of the tetraspanin-partner protein interactions occur (Charrin et al., 2009; 
Hemler, 2005). In addition, this region has a number of conserved residues including 
a CCG motif and at least a further two cysteine residues involved in disulphide bond 
formation. The model of the large extracellular loop has been determined by 
crystallographic studies of CD81 and the bladder-specific tetraspanins, the uroplakins 
(Kitadokoro et al., 2001a; Min et al., 2006). In addition, the majority of tetraspanins 
have between one and three potential N-linked glycosylation sites in this region, but 
their role in tetraspanin function has not been investigated. There are some 
exceptions, for example, CD9 has a single glycosylation site in the small extracellular 
loop and CD81 is not glycosylated. However, the glycosylation status is dependent on 
both the cell type and tissue in which the tetraspanin is expressed. The role of the 
large extracellular loop in tetraspanin function and interaction with partner proteins is 
discussed in more detail below.    
 
1.1.2.5 The carboxy- & amino- termini 
Tetraspanins have both intracellular amino- and carboxy-termini. They are relatively 
short in length, apart from a few exceptions, for example, Tspan32 and retina-specific 
tetraspanins, peripherin and Rom-1. For most tetraspanins, the role of these regions is 
not well understood. However, the role of the carboxy-terminus of CD63 has been 
characterised. It has a tyrosine-based lysosomal targeting motif (G-Y-E-V-M) that 
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 plays a role in trafficking of this tetraspanin by interacting with adaptor-protein-2 
(AP-2) and AP-3 proteins, which promote clathrin-mediated endocytosis 
(Berditchevski and Odintsova, 2007). Mutation of the tyrosine residue to alanine 
abolishes trafficking of CD63 to lysosomes in rat fibroblasts (Rous et al., 2002). 
However, this has been shown to be cell type-dependent, as CD63 trafficking to 
lysosomes in mouse fibroblasts is independent of the motif (Ryu et al., 2000). In 
addition, it is noteworthy that other tetraspanins have a similar tyrosine-based motif 
including CD37, CD82 and CD151 (Berditchevski and Odintsova, 2007). 
 
The tetraspanin CD63 has also been shown to interact directly with the PDZ 
(Postsynaptic density 95, PSD-85; Discs large, Dlg; Zonula occludens-1, ZO-1) 
domain-containing protein syntenin-1 (Latysheva et al., 2006). In common with most 
PDZ domain interactions, which involve binding of the globular PDZ domain to a 
four amino acid region at the carboxy terminus of a partner protein, this has been 
shown to be dependent on the carboxy-terminus of CD63. Syntenin-1 appears to 
negatively regulate CD63 internalisation, thus opposing the AP-2/AP-3 clathrin-
dependent endocytosis (Latysheva et al., 2006). Some other tetraspanins have 
predicted PDZ-binding motifs in their COOH-termini (Berditchevski and Odintsova, 
2007). Since many PDZ domain-containing proteins have more than one PDZ domain 
and function as scaffolds, it is possible that specific tetraspanin-tetraspanin 
interactions might be promoted by such scaffolds. 
 
There are other cytoplasmic proteins that are tetraspanin-associated and are likely to 
bind to the cytoplasmic regions of the tetraspanin. These include small G-proteins, 
phosphatidylinositol 4-kinase (PI4K) and protein kinase C (PKC) α, the latter of 
which is closely associated with the tetraspanins CD9 and CD81 (Berditchevski, 
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 2001; Le Naour et al., 2006b; Zhang et al., 2001). However, the functional 
consequences of these interactions have not been elucidated.  
 
The role of the amino-terminus is less well-defined in tetraspanin biology, and for this 
reason this is the most commonly-used site for epiptope tagging of tetraspanins. It has 
been suggested that ubiquitination, a post-translational modification whereby the 
attachment of ubiquitin to lysine residues labels proteins for internalisation and/or 
proteosomal degradation (Hershko et al., 2000), occurs on the amino-terminus of 
some tetraspanins (Lineberry et al., 2008). Indeed, the GRAIL E3 ligase has been 
shown to be involved in conjugating ubiquitin to the tetraspanins CD151 and CD81 
via lysine residues in the amino-terminus, promoting proteosomal degradation and 
tetraspanin down-regulation (Lineberry et al., 2008).    
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Figure 1.3 Diagrammatic representation of a tetraspanin and a 
tetraspanin/partner protein interaction 
 
(A) Tetraspanins have four transmembrane domains, a small extracellular loop (EC1) 
and a large extracellular loop (EC2), along with intracellular amino- and carboxy-
termini. In addition, the majority of tetraspanins have N-linked glycosylation sites. (B) 
Schematic representation of the structure of one of the tetraspanin uroplakins in 
complex with its non-tetraspanin partner protein uroplakin. Adapted from Min et al. 
2006.   
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Figure 1.4 Diagrammatic representation of the large extracellular loop of a 
tetraspanin 
 
The large extracellular loop (EC2) of a tetraspanin is composed of a constant region 
that contains three α-helices denoted A, B and E. There is a CCG motif after the B 
helix and two other conserved cysteines (brown circles) that form two intramolecular 
disulphide bonds (green lines). A significant number of tetraspanins contain a further 
two cysteine residues that form another disulphide bond (dotted black line). In 
relatively few tetraspanins, there may be seven or eight cysteine residues, the former 
of which allows the formation of an intermolecular disulphide bond. Adapted from 
Hemler, 2005. 
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 1.1.3 Tetraspanin-enriched microdomains 
 
1.1.3.1 Overview 
 
The general consensus is that tetraspanins are thought to function by self-association 
to form tetraspanin-enriched microdomains that may act as molecular organisers of 
the cell surface by modifying the signalling and adhesion of other receptors. This 
concept was first introduced by Maecker et al. (1997) who termed tetraspanins as 
“molecular facilitators” of the cell surface. Since then, it has been shown that 
tetraspanins have specific binding partners (Table 1.1) allowing the formation of 
tetraspanin networks across the cell membrane that control the presentation and 
spatial organisation of membrane complexes (Charrin et al., 2009; Hemler, 2003; 
Hemler, 2005; Le Naour et al., 2006a). Recent evidence has highlighted the 
possibility of discrete tetraspanin microdomains, for example, fluorescence and 
immunoelectron microscopy revealed the presence of several hundred distinct 
tetraspanin-enriched microdomains upon the surface of HeLa cells, each with an 
individual size of 0.2 μm2 (Nydegger et al., 2006). Moreover, individual tetraspanins 
are often expressed at 30,000-100,000 per cell (Hemler, 2003) and each cell type 
generally expresses multiple tetraspanins, for example, megakaryocytes express 19 
different tetraspanins (Protty et al., 2009).  
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 Table 1.1 Tetraspanins and examples of their specific binding partners 
 
Tetraspanin Partner protein Function Reference 
CD9 CD9 Structural unit (Kovalenko et al., 
2004) 
 
 CD9P-1 (EWI-F) Not known (Charrin et al., 
2001; Stipp et al., 
2001) 
 
 EWI-2 Integrin-dependent modulation of cell 
motility and spreading  
 
(Stipp et al., 2001) 
 Claudin-1 CD9 stabilises expression of claudin-1 (Kovalenko et al., 
2007) 
 
CD63 
 
Syntenin-1 
 
Regulation of endocytosis 
 
 
 
(Latysheva et al., 
2006) 
 
CD81 
 
CD81 
 
Structural unit 
 
(Kitadokoro et al., 
2001a) 
  
EWI-2 
 
CD81 involved in maturation and 
surface expression of EWI-2 
 
(Stipp et al., 2001) 
  
CD19 
 
CD81 involved in maturation and 
surface expression of CD19 
 
(Cherukuri et al., 
2004b) 
  
α4β1 integrin 
 
Supports integrin adhesion strengthening 
 
 
(Feigelson et al., 
2003; Serru et al., 
1999) 
 
 
CD151 
 
CD151 
 
Structural unit 
 
(Kovalenko et al., 
2004) 
 
 α3β1 integrin CD151 affects integrin-dependent 
adhesion and motility 
(Serru et al., 1999; 
Yauch and Hemler, 
2000) 
 
 α6β1 integrin CD151 affects integrin adhesion 
strengthening 
(Lammerding et 
al., 2003) 
 
 α6β4 integrin CD151 affects integrin-dependent 
adhesion and motility  
 
(Sterk et al., 2002; 
Winterwood et al., 
2006) 
 
 α7β1 integrin Not known 
 
(Sterk et al., 2002) 
 
UPIa and 
UPIb 
 
UPII and UPIII 
 
Uroepithelial plaque formation 
 
(Min et al., 2006) 
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 1.1.3.2 Molecular interactions of tetraspanins 
There are three levels of tetraspanin interaction: primary, secondary and tertiary 
(Figure 1.5). Tetraspanin interactions with their partner proteins have been 
characterised according to their maintenance in detergents and/or covalent cross-
linking (Charrin et al., 2009; Hemler, 2005).  
 
Primary associations are direct, maintained in stringent detergents (Triton X-100), 
occur at a relatively high stoichiometry and are captured by covalent cross-linking 
(Charrin et al., 2009; Hemler, 2005; Le Naour et al., 2006a). The association between 
the tetraspanin CD151 and integrin α3β1 is an example of a primary interaction that 
occurs at a high stoichiometry of almost 100% (Figure 1.5) (Serru et al., 1999; Yauch 
and Hemler, 2000). Indeed, the association between CD151 and integrin α3β1 occurs 
early in biosynthesis whilst the integrin is still in the endoplasmic reticulum (ER) 
(Kazarov et al., 2002). There are numerous other examples of primary interactions 
including the tetraspanin uroplakins and the relevant non-tetraspanin uroplakin 
partner (Wu et al., 1995) (Table 1.1). 
 
Secondary associations are indirect and typically involve tetraspanin association with 
other tetraspanins that link primary complexes together. Such interactions are 
generally only maintained in less stringent detergents (Brij97) and occur late in 
biosynthesis (Yang et al., 2002). Tetraspanin interactions are promoted or stabilised 
by protein palmitoylation as described in section 1.1.2.2. For example, mutation of 
cysteine residues in CD9, CD81 and CD151 decreases lateral associations with other 
tetraspanins (Berditchevski et al., 2002; Charrin et al., 2002; Delandre et al., 2009; 
Yang et al., 2002). Such data highlights the importance of palmitoylation in 
organising tetraspanins into microdomains.  
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 A third level exists which is a looser network of tetraspanins and their associated 
proteins, whereby larger complexes are formed that are only stable in relatively weak 
detergents such as CHAPS and Brij58 (Charrin et al., 2009; Hemler, 2005). However, 
tetraspanins may not be completely solubilised in such detergents and so the relevance 
of third level interactions is not clear. The biochemical studies discussed above 
regarding the nature of tetraspanin microdomains have been developed further using 
single-molecule particle tracking of CD9 (Espenel et al., 2008). This has revealed that 
tetraspanin-tetraspanin interactions are transient, highly dynamic, with microdomains 
in distinct clusters (Espenel et al., 2008).       
  
1.1.3.3 Comparison of tetraspanin-enriched microdomains and lipid rafts 
 
The view of biological membranes has changed considerably since the proposal of the 
fluid mosaic model (Singer and Nicolson, 1972). It is now generally believed that the 
biological membrane is composed of different compartments, or microdomains, 
containing various lipid and protein compositions (Brown, 2006; Brown and London, 
1998). Indeed, the use of proteomics has facilitated the understanding of the protein 
composition of the biological membrane (Foster et al., 2009). Tetraspanin-enriched 
microdomains are distinct from lipid rafts, a second, better known type of 
microdomain. Lipid rafts are membrane domains that are comprised of cholesterol, 
sphingolipids and saturated phospholipids (Brown, 2006; Brown and London, 1998).  
Tetraspanin-enriched microdomains and lipid rafts do have a number of similarities, 
for example, tetraspanins can associate with cholesterol and are found in low-density 
fractions of sucrose gradients (Charrin et al., 2003; Le Naour et al., 2006a). However, 
only the tetraspanin CD81 has been shown to reside in lipid rafts, to which it 
translocates following co-ligation of the B-cell receptor and CD19/CD21/CD81 co-
receptor complex, and will be discussed in section 1.1.4.3 (Cherukuri et al., 2004a; 
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 Cherukuri et al., 2004b). There are a number of differences between tetraspanin-
enriched microdomains and lipid rafts which suggests they should be considered as 
separate types of microdomain, for example, lipid rafts contain Src family kinases, 
glycosylphosphatidylinositol (GPI)-linked proteins and caveolin which have not been 
observed in tetraspanin-enriched microdomains (Brown and London, 1998). A more 
detailed overview of the similarities and differences between tetraspanin-enriched 
microdomains and lipid rafts is provided in Table 1.2.   
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Figure 1.5 Primary, secondary and tertiary interactions of tetraspanins with 
partner proteins 
 
There are three levels of tetraspanin interactions with partner proteins: primary, 
secondary and tertiary. Primary interactions include CD151 and integrin α3β1, and 
secondary associations include CD9 and integrin α3β1, and CD63 and integrin α3β1 
(Hemler, 2005; Serru et al., 1999; Yauch and Hemler, 2000). Tertiary interactions are 
a looser network of tetraspanins and their associated proteins, whereby larger 
complexes are formed (Hemler, 2005). 
Tertiary - larger complexes 
Secondary  CD9/CD63 - α3β1 
 CD9  CD63 CD151 
  α3β1 Primary  CD151 - α3β1 
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 Table 1.2 Comparison between tetraspanin-enriched microdomains and lipid 
rafts 
 
 Lipid rafts Tetraspanin-enriched 
microdomains 
 
Reference 
Components Src family kinases, 
caveolae and GPI-linked 
proteins present 
Tetraspanins and 
associated proteins 
(Brown, 2006; Brown 
and London, 1998; 
Hemler, 2003; Hemler, 
2005) 
 
Cholesterol 
 
Disrupted following 
cholesterol depletion 
 
Generally resistant to 
cholesterol depletion 
 
(Charrin et al., 2003; 
Claas et al., 2001) 
 
Extraction 
temperature 
 
 
Disrupted at 37 °C 
 
Maintained at 37 °C 
 
(Hemler, 2005) 
 
Detergent solubility  Generally insoluble in 
non-ionic detergents 
Generally soluble in non-
ionic detergents 
(Claas et al., 2001) 
 
 
Palmitoylation Protein palmitoylation 
of raft proteins promotes 
insolubility 
Protein palmitoylation of 
tetraspanin-enriched 
microdomain proteins 
does not promote 
insolubility 
 
(Berditchevski et al., 
2002; Yang et al., 2002) 
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 1.1.4 Tetraspanin function 
 
1.1.4.1 Overview 
 
The function of the majority of tetraspanins remains to be elucidated. However, there 
are a few notable exceptions which have provided valuable insights into the role of 
tetraspanins in a number of cell types and species (Table 1.3). Some of the best 
characterised tetraspanins in relation to their function are CD151 and the regulation of 
integrins (Kagan et al., 1988; Karamatic Crew et al., 2004; Winterwood et al., 2006; 
Wright et al., 2004; Yang et al., 2008), altered signalling of the B-cell receptor in 
CD81-deficient mice (Cherukuri et al., 2004a; Cherukuri et al., 2004b), T-cell 
hyperproliferation in CD37-, CD81-, CD151- and Tspan32-deficient mice (Knobeloch 
et al., 2000; Miyazaki et al., 1997; Tarrant et al., 2002; van Spriel et al., 2004; Wright 
et al., 2004) and unstable haemostasis in CD151- and Tspan32-deficient mice 
(Goschnick et al., 2006; Lau et al., 2004; Orlowski et al., 2009). Other examples of 
tetraspanin function, including those in lower organisms, are discussed in later 
sections.   
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 Table 1.3 Examples of tetraspanin function in different species 
Species Tetraspanin (s) Loss of function phenotype Reference 
Human Peripherin & 
ROM-1 
 
Retinal degeneration (Loewen et al., 2001) 
 CD151 Kidney & skin defects, deafness 
& ß-thalassemia 
(Kagan et al., 1988; Karamatic 
Crew et al., 2004) 
 
 CD81 Hepatocytes no longer susceptible 
to hepatitis C virus (HCV) 
infection 
 
(Cocquerel et al., 2006; Flint 
et al., 2006; Pileri et al., 1998) 
 
Mouse Peripherin & 
ROM-1 
Retinal degeneration (Clarke et al., 2000; Connell et 
al., 1991) 
 
 CD9 Impaired sperm-egg fusion (Kaji et al., 2000; Le Naour et 
al., 2000; Miyado et al., 2000) 
 
 CD37, CD81, 
CD151 & Tspan32 
T-cell hyperproliferation (Knobeloch et al., 2000; 
Miyazaki et al., 1997; Tarrant 
et al., 2002; van Spriel et al., 
2004; Wright et al., 2004) 
 
 CD81 Impaired B-cell receptor 
signalling & sperm-egg fusion 
(Cherukuri et al., 2004a; 
Cherukuri et al., 2004b; 
Miyazaki et al., 1997; 
Rubinstein et al., 2006b) 
 
 CD151 Kidney, skin & platelet defects & 
lymphocyte hyperproliferation 
(Baleato et al., 2008; Lau et 
al., 2004; Orlowski et al., 
2009; Sachs et al., 2006; 
Wright et al., 2004) 
    
Fruit-fly 
(Drosophila 
melanogaster) 
Late bloomer Delayed synaptic contact 
formation in embryos 
(Kopczynski et al., 1996) 
 
 Sunglasses Retinal degeneration due to an 
inability to downregulate 
rhodopsin 
 
(Han et al., 2007; Xu et al., 
2004) 
Worm 
(Caenorhabditis 
elegans) 
TSP-15 Impaired epidermal integrity (Moribe et al., 2004) 
    
Fungi  
 
Magnaporthe grisea 
 
Botrytis cincerea 
 
Podospora anserina 
 
 
MgPls1 
 
BcPls1 
 
PaPls1 
 
 
Impaired host leaf penetration 
 
Impaired host leaf penetration 
 
Impaired host leaf penetration 
 
 
(Clergeot et al., 2001) 
 
(Gourgues et al., 2004) 
 
(Lambou et al., 2008b) 
    
Plants (Arabidopsis 
thaliana) 
 
TORNADO2 Impaired leaf development & 
altered cellular distribution of 
shoot apical meristem 
 
(Chiu et al., 2007; Cnops et 
al., 2006) 
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 1.1.4.2 CD151 and the regulation of integrins 
 
CD151 is one of the best studied tetraspanins and is expressed on a number of cell 
types including epithelial and endothelial cells, Schwann cells, muscle cells, 
megakaryocytes and platelets (Sincock et al., 1997). Mice deficient in CD151 are 
viable and fertile, but do have a number of phenotypes including unstable 
haemostasis, hyper-proliferative T-cells, impaired keratinocyte migration and kidney 
failure (Baleato et al., 2008; Sachs et al., 2006; Wright et al., 2004). CD151 and its 
association with the laminin-binding integrins α3β1, α6β1, α7β1 and α6β4 are 
particularly well characterised (Table 1.1) (Charrin et al., 2009; Hemler, 2005). For 
example, the CD151 and integrin α3β1 association is a strong, direct, primary 
interaction of high stoichiometry and it has been shown that CD151 affects integrin-
dependent adhesion and motility (Serru et al., 1999; Yauch and Hemler, 2000). 
Further studies using CD151 RNAi on carcinoma cells show impaired motility on 
laminin, along with impaired internalisation of integrin α3β1 (Winterwood et al., 2006; 
Yang et al., 2008). Moreover, deletion of CD151 in mice has been shown to decrease 
pathologic angiogenesis both in vivo and in vitro by impaired integrin signalling and a 
failure to associate with tetraspanin-enriched microdomains (Takeda et al., 2007b). 
The interaction between CD151 and integrins α3β1 and α6β1 is dependent on a QRD 
(194-196) motif present in the large extracellular loop of CD151 (Kazarov et al., 2002). 
In addition, mutation of the tyrosine-based sorting motif (Y-R-S-L) in the cytoplasmic 
tail of CD151 reduces its internalisation and also impairs the internalisation of 
associated integrins on laminin (Liu et al., 2007). This reinforces the role of CD151 in 
promoting cell migration by regulating integrin trafficking (Berditchevski and 
Odintsova, 2007; Charrin et al., 2009).  
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 The role of CD151 in human disease is highlighted as a mutation of this tetraspanin 
has been described (Karamatic Crew et al., 2004). This is not a common affliction, as 
only three patients with this mutation have been identified at present. Such a mutation 
would result in a truncated CD151 lacking most of the large extracellular loop 
including its integrin binding domain (QRD (194-196) motif), if the protein is even 
expressed, and the patients have a skin blistering disease, known as pretibial 
epidermolysis bullosa, and end-stage hereditary nephritis (Karamatic Crew et al., 
2004). This is consistent with CD151-α3β1 and CD151-α6β1 complexes having roles in 
the normal organization of the epidermal basement membrane (Karamatic Crew et al., 
2004; Lammerding et al., 2003; Nishiuchi et al., 2005). In addition, two of the patients 
who are siblings have sensorineural deafness and β-thalassaemia minor (Kagan et al., 
1988). Interestingly, glomerular disease of the kidney is observed in mouse models 
due to severe alterations of the glomerular basement membrane; however, this has 
been shown to be dependent upon the mouse genetic background (Baleato et al., 
2008). Similar kidney disruption and/or skin blistering diseases are observed upon 
deletion of the mouse integrin α3 subunit, highlighting the close association between 
integrins and CD151 (Kreidberg, 2000).   
 
1.1.4.3 CD81 is required for B-cell receptor signalling 
 
The role of CD81 in B-cell receptor signalling is one of the best studied examples of a 
tetraspanin having a specific function (Levy and Shoham, 2005; Levy et al., 1998). 
An overview of the B-cell receptor, its signalling pathway, and the role of CD81 is 
provided in Figure 1.6. CD81 functions to enhance B-cell receptor signalling by 
reducing the threshold for B-cell activation. Moreover, this is the only tetraspanin 
identified at present to enter lipid rafts to perform this role (Levy and Shoham, 2005; 
Levy et al., 1998). CD81 is expressed at the surface of B-cells and is directly 
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 associated with CD19, a signalling molecule containing tyrosine-based signalling 
motifs. CD81 is essential for normal glycosylation of CD19 and its trafficking to the 
plasma membrane (Cherukuri et al., 2004b). CD19 associates with CD21, the 
complement 3d (C3d) receptor. Co-ligation of the CD81/CD19/CD21 complex with 
the B-cell receptor is induced by simultaneous binding of complement-tagged 
antigens to CD21 and the B-cell receptor. This signalling complex translocates to 
lipid rafts where CD81 becomes inducibly palmitoylated, which is essential for 
sustained localization of the B-cell receptor-CD19/CD21/CD81 complex to lipid rafts  
and for sustained signalling, probably due to the concentration of certain signalling 
molecules in lipid rafts (Figure 1.6A) (Cherukuri et al., 2004a). This has been 
illustrated by utilising mice deficient in CD81, where co-ligation of the B-cell 
receptor and the CD19/CD21 complex fails to partition normally into lipid rafts 
(Figure 1.6B) (Cherukuri et al., 2004a; Cherukuri et al., 2004b). In addition, it was 
shown that the distribution and trafficking of CD19 from the ER to the Golgi body 
was slower than in CD81-positive cells (Shoham et al., 2003). In summary, CD81 is 
required for normal glycosylation of CD19 and trafficking to the plasma membrane, 
and is inducibly palmitoylated, which is required for the B-cell receptor-
CD19/CD21/CD81 complex to localize to lipid rafts and to signal in a sustained 
manner (Cherukuri et al., 2004a; Cherukuri et al., 2004b). 
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 A. B-cell receptor signalling in the presence of CD81
CD21 
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B. 
B-cell receptor signalling in the absence of CD81 
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IgM 
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CD19/CD21 complex into lipid rafts 
IgM 
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 Igα Igβ 
Complement-
coated antigen 
Weak, transient 
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Figure 1.6 B-cell receptor signalling is impaired in the absence of CD81 
CD81 deletion results in failure of the CD19-CD21 co-receptor complex to partition 
into lipid rafts leading to reduced B-cell signalling (Cherukuri et al., 2004a; Cherukuri 
et al., 2004b). Adapted from Levy & Shoham, 2005.     
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 1.1.4.4 Hyperproliferative T-cells in tetraspanin-deficient mice 
 
Tetraspanins have proposed roles in T-cell function which have been illustrated using 
mice deficient in CD37, CD81, CD151 and Tspan32 (Knobeloch et al., 2000; 
Miyazaki et al., 1997; Tarrant et al., 2002; van Spriel et al., 2004; Wright et al., 2004). 
They all show a remarkably similar phenotype of T-cell hyperproliferation to in vitro 
stimulation using anti-CD3 antibodies. CD3 are signalling units of the T-cell receptor 
which contain immunoreceptor tyrosine-based activation motifs (ITAMs) that 
undergo phosphorylation leading to recruitment and activation of Zap-70/Syk tyrosine 
kinases (Abraham and Weiss, 2004). A more detailed overview of T-cell receptor 
signalling is provided in section 1.3. Such data regarding the T-cell receptor and 
tetraspanins suggests that tetraspanin microdomains negatively regulate T-cell 
receptor signalling, and deletion of any tetraspanin might disrupt the microdomains 
and thus the ability to negatively regulate. It has been hypothesised that tetraspanins 
may recruit a negatively regulatory phosphatase or sequester key molecules into 
tetraspanin-enriched microdomains therefore accounting for the effects observed 
(Hemler, 2008).    
 
1.1.4.5 The platelets of tetraspanin-deficient mice 
The published literature has identified five tetraspanins expressed in platelets: CD9, 
CD63, CD151, Tspan32 and Tspan9 (Goschnick and Jackson, 2007; Protty et al., 
2009; Tomlinson, 2009). Of these, CD151- and Tspan32-deficient mice have a 
bleeding phenotype that the authors propose to be due to defective “outside-in” 
signalling of the major platelet integrin αIIbβ3 (Goschnick et al., 2006; Lau et al., 
2004). Platelets deficient in either of these two tetraspanins have a remarkably similar 
phenotype of defective spreading on fibrinogen, delayed clot retraction and a 
tendency to re-bleed in tail-bleeding assays. In addition, an in vivo thrombus 
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 formation defect is observed in the Tspan32 knockout (Goschnick et al., 2006). 
Further to this, CD151, unlike Tspan32, is expressed on endothelial cells, and the 
Jackson group have recently confirmed that platelet CD151 is more important for 
thrombus formation than endothelial CD151 using a platelet reconstitution model 
(Orlowski et al., 2009). Moreover, the association between CD151 and Tspan32 and 
αIIbβ3 is supported by co-immunoprecipitation data in mouse platelets using the 
stringent detergent Triton X-100 (Goschnick et al., 2006; Lau et al., 2004). However, 
this is not supported by recent evidence in human platelets by Protty et al. (2009). 
Nevertheless, the functional data indicate a role for tetraspanin microdomains in 
platelet activation.   
 
A mild platelet phenotype has recently been reported in CD9-deficient mouse 
platelets (Mangin et al., 2009), despite the fact that CD9 is expressed at approximately 
49,000 copies per human platelet (Higashihara et al., 1990; Protty et al., 2009), 
second only to the major platelet integrin αIIbβ3 at 80,000 copies per platelet (Wagner 
et al., 1996). Tail bleeding assays in mice revealed a shorter bleeding time and 
reduced blood loss in the CD9 knockout compared to wild-type controls (Mangin et 
al., 2009). This data suggests that CD9 does not play a major role in primary 
haemostasis. Indeed, this data is in contrast to that of CD151- and Tspan32-deficient 
mouse platelets, where there is an increase in bleeding and a tendancy to re-bleed 
(Goschnick et al., 2006; Lau et al., 2004). Further experiments by Mangin et al. show 
no difference in aggregation responses in CD9-deficient platelets. However, there was 
increased αIIbβ3 activation as revealed by a significant increase in the binding of its 
ligand fibrinogen (Mangin et al., 2009). It would appear that CD9 may act as a 
repressor of αIIbβ3 “inside-out” signalling, which is in contrast to the role of CD151 
and Tspan32. This hypothesis is supported by in vivo thrombosis data which have 
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 larger thrombi in CD9-deficient mice, and suggests that in wild-type mice CD9 may 
act as a negative regulator of platelet recruitment, thus preventing excessive thrombus 
growth (Mangin et al., 2009).        
 
Mice deficient in the tetraspanin CD63 have been reported with only minor 
differences in platelet function. Slighty stronger aggregation responses are observed 
in the CD63 knockout compared to wild-type controls in vitro (Schroder et al., 2009). 
However, CD63 has been shown to associate with integrin αIIbβ3 and may regulate 
platelet spreading and signalling on fibrinogen (Israels and McMillan-Ward, 2005).  
 
1.1.4.6 Tetraspanins and their role in infectious disease 
1.1.4.6.1 HIV-1 
Tetraspanins appear to play a role in human immunodeficiency virus-1 (HIV-1) 
infection of human macrophages. Once inside macrophages, the virus assembles 
within a membrane domain containing the tetraspanins CD9, CD53, CD63 and CD81 
(Nydegger et al., 2006). Moreover, HIV-1 release occurs at tetraspanin microdomains 
(Nydegger et al., 2006). However, knockdown of CD63 in macrophages does not 
affect the productivity or infectivity of HIV-1 in tissue culture (Ruiz-Mateos et al., 
2008). It is possible that other tetraspanins and/or other molecules present in 
tetraspanin-enriched microdomains may be more important in HIV-1 
productivity/infectivity. Therefore, the exact mechanism by which tetraspanins are 
involved in HIV-1 infection has yet to be fully determined.            
 
1.1.4.6.2 Hepatitis C virus and CD81 
Hepatitis C virus (HCV) infectivity is supported by the tetraspanin CD81 where it is 
an essential part of the HCV receptor complex that also includes the scavenger 
receptor class B type I, claudin-1 and occludin (Ploss et al., 2009). The virus E2 
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 glycoprotein binds to the large extracellular loop of CD81 (Pileri et al., 1998). 
Mutations of CD81 that prevent the binding to E2 reduce, but do not completely 
prevent, infectivity of HCV (Flint et al., 2006). This data suggests that CD81 binds to 
to the virus glycoprotein as a co-receptor, as this binding is not essential for infection 
(Cocquerel et al., 2006). Interestingly, the association of CD81 with tetraspanin-
enriched microdomains is not necessary for HCV infection (Rocha-Perugini et al., 
2009).       
 
1.1.4.7 Tetraspanin association with receptor tyrosine kinases 
The tetraspanin CD82 has been shown to associate with receptor tyrosine kinases of 
the ErbB family, in particular epidermal growth factor receptor (EGFR), whose 
activity alters depending upon expression level of the tetraspanin, since CD82 
diminishes ligand-induced dimerization and endocytosis (Berditchevski and 
Odintsova, 2007; Hemler, 2005). Experiments showed that CD82 expression led to 
composition changes in glycosphingolipids on the plasma membrane and also affected 
EGFR compartmentalization (Odintsova et al., 2006; Odintsova et al., 2000; 
Odintsova et al., 2003). This suggests a role for CD82 in EGFR trafficking to and 
from the membrane. CD82 has a tyrosine-based sorting motif (Y-S-K-V) in the 
cytoplasmic tail. Mutation of the tyrosine to alanine prevents antibody-induced 
internalisation of CD82, suggesting that the residue is important for endocytosis of the 
tetraspanin (Berditchevski and Odintsova, 2007).   
 
1.1.4.8 Tetraspanin microdomains as endothelial adhesive platforms (EAPs) 
 
A recent idea has emerged regarding the formation of endothelial adhesive platforms 
(EAPs) by tetraspanin-enriched microdomains (Barreiro et al., 2008). Leukocytes 
bind to activated endothelial cells, the latter of which possess specialized 
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 microdomains that contain the leukocyte integrin adhesion receptors vascular cell 
adhesion molecule-1 (VCAM-1) and inter-cellular adhesion molecule-1 (ICAM-1), 
along with the tetraspanins CD9 and CD151. Using fluorescence microscopy, along 
with tetraspanin-blocking peptides, the authors show that such EAPs induce 
“nanoclustering” of adhesion receptors to enhance adhesive properties during 
leukocyte adhesion to the endothelium (Barreiro et al., 2008). The tetraspanin-
blocking peptides were soluble forms of the large extracellular loop expressed as a 
GST-fusion protein, and have previously been used to perturb functions regulated by 
tetraspanin microdomains, for example, sperm-egg fusion (Higginbottom et al., 2003).         
 
1.1.4.9 Impaired oocyte fertilisation in CD9-deficient mice 
CD9-deficient mice have been generated and three groups used such mice to show 
that CD9 has a profound effect upon mouse reproductive biology (Kaji et al., 2000; 
Le Naour et al., 2000; Miyado et al., 2000). CD9-deficient females have severely 
reduced fertility as a result of impaired sperm-egg fusion. In addition, CD9-null 
oocytes have altered length, thickness and density of microvilli which may prevent 
them from fusing with sperm (Runge et al., 2007). Further studies have suggested that 
CD9 controls the distribution of some membrane proteins, including the laminin-
binding integrin α6β1, into clusters, which may play a role in gamete fusion (Ziyyat et 
al., 2006). Subsequent data has shown that the tetraspanin CD81 is expressed on 
mouse eggs and is similarly involved in sperm-egg fusion, as mice deficient in this 
tetraspanin have reduced female fertility (Rubinstein et al., 2006a). However, it is not 
as severe as the CD9 phenotype. Interestingly, CD81 over-expression rescues the 
fertility defect in CD9-deficient eggs (Higginbottom et al., 2003). CD9 and CD81 
show 45% identity across the protein, but CD81 lacks a motif in the large 
extracellular loop that has been shown to be critical for sperm-egg fusion in CD9. 
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 Impressively, mice have been generated deficient in both of these tetraspanins and 
female mice are completely infertile (Rubinstein et al., 2006a). This is clear evidence 
that tetraspanins can functionally substitute for one another and suggests the need to 
generate mice deficient in more than one tetraspanin to overcome the subtle 
phenotypes seen in some particular cell types at present.  
 
1.1.4.10 Tetraspanin function in lower organisms 
1.1.4.10.1 Drosophila melanogaster 
The role of tetraspanins in the fruit-fly is highlighted as the tetraspanin gene, late 
bloomer (lbm), is linked to delayed synaptic contact formation in embryos 
(Kopczynski et al., 1996). Deletion of a further two tetraspanins, CG10106 and 
CG12143, delays formation even further (Fradkin et al., 2002). These studies suggest 
that more than one tetraspanin can perform a similar role in a cell type. In addition, a 
lysosomal tetraspanin, sunglasses (sun), is required for downregulation of the light-
sensing GPCR rhodopsin upon prolonged stimulation, presumably by playing a role 
in its lysosomal degradation (Han et al., 2007; Xu et al., 2004). Rhodopsin is also 
important for the formation of photoreceptor cells. Indeed, in mutant flies that lack 
sun, the eyes undergo light-induced retinal degeneration. (Han et al., 2007; Xu et al., 
2004).  
 
1.1.4.10.2 Caenorhabditis elegans 
In Caenorhabditis elegans there are 20 tetraspanins. However, only Tsp-15 has been 
linked to a specific function (Todres et al., 2000). This particular tetraspanin is 
necessary for normal epidermal integrity, as knockdown of Tsp-15 resulted in 
degeneration of the hypodermis, an epidermal layer of cells, and blistering of the 
cuticle, an extracellular structure shed during moulting (Moribe et al., 2004). 
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 Interestingly, Tsp-15 is 24% similar to CD151 according to amino-acid identity, 
consistent with the hypothesis that CD151 plays a role in epidermal integrity in 
mammals (Hemler, 2005).    
 
1.1.4.10.3 Magnaporthe grisea, Botrytis cincerea and Podospora anserina 
Three tetraspanin families have been identified in fungi: Pls1, Tspan2 and Tspan3. 
The fungi, Magnaporthe grisea, Botrytis cincerea and Podospora anserina and their 
respective tetraspanin proteins, MgPls1, BcPls1 and PaPls1 have been studied and 
highlight the role of tetraspanin proteins in fungal pathogenicity. Pls1, also known as 
punchless, is required for the pathogenicity of Magnaporthe grisea, Botrytis cincerea 
and Podospora anserine, in particular their penetration into host plant leaves 
(Clergeot et al., 2001; Gourgues et al., 2004; Lambou et al., 2008a). Other 
tetraspanins include Tspan2, whose function remains to be elucidated, and Tspan3, 
which has been shown to be involved in the infection of the plant pathogenic fungus 
Magnaporthe grisea (Lambou et al., 2008b). 
 
1.1.4.10.4 Arabidopsis thaliana 
The plant, Arabidopsis thaliana, is a model organism in which the tetraspanin 
TORNADO2 has been shown to be essential for normal function. Mutants of this 
tetraspanin result in defective leaves in both symmetry and size, a defective venation 
network and an altered distribution of the plant hormone auxin (Cnops et al., 2006). In 
addition, mutations of the tornado2 gene affect the cellular distribution of the shoot 
apical meristem in Arabidopsis thaliana highlighting the role of tetraspanins in plants 
(Chiu et al., 2007).   
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 1.2 C-type lectins 
1.2.1 Overview 
 
The C-type lectin receptors were originally classified as proteins that bind to 
carbohydrates via a distinct fold, referred to as a carbohydrate recognition domain 
(CRD) in a calcium-dependent manner (Drickamer, 1999). This superfamily, which 
includes both classical and non-classical members, consists of over 75 separate gene 
products and is sub-divided into 17 sub-groups depending on their domain 
architecture (Drickamer, 1999; Zelensky and Gready, 2005). Proteins that bind in a 
calcium-dependent manner are considered ‘classical’ C-type lectins and examples 
include DC-SIGN and langerin. Protein sequence alignment suggested that other 
members were calcium-independent and could not bind carbohydrate. In this case, the 
domain is referred to as a C-type lectin-like domain (CTLD) (Drickamer, 1999). 
These proteins are considered ‘non-classical’ C-type lectins and examples include 
dectin-1, CLEC-2 and CLEC9A.  
 
1.2.2 Group V C-type lectin-like receptors 
Dectin-1, CLEC-2 and CLEC9A (Figure 1.7) belong to group V of non-classical C-
type lectin-like receptors, as they share the same domain architecture and, generally 
speaking, are encoded within the same natural killer (NK) gene complex (Sobanov et 
al., 2001). Other members of the group include CLEC-1, LOX-1, MICL and AICL 
(Sobanov et al., 2001). All members are type II transmembrane proteins and have a 
single CTLD, stalk region, transmembrane region and a cytoplasmic tail that often 
contains a signalling or internalisation motif (Figure 1.8). Table 1.4 provides an 
overview of some of the most thoroughly characterised group V C-type lectin 
receptors.      
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Figure 1.7 Members of the group V C-type lectin-like family of receptors 
 
Diagrammatic representation of the members of the group V C-type lectin-like family 
of proteins including dectin-1, CLEC-2 and CLEC9A. 
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Figure 1.8 Sequence alignment of dectin-1, CLEC-2 and CLEC9A 
 
Human dectin-1, CLEC-2 and CLEC9A amino-acid sequences were aligned using the 
Clustalw alignment programme (www.ebi.ac.uk/clustalw). Sequence alignment 
symbols denote degree of conservation: “*” = identical residues, “:” = conserved 
substitution and “.” = semi-conserved substitution.    
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 Table 1.4 Group V C-type lectin-like proteins 
 
Name Expression Ligand Function Reference 
Dectin-1 Dendritic cells, 
macrophages, 
monocytes 
 
β-glucan Anti-fungal immunity (Brown, 2006; 
Willment and 
Brown, 2008) 
CLEC-2 Platelets, 
monocytes, 
dendritic cells, 
granulocytes 
 
Receptor for   
rhodocytin, 
podoplanin 
 
 
 
 
Platelet activation (Colonna et al., 
2000; May et 
al., 2009; 
Suzuki-Inoue 
et al., 2006; 
Suzuki-Inoue 
et al., 2007) 
 
CLEC9A Dendritic cells, 
subset of monocytes  
? Activation receptor, 
role in cross-
presentation of necrotic 
cells 
 
(Huysamen et 
al., 2008; 
Sancho et al., 
2009) 
 
CLEC-1 Dendritic cells 
 
 
? ? (Colonna et al., 
2000) 
LOX-1 Vascular endothelial 
cells 
Oxidised LDL Platelet-endothelial 
interactions 
 
(Dunn et al., 
2008) 
MICL Dendritic cells, 
moncytes, 
granulocytes 
 
? Signals via an ITIM 
sequence in the 
cytoplasmic tail 
(Marshall et 
al., 2004; Pyz 
et al., 2008) 
AICL Lymphocytes,  
monocytes, 
granulocytes 
NKp80 Cytolysis of malignant 
myeloid cells & 
stimulates release of 
cytokines from NK 
cells & monocytes 
 
(Welte et al., 
2006) 
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 1.2.3 Dectin-1 
 
1.2.3.1 Overview 
 
Antigen-presenting cells (APCs) express pattern-recognition receptors, such as the 
Toll-like receptors (TLRs) and the C-type lectins that recognise pathogen-associated 
molecular patterns (PAMPs) upon microbial structures (Brown, 2006; Willment and 
Brown, 2008). These highly conserved PAMP microbial structures are generally 
essential for micro-organism survival and so are immutable. Dectin-1 is a pattern 
recognition receptor that is expressed at high levels on APCs in portals of pathogen 
entry such as the lung and intestine, supporting the hypothesis that it has a role in 
immune responses against pathogens (Reid et al., 2004; Taylor et al., 2002). Recent 
evidence has shown the importance of dectin-1 in host defence, as mice deficient in 
this receptor are immuno-compromised in response to pathogenic fungi such as 
Candida albicans (Taylor et al., 2007) and Pneumocystis carinii (Saijo et al., 2007). A 
key difference between the papers is that Saijo et al. found no requirement of dectin-1 
for protection against Candida albicans. This could be explained by the differing 
routes of infection, fungal strains used and genetic background of the mice (Dostert 
and Tschopp, 2007).      
 
1.2.3.2 The dectin-1 ligand, β-glucan  
 
The dectin-1 ligand β-glucan, a polymer of D-glucose, is a major component of fungal 
cell walls. Indeed, it is estimated that more than 50% of the cell wall of 
Saccharmoyces cerevisiae is made up of β-glucan polymers (Klis et al., 2002). A 
number of dectin-1 ligands, such as curdlan and zymosan, contain high amounts of β-
glucan and are used to investigate the role of this receptor in immune response against 
pathogenic fungi both in vitro and in vivo. Curdlan is isolated from Alcaligenes 
faecalis and is composed of linear glucan polymers. In comparison, zymosan is 
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 isolated from Saccharmoyces cerevisiae, but is less specific than curdlan, as it 
contains mannan, chitin and other proteins and has the ability to activate receptors 
other than dectin-1 (McGreal et al., 2006).  
 
1.2.3.3 Dectin-1 structure and signalling 
 
The dectin-1 CTLD has a binding site for β-glucan, as a mutation in this region 
(W221?A & H223?A) impairs binding of the dectin-1 ligand (Adachi et al., 2004). 
The cytoplasmic tail of dectin-1 contains a signalling motif that is made up of one 
tyrosine residue in a YXXL motif. This undergoes tyrosine phosphorylation by Src 
family kinases and is required for signalling events via phospholipase C (PLC) γ2 
(Figure 1.9) (Rogers et al., 2005; Xu et al., 2009b). This was supported by Fuller et al. 
who used cell line reporter assays in DT40 B- and Jurkat T-cells to show that dectin-1 
signals via the YXXL motif through interaction with a Syk/Zap-70 family kinase 
(Fuller et al., 2007).  
 
When β-glucan binds to dectin-1 induction of various cytokines and chemokines 
ensues, including the interleukins (IL)-2, -6, -10, -12, tumour necrosis factor (TNF) 
and CXC-chemokine ligand 2 (CXCL2), in addition to respiratory burst, phagocytosis 
and possibly endocytosis (Brown, 2006; Willment and Brown, 2008). There is a 
plethora of evidence to suggest that the above are important in the control of fungal 
infection. For example, IL-6 is secreted by T-cells and macrophages in response to 
tissue damage, leading to inflammation, and mice deficient in this interleukin have 
increased susceptibility to systemic candidiasis and Streptococcus pneumoniae (van 
Enckevort et al., 1999). However, IL-12 and TNF production are not solely dependent 
on dectin-1, but can be activated via signals from TLR2 and TLR6 via the adaptor 
protein MyD88 and the transcription factor nuclear factor-κB (NF-κB). The caspase-
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 recruitment domain adaptor protein CARD9 is also involved in linking dectin-1-Syk 
activation to adaptor protein Bcl-10-MALT1-dependent activation of transcription 
factor NF-κB and cytokine production following stimulation with Candida albicans 
or zymosan in dendritic cells (Figure 1.9) (Gross et al., 2006; LeibundGut-Landmann 
et al., 2007). CARD9 plays an intermediate role in linking dectin-1 signalling to NF-
κB activation and is involved in additional secretion of IL-12 (Colonna, 2007; Gross 
et al., 2006). Moreover, the importance of CARD9 is illustrated as mice deficient in 
this protein have reduced survival following Candida albicans infection (Gross et al., 
2006). However, the mechanism by which CARD9 activates downstream signalling 
events is yet to be determined, but it is hypothesised that other adaptor 
proteins/mediators are involved (Colonna, 2007). This indicates that the interaction 
between these proteins is complex and not only dependent on dectin-1. However, it 
does illustrate the importance of this C-type lectin-like receptor in generating an 
appropriate immune response.      
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Figure 1.9 Diagrammatic representation of dectin-1 signalling 
 
Dectin-1 signals following stimulation with β-glucan. The tyrosine residue in the 
cytoplasmic tail of dectin-1 undergoes phosphorylation and subsequently signals via 
Syk. This ultimately results in NF-κB, AP-1 and NFAT activation.  
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 1.2.3.4 CD37 inhibits dectin-1-mediated IL-6 production 
 
The van Spriel group has shown that CD37 plays a role in dectin-1-mediated 
signalling, as macrophages from CD37-null mice have increased dectin-1-mediated 
IL-6 production despite decreased cell surface dectin-1 expression (Meyer-Wentrup et 
al., 2007). Moreover, the relatively low endogenous dectin-1 expression on RAW 
mouse macrophages increases by transfection of CD37 into this cell line. In addition, 
a co-immunoprecipitation between dectin-1 and CD37 was observed in transfected 
HEK293T cells using the relatively stringent detergent Triton X-100 (Meyer-Wentrup 
et al., 2007). This suggests a strong, direct tetraspanin-partner protein interaction 
(Claas et al., 2001) and was the first published report of a tetraspanin to functionally 
interact with a C-type lectin-like receptor. In addition, an interaction between the 
tetraspanin CD63 and dectin-1 on dendritic cells was reported using the relatively 
weak detergent CHAPS (Mantegazza et al., 2004). Nevertheless, this is consistent 
with the idea that dectin-1 interacts with tetraspanin microdomains via CD37. The 
Meyer-Wentrup et al. (2007) paper suggests that CD37 is involved in dectin-1 
stabilisation at the cell surface and negative regulation of dectin-1-mediated signalling 
and these were key findings that stimulated the studies in this thesis. In addition, 
further studies by the van Spriel group show that CD37-deficient mice exposed to 
Candida albicans have increased IL-6 production and immunoglobulin (Ig) A levels, 
and are therefore better protected from this fungal species compared to wild-type mice 
(van Spriel et al., 2009).   
 
1.2.4 CLEC-2 
 
1.2.4.1 CLEC-2 expression pattern 
The C-type lectin-like receptor CLEC-2 is expressed on a number of human 
haematopoietic cells, namely monocytes, granulocytes, dendritic cells and platelets 
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 (Colonna et al., 2000; Suzuki-Inoue et al., 2006). A mouse homologue has also been 
identified (Colonna et al., 2000; Xie et al., 2008). However, CLEC-2 may not be 
expressed on mouse dendritic cells as serial analysis of gene expression (SAGE) of 
six different dendritic cell libraries revealed no SAGE tags out of 162,312 total 
compared to 52 SAGE tags in a mouse megakaryocyte library of 53,046 total tags 
(Senis et al., 2007). The physiological role of CLEC-2 has yet to be determined and 
there were no functional reports of CLEC-2 until it was identified on platelets as a 
receptor for rhodocytin (Suzuki-Inoue et al., 2006).    
 
1.2.4.2 The identification of CLEC-2 as a platelet receptor for rhodocytin 
Rhodocytin is purified from the venom of the Malayan pit viper, Calloselasma 
rhodostoma, and induces platelet activation with a distinct lag phase (Suzuki-Inoue et 
al., 2006). There were previous reports that rhodocytin could bind to the collagen 
binding integrin α2β1 and the GPIb/IX/V complex (Shin and Morita, 1998). This was 
questioned by Bergmeier et al., since platelets from mice deficient in the integrin β1 
subunit and treated with O-sialoglycoprotein endopeptidase, to remove surface 
expression of GPIbα, could still respond to rhodocytin (Bergmeier et al., 2001). This 
suggested that there was another receptor on platelets that was activated following 
rhodocytin stimulation. CLEC-2 was identified as a candidate by rhodocytin affinity 
chromatography and confirmed as a rhodocytin receptor using cell line models (Fuller 
et al., 2007; Mori et al., 2008; Suzuki-Inoue et al., 2006). Interestingly, recent 
evidence has suggested that CLEC-2 acts as an activation receptor on neutrophils as it 
induced the production of pro-inflammatory cytokines including TNFα (Kerrigan et 
al., 2009).  
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 1.2.4.3 CLEC-2 is an essential platelet activating receptor in haemostasis and 
thrombosis 
 
During the writing of this thesis the Nieswandt group have shown that CLEC-2 is 
essential in haemostasis and thrombosis (May et al., 2009). CLEC-2-deficient 
platelets were generated by treatment of mice with a CLEC-2 antibody that leads to a 
specific loss of CLEC-2 from the surface of circulating platelets for several days, 
which may be attributable to the shedding or internalisation of the receptor. Such 
platelets have normal adhesion under flow but aggregate formation is defective both 
in vitro and in vivo leading to increased bleeding times and impaired occlusive 
thrombus formation (May et al., 2009). The authors suggest that the ligand (s) of 
CLEC-2 may be present in the plasma, on the surface of other platelets or released 
upon platelet activation (May et al., 2009). Such data highlights the role of CLEC-2 in 
thrombosis and haemostasis, with the generation of CLEC-2-deficient mice the next 
logical step in the study of this receptor, and is discussed in more detail in the 
discussion of this thesis.     
 
1.2.4.4 CLEC-2 structure and signalling  
 
CLEC-2 has a C-type lectin-like domain, a stalk region, transmembrane region and a 
cytoplasmic tail. In common with dectin-1, the latter contains a YXXL signalling 
motif that undergoes phosphorylation to generate downstream signalling events. This 
motif is highly conserved between a number of species (Figure 1.10). The signalling 
of CLEC-2 is dependent on Syk and PLCγ2 in murine platelets and in cell line 
reporter assays using DT40 B-cells following stimulation with rhodocytin (Fuller et 
al., 2007; Mori et al., 2008; Spalton et al., 2009; Suzuki-Inoue et al., 2006). In 
addition, there is a highly conserved DEDG motif directly upstream of the YXXL 
tyrosine and it has been shown that the glycine residue is important for CLEC-2 
 42
 signalling (Fuller et al., 2007). Further studies conducted during the writing of this 
thesis have demonstrated that CLEC-2 signals as a dimer (Hughes et al., 2010; 
Watson et al., 2009). Peptide pull down studies, Biacore, quantitative western 
blotting, tryptophan fluorescence measurements and competition experiments showed 
that Syk activation by CLEC-2 is mediated by the cross-linking through the tandem 
SH2 domains with a stoichiometry of 2:1 (Hughes et al., 2010). In addition, cross-
linking and electron microscopy demonstrated that CLEC-2 is present as a dimer in 
resting platelets and converted to larger complexes upon activation (Hughes et al., 
2010). These data have shown a model by which Syk activation occurs through 
interaction with a single YXXL-containing receptor.             
 
The crystal structure of the extracellular domain of CLEC-2 has been determined 
(Watson et al., 2008). In addition, the crystal structure of rhodoyctin has been 
determined and suggests that it assembles as a non-disulphide linked tetramer (Hooley 
et al., 2008; Watson et al., 2008). As a result, the authors hypothesise that rhodocytin 
binding to CLEC-2 may result in clustering of the receptor upon the platelet surface 
leading to platelet activation (O'Callaghan, 2009; Watson et al., 2008). 
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Figure 1.10 Sequence alignment of the cytoplasmic tail of CLEC-2 from different 
species 
 
CLEC-2 cytoplasmic tail amino-acid sequences from various species were aligned 
using the Clustalw alignment programme (www.ebi.ac.uk/clustalw). The YXXL 
signalling motif is highlighted. Sequence alignment symbols denote degree of 
conservation: “*” = identical residues, “:” = conserved substitution and “.” = semi-
conserved substitution.    
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 1.2.4.5 Identification of the CLEC-2 ligand, podoplanin 
 
A ligand, podoplanin (also known as aggrus), has been identified for CLEC-2 (Ozaki 
et al., 2009; Suzuki-Inoue et al., 2007). It is expressed on tumour cells, lymphatic 
endothelial cells and kidney podocytes (Christou et al., 2008; Wicki and Christofori, 
2007). Podoplanin is a transmembrane sialoglycoprotein involved in tumour cell-
induced platelet aggregation and tumour metastasis (Wicki and Christofori, 2007). 
Suzuki-Inoue et al. (2007) show that podoplanin-induced platelet aggregation is 
dependent on Src family kinases and PLCγ2, and the response was similar to that 
observed with rhodocytin. In addition, recombinant CLEC-2 inhibits platelet 
activation using podoplanin-expressing tumour cells or lymphatic endothelial cells 
suggesting that podoplanin is a ligand for CLEC-2 (Fuller et al., 2007; Suzuki-Inoue 
et al., 2006). This has been confirmed using HEK293T cells, which express 
podoplanin endogenously, and which were able to activate platelets (Suzuki-Inoue et 
al., 2006; Fuller et al., 2007). Moreover, the interaction of recombinant podoplanin 
with CLEC-2 was confirmed by Biacore (Christou et al., 2008). These findings 
suggest that tumour cells might bind to platelets via podoplanin and CLEC-2 to 
facilitate immune evasion during metastasis, and promote subsequent tumour growth, 
since platelets contain several growth factors. However, this hypothesis has yet to be 
tested.    
 
During the writing of this thesis, it was reported that the tetraspanin CD9 interacts 
with podoplanin and inhibits podoplanin-mediated platelet aggregation and suppresses 
pulmonary metastasis therefore suggesting a link between tetraspanins, CLEC-2 and 
podoplanin (Nakazawa et al., 2008). This will be further discussed in Chapter Seven. 
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 1.2.4.6 CLEC-2, an attachment factor in HIV-1 capture by platelets 
It has been reported that CLEC-2, along with the C-type lectin DC-SIGN, can 
facilitate the capture of HIV-1 by CLEC-2-transfected cells and platelets (Chaipan et 
al., 2006). A anti-CLEC-2 antibody, which binds specifically to the CLEC-2 
ectodomain, potently reduces the HIV-1 association with platelets suggesting that this 
C-type lectin-like receptor is required for efficient binding. This may have 
implications in facilitating HIV-1 dissemination in patients infected with the virus 
(Chaipan et al., 2006). 
 
1.2.5 CLEC9A 
 
CLEC9A has recently been identified as a novel C-type lectin-like activation receptor 
(Huysamen et al., 2008). It has restricted expression being detected on small subsets 
of dendritic cells and monocytes. Unlike dectin-1 and CLEC-2, a ligand for CLEC9A 
has yet to be identified and Huysamen et al. activate the receptor by generating a 
dectin-1-CLEC9A chimera and stimulating with the dectin-1 ligand, β-glucan. 
However, it has recently been shown that CLEC9A is used as a receptor on a subset 
of dendritic cells for necrotic cells that regulates the cross-presentation of dead-cell-
associated antigens (Sancho et al., 2009). Indeed, CLEC9A is similar to dectin-1 and 
CLEC-2 in its ability to signal via a YXXL motif through interaction with a Syk 
kinase (Huysamen et al., 2008; Sancho et al., 2009). However, a key difference is that 
human CLEC9A has been shown to be expressed as a disulphide-linked dimer using 
western blot analysis under non-reducing conditions (Huysamen et al., 2008). 
However, the functional significance of this has yet to be fully determined.   
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 1.3 Tyrosine kinase-linked signalling pathways 
1.3.1 Overview 
As described previously, both dectin-1 and CLEC-2 signal via a single YXXL (Table 
1.5) motif that undergoes tyrosine phosphorylation by Src family protein kinases to 
generate downstream signalling events, such as cytokine production and platelet 
activation respectively (Rogers et al., 2005; Suzuki-Inoue et al., 2006). This is distinct 
from the signalling of the major platelet collagen receptor, GPVI and the T- and B-
cell antigen receptors, which utilise dually phosphorylated tyrosine residues in the 
form of an ITAM, which has the consensus sequence YXXL/IX6-12YXXL/I (where 
‘X’ denotes any amino-acid) (Table 1.6). 
 
1.3.2 ITAM signalling 
 
To generate positive signals leading to cellular activation, ITAMs play a key role. For 
example, the major platelet collagen receptor GPVI couples to the ITAM-containing 
FcRγ chain to evoke platelet activation (Bori-Sanz et al., 2003; Locke et al., 2003; 
Suzuki-Inoue et al., 2002; Watson et al., 2001). Similarly, the B-cell receptor couples 
to the ITAM-containing Igα-Igβ heterodimer, and the T-cell receptor to the ITAM-
containing CD3 to induce B- and T-cell activation respectively (Table 1.6) (Abraham 
and Weiss, 2004; Gupta and DeFranco, 2007). Upon recognition and clustering of the 
receptor in question, the tyrosine residues of the ITAM become phosphorylated by 
Src protein tyrosine kinases, for example, Fyn and Lyn in platelets and B-cells, and 
Lck and Fyn in T-cells. The ITAMs act as docking sites for Syk family protein 
tyrosine kinases, Syk in platelets and B-cells and Zap-70 in T-cells (Barrow and 
Trowsdale, 2006). Both Syk and Zap-70 have two Src homology 2 (SH2) domains 
which are recruited to the dually phosphorylated ITAM upon activation. These 
tyrosine kinases then phosphorylate a number of adaptor proteins, for example, 
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 BLNK in B-cells and LAT and SLP-76 in platelets and T-cells which then recruit 
other signalling molecules (Fu et al., 1998; Judd et al., 2002; Zhang et al., 1998). This 
forms a scaffold which controls the spatial organisation of other effector molecules to 
initiate a downstream signalling cascade (Smith-Garvin et al., 2009).  
 
1.3.3 The differences between YXXL and ITAM signalling 
 
There are some notable differences between signalling via a single YXXL motif and 
ITAMs (Figure 1.11). In respect of ITAMs, it has been observed that phosphorylation 
of both tyrosine residues is required for recruitment and full activation of Syk and 
Zap-70 tyrosine kinases in B- and T-cells respectively (Iwashima et al., 1994; Rowley 
et al., 1995). Therefore, a key question is how the two SH2 domains of Syk/Zap-70 
bind to the single YXXL signalling motif. As discussed in section 1.2.4.4, CLEC-2 
has recently been shown to signal as a dimer resulting in two YXXL motifs 
undergoing phosphorylation to recruit Syk and generate signalling events (Hughes et 
al., 2010; Watson et al., 2009). 
 
Another difference between C-type lectin-like receptor single YXXL signalling and 
ITAMs is the only partial dependence of dectin-1 and CLEC-2 upon the SLP-76 and 
BLNK family of adaptor proteins (Fuller et al., 2007; Judd et al., 2002). Using nuclear 
factor of activated T-cell (NFAT)/activator protein (AP)-1-luciferase reporter assays 
in SLP-76- and BLNK-deficient Jurkat T- and DT40 B-cells respectively, the 
signalling of both dectin-1 and CLEC-2 is reduced by approximately 60-70% 
compared to wild-type cells (Fuller et al., 2007). This is distinct from GPVI 
signalling, where the presence of these adaptor proteins is imperative for signalling 
using cell line reporter assays (Fuller et al., 2007). Consistent with this, the platelets 
of SLP-76-deficient mice have an almost completely abolished GPVI-induced 
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 aggregation, but only a partial reduction is observed in aggregation following CLEC-2 
activation (Judd et al., 2002; Suzuki-Inoue et al., 2006).         
 
 
Table 1.5 C-type lectin-like receptors that contain YXXL motifs used in this 
thesis 
 
Name Sequence Signalling 
Dectin-1 DEDGYTQL Activatory 
 
CLEC-2 
 
DEDGYITL 
 
 
Activatory 
 
 
Table 1.6 ITAM receptor sequences 
  
Receptor Name Sequence 
T-cell ζ chain 1 
 
ζ chain 2 
 
ζ chain 3 
 
CD3γ 
 
CD3δ 
 
CD3ε 
 
QNQLYNELNLGRREEYDVL 
 
QEGLYNELQKDKMAEAYSEI 
 
HGDLYQGLSTARKDTYDAL 
 
NDQLYQPLKDREDDQYSHL 
 
NDQVYQPLRDRDDAQYSHL 
 
PNPDYEPIRKGQRDLYSGL 
B-cell Igα 
 
Igβ 
 
DENLYEGLNLDDCSMYEDI 
 
EDHTYEGLDIDQTATYEDI 
GPVI FcR γ-chain SDGVYTGLSTRNQETYETL 
 
 
 
 
 
 
Figure 1.11 A comparison of the signalling of CLEC-2 with GPVI and the T- and 
B-cell antigen receptors 
 
The key signalling and adaptor proteins involved in CLEC-2 single YXXL signalling 
are compared with GPVI and the T- and B-cell antigen receptors. One of the main 
differences is how the two SH2 domains of the Syk/Zap-70 family of tyrosine kinases 
bind to a single YXXL motif in the cytoplasmic tail of both CLEC-2 and dectin-1. 
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 1.4 Aims of this thesis 
 
The work in this thesis was stimulated by a publication of the van Spriel group, which 
suggested that CD37 negatively regulates dectin-1-mediated signalling (Meyer-
Wentrup et al., 2007). The mechanism of inhibition was not clear from this study, in 
part because of their focus on primary cells which are not readily transfectable and 
thus amenable to mechanistic studies. The aims are as follows: 
 
• To determine whether CD37 and other tetraspanins negatively regulate dectin-
1 signalling in model cell lines. 
• To investigate the mechanism of dectin-1 regulation by tetraspanins. 
• To determine whether tetraspanins also negatively regulate CLEC-2. 
• To investigate CLEC-2-induced platelet aggregation in mice deficient in the 
major platelet tetraspanin CD9.  
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 2.1 Agonists and antibodies 
 
The agonists used are described in Table 2.1. The antibodies used are described in 
Table 2.2. All other materials were from Sigma (Poole, UK) unless otherwise stated.  
 
Table 2.1 - Agonists 
Agonist Target receptor Source 
ADP P2Y1, P2Y12 Sigma (Saint Quentin-Fallavier, 
France) 
 
Collagen (HORM) GPVI 
α2β1 
 
Nycomed (Munich, Germany) 
Curdlan dectin-1 Sigma (Poole, UK) 
Ionomycin Ca2+ pathway Sigma (Poole, UK) 
PMA PKC/ RasGRP Sigma (Poole, UK) 
Rhodocytin CLEC-2 Dr J.A. Eble (University of 
Munster, Germany) 
 
Zymosan dectin-1 Sigma (Poole, UK) 
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 Table 2.2 - Antibodies 
Antibody reactivity Species of origin Experimental uses* Source 
Primary antibodies 
 
   
FLAG Rabbit WB: 0.5 μg/ml Sigma (Poole, UK) 
FLAG-M2 agarose Mouse IP: 10 μl Sigma (Poole, UK) 
MOPC (IgG) Mouse FC: 10 μg/ml 
IP: 1 μg 
 
Sigma (Poole, UK) 
MYC (9B11) Mouse FC: 10 µg/ml 
WB: 1 μg/ml 
Cell Signaling Technology (MA, 
USA) 
 
Normal goat IgG Goat IP: 1 μg R & D Systems (MN, USA) 
4G10 anti-phosphotyrosine 
 
Mouse WB: 1 μg/ml Upstate (Bucks, UK) 
Mouse CLEC-2 Rabbit FC: 10 μg/ml Dr. K. Suzuki-Inoue 
Human CLEC-2 Goat WB: 1 μg/ml R & D Systems (MN, USA) 
Human CD9 (1AA2)  Mouse FC: 10 μg/ml 
IP: 1 μg 
 
Prof. L. Ashman 
 
Mouse CD9 Rat FC: 10 μg/ml 
WB: 1 μg/ml 
 
Prof. B. Nieswandt 
Human CD53 (MEM53) Mouse FC: 10 μg/ml Dr. V. Horejsi 
 
Human CD63 (6H1) Mouse FC: 10 μg/ml Dr. F. Berditchevski 
Human CD81 (M38) Mouse FC: 10 μg/ml Dr. F. Berditchevski 
 
Human CD82 (M104) 
 
Mouse FC: 10 μg/ml Dr. O. Yoshie 
Human CD151 (11B1) 
 
Mouse FC: 10 μg/ml Prof. L. Ashman 
Human Tspan4 Mouse FC: 10 μg/ml Dr. F. Berditchevski 
Human GPVI (204-11) Mouse IP: 1 μg Dr. M. Moroi 
Human ADAM10 (11G2) Mouse IP: 1 μg Dr. E. Rubinstein 
Conjugated antibodies 
 
   
Human CD37 FITC-conjugate  
 
Mouse FC: 10 µg/ml AbD Serotec (Oxford, UK) 
Mouse IgG FITC-conjugate Goat FC: 1/100 DakoCytomation 
(Cambridgeshire, UK) 
Mouse IgG HRP-conjugate Sheep WB: 1/10, 000 Amersham (Buckinghamshire, 
UK) 
Rabbit IgG HRP-conjugate Donkey WB: 1/10, 000 Amersham (Buckinghamshire, 
UK) 
* IP: Immunoprecipitation, WB: Western Blot, FC: Flow Cytometry 
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 2.2 Molecular Biology 
2.2.1 Cloning PCR products into vectors 
The constructs used are in Table 2.3, all of which were gifts, the only exception being 
mouse integrin αIIbβ3. An overview of the general protocol to clone a polymerase 
chain reaction (PCR) product into the pEF6 vector with a MYC epiptope (Invitrogen, 
Paiseley, UK) is detailed below. Primers were designed to amplify the appropriate 
product from complementary DNA (cDNA) using the proofreading polymerase 
HighFidelity (Promega, Wisconsin, USA) or PfuTurbo (Stratagene, California, USA). 
An example of a thermocycling programme used for PCR is provided in Tables 2.5 
and 2.6. PCR product amplification was confirmed by separating DNA using standard 
gel electrophoresis 1% agarose gels containing 10 ng/ml ethidium bromide in TBE 
(89 mM Tris, 89 mM boric acid, 20 mM EDTA, pH 8) buffer and imaged under ultra-
violet (UV) light. The PCR product was purified using a QIAquick purification kit 
(QIAGEN, West Sussex, UK) and digested with the appropriate restriction enzymes 
(NEB, MA, USA) for 3 hours at 37 °C. Digested product was ligated into cut pEF6 
vector (Invitrogen, Paiseley, UK) in frame with a C-terminal MYC tag using the 
Rapid DNA ligation kit (Roche, MA, USA). Competent DH5α Escherichia coli were 
transformed with pEF6-insert construct using the heat shock method. DNA was mixed 
with bacteria, incubated on ice for 30 minutes, 20 seconds at 37 °C, and 5 minutes at 
room temperature, before the addition of 250 μl SOC medium (Sigma, Poole, UK). 
This was then incubated for 30 minutes at 37 °C and plated on agar plates (22% NaCl, 
22% Tryptone, 11% yeast extract, 44% agar, deionized water to 1 litre, pH 7) 
containing 100 μg/ml ampicillin. Individual colonies were screened by colony PCR 
using one insert primer and one vector primer and positive colonies were confirmed 
by gel electrophoresis using 1% agarose gels. A positive colony was inoculated in 250 
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 ml Luria-Bertani (LB) broth (22% NaCl, 22% Tryptone, 11% yeast extract, deionized 
water to 1 litre, pH 7), grown for 20 hours at 37 °C and plasmid DNA purified 
according to the Plasmid Maxiprep Kit (QIAGEN, West Sussex, UK). Confirmation 
of the correct sequence was performed by DNA sequencing using the ABI Prism 
3,700 DNA analyser (Functional Genomics Laboratory, The School of Biosciences, 
The University of Birmingham, UK). 
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 Table 2.3 - Expression constructs 
Insert 
 
Vector Epitope 
tag 
 
Origin 
Mouse dectin-1 pEF6 MYC J.A. Williams (University of 
Birmingham) 
 
Human CLEC-2 pEF6 MYC Dr. K. Suzuki-Inoue (University 
of Yamanashi, Japan) 
 
Human GPVI pCDNA3 MYC Prof. S.P. Watson 
Human FcRγ  pEF6 - Dr. M.G. Tomlinson 
Mouse αIIb pEF6 MYC N.D. Tomlinson 
Mouse β3 pEF6 MYC N.D. Tomlinson 
Human L6 antigen pCDNA3 - Dr. F. Berditchevski (University 
of Birmingham) 
 
Mouse CD9 pEF6 FLAG Dr. M.G. Tomlinson 
Mouse CD37 pEF6 FLAG Dr. M.G. Tomlinson 
Mouse CD63 pEF6 FLAG Dr. M.G. Tomlinson 
Mouse CD81 pEF6 FLAG Dr. M.G. Tomlinson 
Human CD81 pEF6 - Prof. J.A. McKeating (University 
of Birmingham) 
 
Human CD81 P.M. pEF6 - Prof. J.A. McKeating 
Mouse CD82 pEF6 FLAG Dr. M.G. Tomlinson 
Mouse CD151 pEF6 FLAG Dr. M.G. Tomlinson 
Human CD151 pCDNA3 FLAG Dr. F. Berditchevski 
Human CD151 pCDNA3 - Dr. F. Berditchevski 
Mouse Tspan3 pEF6 FLAG Dr. M.G. Tomlinson 
Mouse Tspan4 pEF6 FLAG Dr. M.G. Tomlinson 
Mouse Tspan5 pEF6 FLAG Dr. M.G. Tomlinson 
Mouse Tspan6 pEF6 FLAG Dr. M.G. Tomlinson 
Mouse Tspan9 pEF6 FLAG Dr. M.G. Tomlinson 
Mouse Tspan14 pEF6 FLAG Dr. M.G. Tomlinson 
Mouse Tspan15 pEF6 FLAG Dr. M.G. Tomlinson 
Mouse Tspan17 pEF6 FLAG Dr. M.G. Tomlinson 
Mouse Tspan18 pEF6 FLAG Dr. M.G. Tomlinson 
Mouse Tspan31 pEF6 FLAG Dr. M.G. Tomlinson 
Mouse Tspan32 pEF6 FLAG Dr. M.G. Tomlinson 
Mouse Tspan33 pEF6 FLAG Dr. M.G. Tomlinson 
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 2.3 Cell culture and functional studies 
2.3.1 Cell culture 
Jurkat human T-cells (clones E6.1 & DNAX) and those stably over-expressing human 
CD9 (clones AE9 & AE12) were cultured in RPMI supplemented with 10% foetal 
bovine serum, 100 units/ml penicillin, 100 μg/ml streptomycin and 20 mM 
GlutaMAX. DT40 chicken B-cells were cultured in RPMI supplemented with 10% 
foetal bovine serum, 100 units/ml penicillin, 100 μg/ml streptomycin, 20 mM 
GlutaMAX, 1% chicken serum and 50 μM 2β-mercaptoethanol. RBL-2H3 rat 
basophilic leukaemia cells and HEK293T cells were cultured in DMEM 
supplemented with 10% foetal bovine serum, 100 units/ml penicillin, 100 μg/ml 
streptomycin and 20 mM GlutaMAX. 
 
2.3.2 Cell transfection 
Jurkat were transfected by using 2 x 107 cells from a log phase culture per 
transfectant. Cells were washed in 50 ml non-supplemented RMPI, re-suspended in a 
volume of 400 μl non-supplemented RPMI, the DNA constructs were added and the 
cells electroporated using a GenePulser II (Biorad, Hertfordshire, UK) set at 250 V 
and 950 μF. Jurkat were then left at room temperature for 10 minutes before adding to 
8 ml complete RPMI. Cells were assayed approximately 20 hours post-transfection. 
 
DT40 were transfected by using 1 x 107 log phase cells per transfectant. Cells were 
washed in 50 ml cytomix (120 mM KCl, 0.5 mM CaCl2, 10 mM K2HPO4, 10 mM 
KH2PO4, 25 mM HEPES, 2 mM EGTA, 5 mM MgCl2, 0.04 mM ATP, 5 mM 
glutathione, pH 7.6) before re-suspension in a volume of 400 μl cytomix. DT40 were 
left at room temperature for 10 minutes, electroporated at 350 V and 500 μF and 
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 incubated 10 minutes on ice, before adding to 8 ml complete RPMI. Cells were 
assayed 20 hours post-transfection. 
 
RBL-2H3 cells were transfected by using 1 x 107 log phase cells per transfectant. 
Cells were washed in 50 ml non-supplemented RPMI before re-suspension in 400 μl 
non-supplemented RPMI, and electroporated at 276 V and 950 μF. RBL-2H3 cells 
were then left at room temperature for 10 minutes before adding to 8 ml complete 
RPMI. Cells were assayed 20 hours post-transfection.   
 
HEK293T cells were counted and 3 x 106 cells plated per 10 cm plate. The following 
day, DNA was mixed with 450 μl dH2O and 63 μl 2M calcium chloride, then 500 μl 
HBS (HEPES-buffered saline) (50 mM HEPES, 12 mM dextrose, 1.5 mM 
Na2HPO4.2H20, 10 mM KCl, 280 mM NaCl) was added drop-wise to the solution, 
mixing the tube contents between drops. This was left for 5-15 minutes to allow for a 
calcium-phosphate precipitate to form to which air was then bubbled through the 
solution for 10 seconds, to break up large clumps, before adding to cells. Media was 
replaced 24 hours later before harvest the following day.      
 
2.3.3 Luciferase assay 
The NFAT/AP-1-luciferase reporter assay used in this thesis is a highly sensitive 
readout for calcium and mitogen-activated protein (MAPK) signalling and has 
previously been used to study a number of receptors, including the C-type lectin-like 
proteins, dectin-1 and CLEC-2, the major platelet collagen receptor GPVI, and the T- 
and B-cell antigen receptors (Abraham and Weiss, 2004; Fuller et al., 2007; Gupta 
and DeFranco, 2007; Tomlinson et al., 2007). The NFAT/AP-1 reporter contains three 
copies of a composite NFAT/AP-1 element from the human IL-2 promoter (Shapiro et 
al., 1996) and is maximally activated by combined calcium elevation and MAPK 
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 signalling, which activate NFAT and AP-1 respectively (Figure 2.1). NFAT refers to 
a group of transcription factors that are crucial in the development and function of the 
immune system (Macian, 2005; Macian et al., 2001). Indeed, optimal NFAT 
activation requires sustained calcium signalling to maintain NFAT in the nucleus 
(Dolmetsch et al., 1997; Macian, 2005). AP-1 is the main transcriptional partner of 
NFAT that promotes gene transcription following T-cell activation (Macian, 2005; 
Macian et al., 2001; Rao et al., 1997).  
 
The NFAT/AP-1-luciferase transcriptional reporter assay is a sensitive readout for 
activation of this calcium/MAPK signalling pathway (Figure 2.1). Cells are stimulated 
and incubated for six hours to allow for transcription and translation of luciferase. 
Luciferase activity can then be measured as light emission in a luminometer following 
the addition to cell lysates of luciferin, the substrate of luciferase, plus ATP and Mg2+. 
In all of these reporter assays, the phorbol ester, phorbol 12-myristate 13-acetate 
(PMA), and the calcium ionophore, ionomycin, drive luciferase expression 
downstream of receptor-induced proximal signalling and serve as a positive control. 
PMA acts as an activator of PKC by mimicking DAG, and ionomycin stimulates the 
influx of calcium ions across the cell membrane by acting as a selective mobile ion 
carrier. Finally, it is important to note that the NFAT/AP-1 transcriptional reporter 
assay is a highly sensitive readout for sustained signalling over several hours, and 
does not necessarily reflect membrane-proximal signalling events immediately after 
receptor activation (Tomlinson et al., 2007). This is because a sustained signal is 
required to prevent nuclear export of NFAT proteins (Macian, 2005). Indeed, a 
sustained elevation of intracellular calcium, that is too weak to be detected by 
fluorimetry, can nevertheless induce robust NFAT activation (Dolmetsch et al., 1997).  
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 The NFAT/AP-1 luciferase assays were performed as follows. Cells were transfected 
with the desired expression constructs, in addition to 20 μg of the luciferase reporter 
construct (p∆ODLO-NFAT/AP-1) (Shapiro et al., 1996) and 2 μg of pEF6-lacZ 
(Invitrogen, Paiseley, UK) to control for transfection efficiency. Twenty hours after 
transfection, live cells were counted by Trypan blue exclusion, and samples were 
divided for luciferase assay, β-galactosidase assay and flow cytometry. Luciferase 
assays were performed in triplicate with 105 live cells in a total volume of 100 μl. 
Samples were stimulated for 6 hours with the agonist of choice, or with phorbol 12-
myristate 13-acetate (PMA) (50 ng/ml) plus ionomycin (1 μM) as a positive control. 
The assay was harvested by adding 11 μl of harvest buffer (200 mM potassium 
phosphate buffer, pH 7.8, 12.5% Triton X-100 and 4 mM DTT) for 5 minutes. 100 μl 
of this lysate was added to 100 µl of assay buffer (200 mM potassium phosphate 
buffer, pH 7.8, 20 mM MgCl2 and 10 mM ATP). The luciferase activity was 
measured using a Centro LB 960 microplate luminometer (Berthold Technologies, 
Germany) which injects 50 µl of 1 mM luciferin (MP Biomedicals, UK) and measures 
luminescence over a 10 second period. Data was expressed as luminescence units 
normalised to β-galactosidase activity in individual experiments. Data from two to 
three independent experiments was combined and shown as mean ± standard error.    
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Figure 2.1 An overview of the signalling pathway of the NFAT/AP-1-luciferase 
reporter assay used in the Jurkat T- and DT40 B-cell lines 
 
Following receptor activation, in this case dectin-1, the tyrosine residue in the single 
YXXL undergoes phosphorylation by Src family kinases (Fyn/Lyn in DT40 B-cells or 
Lck/Fyn in Jurkat T-cells). This leads to the recruitment of protein tyrosine kinases 
(Syk in DT40 B-cells or Zap-70 in Jurkat T-cells). In B-cells, Syk targets BLNK, 
which becomes phosphorylated. In T-cells, Zap-70 targets LAT and SLP-76, which 
become phosphorylated. Activation of PLCγ induces the hydrolysis of PIP2, which 
generates IP3 and DAG. IP3 binds to its receptor, the IP3-gated calcium channel 
(IP3R), which releases calcium from ER stores. The ER transmembrane protein 
STIM1 senses empyting of ER stores and responds by interacting with the plasma 
membrane CRAC channel Orai1, which opens and leads to sustained elevation of 
intracellular calcium. Calcium activates calcineurin, which in turn dephosphorylates 
NFAT. NFAT translocates to the nucleus and interacts with AP-1, which is induced 
by MAPK activation. This promotes gene transcription and luciferase generation, 
which can be detected as light emission following addition of luciferin, ATP and 
Mg2+ to cell lysates. Stimulation with the phorbol ester, PMA, and the calcium 
ionophore, ionomycin, serve as a positive control in the experiments, as they drive 
luciferase expression downstream of dectin-1-proximal signalling. Adapted from 
Macian (2005).   
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 2.3.4 β-galactosidase assay 
β-galactosidase assays were performed in triplicate using half a million cells using the 
Light Chemiluminescent Reporter Assay Kit (Applied Biosystems, MA, USA). Cells 
were lysed for 5 minutes in 80 μl lysis solution with the addition of 0.5 mM DTT, 
0.01 mg/ml leupeptin and 0.2 mg/ml 4-(2-aminoethyl)-benzenesulfonyl fluoride 
hydrochloride (AEBSF). This was then centrifuged for 2 minutes at 18,000 x g. 
Galacton, a β-galactosidase substrate, was diluted (1:100) in Galacton reaction buffer 
(0.5 M sodium phosphate (pH 7.1), 50 mM KCl and 5 mM MgSO4) before the 
addition of 70 μl per well of a 96-well plate. 20 μl of cell lysate was added to each 
well containing the diluted galacton. Samples were left in the dark for 30 minutes 
before β-galactosidase activity was measured using a microplate luminometer, which 
injects 100 μl light emission accelerator and measures luminescence over a 1 second 
period. All luciferase assay data was normalised to β-galactosidase values.   
 
2.3.5 RNAi 
RNAi was performed in Jurkat using negative medium GC content control or CD81 
Stealth Select siRNA oligo (sequence: GCG CUG UCA UGA UGU UCG UUG GCU 
U) (Invitrogen, Paisely, UK) used at a final concentration of 20 nM. This dose has 
been shown previously to be 100% effective in CD81 knockdown on human umbilical 
vein endothelial cells (HUVECs) (MGT, unpublished data). Jurkat were transfected as 
in section 2.3.2 but were incubated for 48 hours for maximal knockdown of CD81 
compared to 24 hours in all other experiments. Luciferase assays and β-galactosidase 
were performed as in 2.3.3 and 2.3.4 respectively and cell surface expression of CD81 
and dectin-1 was confirmed by flow cytometry as in section 2.4.    
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 2.4 Flow cytometry studies of cell lines 
Jurkat, DT40 and RBL-2H3 cells (5 x 105 per sample) were incubated with 50 μl 
FACS buffer (PBS, 0.2% BSA, 0.02% sodium azide) containing 10 μg/ml primary 
antibody for 30 minutes on ice. Cells were washed with 1 ml FACS buffer and then 
incubated with 50 μl FACS buffer containing 10 μg/ml FITC-conjugated secondary 
antibody for 30 minutes on ice. A volume of 250 μl of FACS buffer containing 2 
μg/ml propidium iodide was added before analysis on a FACScalibur flow cytometer 
using Cell Quest software (Becton Dickinson, CA, USA). Dead cells, positive for 
propidium iodide, were gated out.  
 
2.5 Co-immunoprecipation studies 
Jurkat were isolated by centrifuging cells for 5 minutes at 200 x g and washed in 1 ml 
PBS. HEK293T cells were isolated by aspirating media, scraping the cells in 1 ml 
PBS and centrifuging for 5 minutes at 200 x g. Cell pellets were lysed on ice for 30 
minutes in ice-cold lysis buffer. For Jurkat cells, 1% Brij97 (1% Brij97, 1 mM CaCl2, 
1 mM MgCl2, 10 mM Tris, pH 7.5, 150 mM NaCl, 0.02% sodium azide) was used; 
for HEK293T cells either 1% Brij97 or 1% Triton X-100 (1% Triton X-100, 10 mM 
Tris, pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.02% sodium azide) were used. Each 
lysis buffer contained the protease and phosphatase inhibitors 200 μg/ml AEBSF, 10 
μg/ml aprotonin, 10 μg/ml leupeptin, 1 μg/ml pepstatin A, 10 μM sodium fluoride and 
2 mM sodium orthovanadate. Following lysis, cells were centrifuged for 15 minutes at 
18,000 x g at 4 °C and a 50 μl sample was removed for whole cell lysates and mixed 
with an equal volume of 2 x reducing sample buffer (0.5 M Tris, pH 6.8, 5% β-
mercaptoethanol, 10% sodium dodecyl sulphate (SDS), 20% glycerol, 0.05% 
Bromophenol blue). The remainder of the lysate was immunoprecipitated at 4 °C for 
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 90 minutes on a rotating wheel with FLAG-M2 agarose (20 μl per 
immunoprecipitation) and samples were washed four times with ice-cold lysis buffer. 
Samples were re-suspended in 50 μl reducing sample buffer, of which 25 μl was 
loaded for SDS-polyacrylamide gel electrophoresis (PAGE).      
 
2.6 Platelet studies 
2.6.1 Mouse platelet studies 
2.6.1.1 Animals 
Genetically modified mice deficient in the tetraspanin CD9 were provided by 
François Lanza and Christian Gaçhet and had been back-crossed at least ten times on 
a C57BL/6 background. Colonies were established at the animal facilities at the 
Etablissement Français du Sang-Alsace (Strasbourg, France). Wild-type control mice 
were from Charles River (MA, USA).   
 
2.6.1.2 Platelet preparation 
Washed mouse platelets were prepared by drawing blood from the abdominal aorta 
into acid-citrate dextrose (ACD) (120 mM sodium citrate, 110 mM glucose, 80 mM 
citric acid) (1 volume ACD/6 volumes blood) and pooled (3ml) from more than one 
mouse. Blood was rested for 10 minutes at 37 °C before centrifugation at 200 x g, 
whereby the platelet-rich plasma (PRP) was removed and platelets re-suspended in 5 
ml Tyrodes (134 mM NaCl, 0.34 mM Na2HPO4, 2.9 mM KCl, 12 mM NaHCO3, 20 
mM HEPES, 5 mM glucose, 1 mM MgCl2, pH 7.3)-albumin buffer containing 
apyrase (0.02 U/ml) and prostacylcin (PGI2) (0.5 μl/ml). A further incubation at 37 °C 
for 10 minutes followed before centrifugation at 1,900 x g. Platelets were re-
suspended in 5 ml Tyrodes-albumin buffer containing PGI2 (0.5 μl/ml) and 
centrifuged at 1000 x g. The final platelet suspension was adjusted to 2 x 105 
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 platelets/μl in Tyrodes-albumin buffer containing apyrase (0.02 U/ml) and were kept 
at 37 °C for 30 minutes before use, to allow for the effects of prostacyclin to wear off.     
 
2.6.1.3 Platelet aggregation 
 
Platelets were kept at 37 °C during all experiments and aggregation was measured by 
turbidometry using a Payton aggregometer (Payton Associates, Ontario, Canada). 
Platelets were used at a concentration of 2 x 105/μl per aggregation and human 
fibrinogen (0.32 mg/ml) (Inter-Transfusion, Lingolsheim, France) was added, stirred 
at 1,500 x g for 30 seconds, before the agonist of choice was added to the suspension 
to a final volume of 500 μl and allowed to continue for 3 minutes in most cases. 
 
2.6.1.4 Platelet phosphorylation studies  
Aggregations were terminated by the addition of an equal volume of 2% NP-40 lysis 
buffer (2% NP-40, 100 mM Tris, pH 7.5, 500 mM NaCl, 5 mM MgCl2, 2 mM EDTA, 
2 mM sodium orthovanadate, 2 mM sodium fluoride) containing complete protease 
inhibitor cocktail (Roche, Germany). Lysates were used to determine tyrosine 
phosphorylation profiles and to confirm that the mice used were either CD9-deficient 
or wild-type controls.   
 
2.6.1.5 Platelet flow cytometry 
Flow cytometry on platelets was performed essentially as described in section 2.4 at a 
concentration of 2 x 108/ml in a volume of 50 μl in the presence of 0.1 mM EGTA to 
prevent aggregation. 
 
 
 
 
 
 
 
 66
 2.6.2 Human platelet studies 
 
2.6.2.1 Platelet preparation 
 
Washed human platelets were prepared by drawing blood into sodium citrate (Sigma, 
Poole, UK) (1 volume sodium citrate/9 volumes of blood) from healthy drug-free 
volunteers. ACD (120 mM sodium citrate, 110 mM glucose, 80 mM citric acid) (1 
volume ACD/9 volumes blood) was then added. Blood was centrifuged at 200 x g for 
20 minutes and PRP collected. PGI2 (0.4 μg/ml) was added and platelets centrifuged 
at 1,000 x g for 10 minutes. Platelets were washed in modified Tyrodes buffer (134 
mM NaCl, 0.34 mM Na2HPO4, 2.9 mM KCL, 12 mM NaHCO3, 20 mM HEPES, 5 
mM glucose, 1 mM MgCl2, pH 7.3) in the presence of 0.4 μg/ml PGI2 and ACD (1:8), 
then centrifuged at 1,000 x g for 10 minutes. Platelets were resuspended in modified 
Tyrodes buffer and counted using a particle counter (Beckman Coulter, CA, USA). 
Platelets were allowed to rest for 30 minutes prior to use to allow the effects of the 
prostacyclin to wear off. 
 
2.6.2.2 Co-immunoprecipitation studies in rhodocytin-stimulated platelets 
 
Washed human platelets were re-suspended at a concentration of 1 x 109/ml in 
modified Tyrodes buffer and stimulated in an aggregometer for 5 minutes at 37 °C 
with 300 nM rhodocytin or left unstimulated. Platelets were lysed/pre-cleared in ice-
cold 1% Brij97 in the presence of inhibitors and 20 μl protein G sepharose (PGS) 
(Sigma, Poole, UK) (50% slurry PBS) and rotated for 60 minutes at 4 °C. At this 
point, 1 μg of isotype negative control, CLEC-2, CD9 or ADAM-10 antibodies were 
coated to 20 μl PGS in 1% Triton X-100 and rotated for 60 minutes at room 
temperature before washing three times with 1% Brij97. Following lysis/pre-clear, 
platelets were centrifuged for 10 minutes at 13,000 x g at 4 °C and a 25 μl sample was 
removed for whole cell lysates and mixed with an equal volume of non-reducing 
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 sample buffer. The remainder of the lysate was immunoprecipitated at 4 °C for 90 
minutes with either isotype negative control, CLEC-2, CD9 or ADAM-10 antibodies. 
Samples were washed four times with ice-cold lysis buffer and were re-suspended in 
50 μl sample buffer, of which, 20 μl was loaded for SDS-PAGE.      
 
2.7 Semi-quantitative PCR of mouse megakaryocytes 
 
cDNA was provided by M.G. Tomlinson, and was generated using the first strand 
cDNA synthesis kit (Roche, Germany), from RNA prepared using Trizol (Invitrogen, 
Paiseley, UK) from mouse megakaryocytes kindly provided by P. Mangin. A semi-
quantitative PCR was performed using cDNA from wild-type and CD9-deficient 
megakaryoctyes at three dilutions: undiluted, 1:10 and 1:100. A 2 x ReadyMix Taq 
PCR Reaction Mix (Sigma, Poole, UK), dH20 and primers for tetraspanins and the 
GAPDH positive control (final primer concentration 20 pmol/μl) were mixed (Table 
2.4). The generic thermocycling programme is provided in Table 2.5. Variations in 
the thermocycling programmes in regard to the annealing temperature and number of 
cycles is provided in Table 2.6. Following PCR, 10 μl samples were run on a 1% 
agarose gel to determine product amplification.    
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 Table 2.4 Primers used for semi-quantitative PCR  
Tetraspanin 
 
Forward primer Reverse primer 
CD9 TAGTAGAGATCTCCGGTCAAAGGAGGTAGCAAG TAGTAGGCGGCCGCCTAGACCATTTCTCGGCTCC 
CD63 TAGTAGAGATCTGCGGTGGAAGGAGGAATGAAG TAGTAGGCGGCCGCCTACATTACTTCATAGCCAC 
CD81 TAGTAGGGATCCGGGGTGGAGGGCTGCACCAAATG TAGTAGGCGGCCGCTCAGTACACGGAGCTGTTCCGG 
CD151 TAGTAGAGATCTGGTGAATTCAATGAGAAGAAGG TAGTAGGCGGCCGCTCAGTAGTGTTCCAGCTTGAG 
Tspan2 TAGTAGAGATCTGGGCGTTTTCGCGGGGGCCTG TAGTAGGCGGCCGCTCAGATCACATCGCGTGAGTTC 
Tspan9 TAGTAGAGATCTGCCAGGGGCTGTCTCTGCTG TAGTAGGCGGCCGCTCAGGCGTCGTACTTTTTACCTG 
Tspan32 TAGTAGAGATCTGGGCACTGGAATCGAATCAAG TAGTAGGCGGCCGCCTAGGTCCATCTGAAGAGGC 
GAPDH control 
 
GACCCCTTCATTGACCTCAA GCATGGACTGTGGTCATGAGT 
  
Table 2.5 The generic thermocycling programme used for semi-quantitative PCR 
 
Step 
 
Temperature °C Time 
Denaturation 94 2 minutes 
Denaturation 94 30 seconds 
(30-35 cycles) 
 
Annealing See Table 2.6 30 seconds 
(30-35 cycles) 
 
Elongation 72 2 minutes 
(30-35 cycles) 
 
 
Table 2.6 The annealing temperatures and number of cycles used for semi-
quantitative PCR 
 
Tetraspanin 
 
Annealing temperature °C Number of cycles 
CD9 55 30 
GAPDH control 55 30 
CD63 55 35 
CD151 55 35 
Tspan32 55 35 
CD81 60 35 
Tspan2 60 35 
Tspan9 60 35 
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 2.8 SDS-PAGE and western blotting 
 
Proteins were resolved by running on reducing or non-reducing gradient 4-12% or 
12% non-gradient SDS-PAGE, along with pre-stained molecular weight markers 
(NEB, Hertfordshire, UK). Gels were transferred to polyvinylidene difluoride (PVDF) 
membranes by the semi-dry method (25 mM Tris, 250 mM glycine, 15% methanol) at 
110 mA for 35 minutes and subsequently blocked overnight at 4 °C in TBS-T (137 
mM NaCl, 20 mM Tris, 10% Tween-20, pH 7.6) 5% milk. Membranes were 
immunoblotted with primary antibodies in blocking buffer (TBS-T containing 3% 
BSA and 0.1% sodium azide) for 1.5 hours at room temperature. Membranes were 
washed 3 times in TBS-T high salt (500 mM NaCl) for 10 minutes and subsequently 
incubated for 1.5 hours with HRP-conjugated antibodies in TBST-T milk or TBST. 
Membranes were washed 5 more times for 5 minutes each. Western blots were 
developed using enhanced chemiluminescence (ECL, Amersham Bioscience, 
Buckinghamshire, UK) and Hyperfilm (Amersham) and were developed in a Compact 
X4 Film Processor (Xograph Imaging Systems).  
 
2.9 Analysis of data 
Data is shown either as combined from 2-3 individual experiments for luciferase 
assay or as a representative of 1-3 individual experiments for western blots, flow 
cytometry histograms/dot plots and platelet assays. For luciferase assay, a β-
galactosidase assay was performed, to which all data were normalised. β-
galactosidase corrected luciferase data were then analysed, where one value was set to 
100% and other values were calculated relative to this, as indicated in individual 
figure legends. When it was needed to determine whether there was a significant 
difference between data sets, an analysis of variance (ANOVA) was performed. 
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 Where ANOVA showed a difference between data sets for luciferase assay, an 
unpaired Student’s t-test was performed, with P<0.05 taken as significant.   
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CHAPTER 3 – 
 
TETRASPANIN OVER-EXPRESSION INHIBITS 
DECTIN-1 SIGNALLING 
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 3.1 INTRODUCTION 
 
3.1.1 Dectin-1 
 
Dectin-1 plays a key role in the immune response against fungal pathogens by 
inducing cytokine and chemokine production, respiratory burst, phagocytosis and 
possibly endocytosis (Brown, 2006; Willment and Brown, 2008). The cytoplasmic tail 
of dectin-1 contains one conserved tyrosine residue involved in signalling. This motif 
has been shown to be required for the recruitment of Syk via its tandem SH2 domains 
in response to zymosan, which contains high amounts of the dectin-1 ligand β-glucan, 
to generate signalling events (Rogers et al., 2005). The dissection of the dectin-1 
signalling pathway has also been investigated by the Watson group using NFAT/AP-
1-luciferase reporter assays in Jurkat T- and DT40 B-cell mutant lines. Studies using 
this assay have generated a model in which dectin-1 signalling is dependent on Src, 
Syk and Tec family tyrosine kinases and PLCγ, but is only partially dependent on the 
SLP-76/BLNK family of adaptor proteins (Fuller et al., 2007). Therefore, this assay is 
a useful model to study the signalling of dectin-1 and its regulation by tetraspanins.  
 
3.1.2 Dectin-1 signalling is regulated by CD37 
 
The tetraspanin CD37 has been shown to interact with dectin-1 and to negatively 
regulate its signalling, as macrophages of CD37-deficient mice have increased dectin-
1-mediated IL-6 production despite lower levels of surface dectin-1 (Meyer-Wentrup 
et al., 2007). In addition, the relatively low level of endogenous of dectin-1 increases 
following tranfection of CD37 into the RAW 264.7 mouse macrophage cell line 
(Meyer-Wentrup et al., 2007). The authors hypothesise that CD37 may negatively 
regulate dectin-1 signalling and stabilise its expression at the cell surface. This was 
the first report of a tetraspanin to functionally regulate a C-type lectin-like protein. 
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 Further studies by the van Spriel group have shown that CD37-deficient mice exposed 
to Candida albicans have increased IL-6 production and IgA levels, and are therefore 
better protected from this fungal species compared to controls (van Spriel et al., 
2009).  However, the studies did not address whether other tetraspanins could interact 
with and negatively regulate dectin-1. Therefore, the aim of this Chapter was to 
determine whether CD37 and other tetraspanins regulate the signalling of dectin-1 
using an NFAT/AP-1-luciferase reporter assay in the Jurkat T-cell line.  
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 3.2 AIMS 
 
• To determine whether CD37 over-expression inhibits dectin-1 signalling in a 
model cell line. 
• To determine whether other tetraspanins inhibit dectin-1 signalling. 
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 3.3 RESULTS 
 
3.3.1 The Jurkat T-cell line expresses relatively low levels of CD37 
 
The initial aim was to identify a model cell line that expresses low levels of the 
tetraspanin CD37, such that dectin-1 signalling could be measured in the presence or 
absence of transfected CD37. Jurkat is a widely used model T-cell line to study T-cell 
receptor signalling (Abraham and Weiss, 2004) which was found to express relatively 
low levels of surface CD37, as detected by flow cytometry (Figure 3.1). In contrast, 
Jurkat expressed relatively high levels of the tetraspanins CD53, CD81 and CD82, 
whereas CD9, CD63, CD151 and Tspan4 were weakly expressed (Figure 3.1). 
Therefore, Jurkat would appear to be a useful model system to study the effect of 
CD37 on dectin-1 signalling.  
 
3.3.2 Dectin-1 induces NFAT/AP-1 activation in Jurkat in response to its ligands 
curdlan and zymosan 
 
The Watson group have previously demonstrated that, in Jurkat, transfected dectin-1 
induces NFAT/AP-1 activation in response to its ligand zymosan (Fuller et al., 2007). 
In order to establish this assay to ultimately address the effect of CD37, Jurkat were 
initially transfected with four different amounts of a dectin-1 expression construct, 
and NFAT/AP-1 activation was measured in response to zymosan and curdlan, the 
latter of which, unlike zymosan, is a relatively pure source of the dectin-1 ligand β-
glucan. For both ligands, the degree of NFAT/AP-1 activation was similar between 5 
μg and 20 μg of the dectin-1 expression construct and appeared maximal at these 
doses (Figure 3.2A). To establish a dose response for dectin-1 stimulation, Jurkat 
transfected with 10 μg of dectin-1 were stimulated with different amounts of curdlan 
and zymosan. The degree of NFAT/AP-1 activation increased with increasing 
amounts of curdlan between 10 and 250 μg/ml and increased with zymosan between 1 
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 and 10 μg/ml, at which the dose response appeared to be maximal (Figure 3.2B). As a 
positive control for these transfections, NFAT/AP-1 activation in response to PMA 
and ionomycin, which bypasses receptor proximal signalling events, was found to be 
similar at each dose of dectin-1 (Figure 3.2C). However, the degree of PMA and 
ionomycin response was relatively weak due to a suboptimal batch of the agonists. In 
addition, dectin-1 surface expression was also maximal between 5 μg and 20 μg of 
dectin-1, as measured by flow cytometry (Figure 3.2D). Together, these data suggest 
that for future experiments, a dose of 10 μg of dectin-1 will provide a maximal level 
of dectin-1 surface expression, and curdlan concentrations of 30 and 250 μg/ml will 
provide suboptimal and optimal levels of dectin-1 stimulation, respectively, to allow 
the effect of CD37 transfection to be evaluated.  
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Figure 3.1 Endogenous cell surface expression of tetraspanins on Jurkat T-cells 
CD37 levels were detected by flow cytometry using FITC-conjugated CD37 antibody. 
The other tetraspanins were stained with the indicated primary antibody and then anti-
mouse FITC-conjugated secondary antibody. Filled histograms represent the negative 
control antibody stain and open histograms the relevant tetraspanin antibody stain. 
Dead cells were gated out using propidium iodide. Data is representative of at least 
two independent experiments.    
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Figure 3.2 Dectin-1 induces NFAT/AP-1 activation in response to curdlan and 
zymosan in Jurkat T-cells 
 
Jurkat T-cells were transiently transfected with an NFAT/AP-1-luciferase reporter 
construct, a β-galactosidase construct to control for transfection efficiency, pEF6-
MYC-dectin-1 or empty pEF6 vector (mock). Cells were stimulated with media alone 
(unstimulated), curdlan, zymosan (A (250 μg/ml curdlan and 100 μg/ml zymosan) & 
B) and PMA/ionomycin (C) for six hours as indicated. The PMA/ionomycin 
stimulation was weak due to a suboptimal batch of these agonists. Luciferase activity 
was measured following stimulation and transfection efficiency was corrected to β-
galactosidase activity in individual experiments. The dectin-1 (10 μg) with 250 μg/ml 
curdlan stimulation value was set to 100% and other conditions presented were 
calculated relative to this. Error bars represent the standard error of the mean. 
Experiments were performed three times. (D) Cells were stained with MYC primary 
antibody and then anti-mouse FITC-conjugated secondary antibody. Dead cells were 
gated out using propidium iodide. Dot plots were analysed and values indicate the 
average transfection efficiency (TF) and mean fluorescence intensity (MFI) of protein 
on the cell surface. Data is representative of three independent experiments.  
 81
 3.3.3 CD37 inhibits dectin-1 signalling in a dose-dependent manner in Jurkat 
 
It has been shown that CD37 negatively regulates dectin-1 signalling (Meyer-Wentrup 
et al., 2007). Therefore, the NFAT/AP-1-luciferase reporter assay was performed to 
determine whether CD37 inhibits dectin-1 signalling in Jurkat. Four different amounts 
of a CD37 expression construct were co-transfected with dectin-1 and NFAT/AP-1 
activation was measured in response to a suboptimal (30 μg/ml) and optimal (250 
μg/ml) level of curdlan. CD37 inhibited dectin-1 signalling in a dose-dependent 
manner when stimulated with curdlan, and signalling was inhibited by over 90% 
when dectin-1 was co-transfected with 10 or 20 µg of CD37 (Figure 3.3A). 
NFAT/AP-1 activation in response to PMA and ionomycin control stimulation was 
found to be generally similar in all transfectants indicating that CD37-expressing cells 
retained the capacity to activate NFAT/AP-1 (Figure 3.3B). Cell surface expression of 
dectin-1 was determined by flow cytometry and ANOVA suggested that there was no 
difference in dectin-1 surface expression when co-transfected with all CD37 levels 
(Figure 3.3C). In addition, a Student’s t-test was performed to determine whether 
there was a significant difference in dectin-1 cell surface expression between 0 and 20 
μg of CD37. There was no significant difference (P=0.056). However, there was a 
general downwards trend as the amount of CD37 was increased, although this slight 
reduction in dectin-1 levels was not observed in later experiments in this Chapter, and 
cannot account for the substantial loss of signalling, as shown in the previous dectin-1 
titration (Figure 3.2A). This allowed one to show that any effect on dectin-1 
signalling was due to CD37, not as a result of reduced dectin-1 surface expression. 
Together these data suggest that CD37 potently inhibits dectin-1 signalling. 
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 3.3.4 CD82 and Tspan31 also inhibit dectin-1 signalling in Jurkat 
 
The role of CD82 and Tspan31 in dectin-1 signalling was investigated to determine 
whether CD37 inhibition of dectin-1 was specific to this tetraspanin using the 
NFAT/AP-1-luciferase assay. These tetraspanins were selected on the basis that CD82 
is the most related (36% amino acid identity) and Tspan31 the least related (14% 
amino acid identity) to CD37, using the ClustalW alignment programme 
(www.ebi.ac.uk/clustalw). CD82 and Tspan31 had, in common with CD37, a potent 
inhibitory effect upon dectin-1 signalling following stimulation with 250 μg/ml 
curdlan (Figure 3.4A). Moreover, all transfection conditions responded following 
stimulation with the PMA and ionomycin positive control (Figure 3.4B). In some 
cases, for example dectin-1 plus Tspan31, these control stimulations yielded 
NFAT/AP-1 activation that was only 50% of that with dectin-1. The reason for this is 
not clear, but is not due to different transfection efficiencies because a β-galactosidase 
construct was co-transfected in all experiments, and a β-galactosidase assay 
performed to normalise the data for transfection efficiency. Nevertheless, it cannot 
account for the 90% inhibition of dectin-1-induced NFAT/AP-1 activation. Cell 
surface expression of dectin-1 was determined by flow cytometry and was similar 
between transfectants suggesting that signal inhibition was not a result of reduced 
dectin-1 expression when co-transfected with tetraspanins (Figure 3.4C). These data 
suggests that dectin-1 inhibition is not specific to CD37 and that over-expression of 
any tetraspanin may inhibit dectin-1 signalling.  
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Figure 3.3 CD37 inhibits dectin-1 signalling 
 
Jurkat T-cells were transiently transfected with an NFAT/AP-1-luciferase reporter 
construct, β-galactosidase construct, pEF6-MYC-dectin-1 (10 μg) and pEF6-CD37 or 
empty pEF6 vector (mock). Cells were stimulated with media alone (unstimulated), 
curdlan (250 μg/ml) (A) and PMA/ionomycin (B) for six hours as indicated. The 
PMA/ionomycin stimulation was weak due to a suboptimal batch of these agonists. 
Luciferase activity was measured following stimulation and transfection efficiency 
was corrected to β-galactosidase activity in individual experiments. The dectin-1 with 
250 μg/ml curdlan stimulation value was set to 100% and other conditions presented 
were calculated relative to this. An unpaired Student’s t-test indicated a statistically 
significant difference (P<0.05) between dectin-1 transfected alone compared to 
dectin-1 co-transfected with relatively high levels of CD37 as indicated *. Error bars 
represent the standard error of the mean. Experiments were performed three times. (C) 
Cells were stained and analysed by flow cytometry as described previously. Flow 
cytometry plots were analysed minus mock background fluorescence and data shown 
indicates geometric mean ± standard error. Analysis of variance (ANOVA) showed 
that there was no significant difference between groups. A Student’s t-test was 
performed to determine whether there was a significant difference in dectin-1 cell 
surface expression between 0 and 20 μg of CD37, and this failed to reach significance 
(P=0.056) (n=3). Experiments were performed three times. 
 85
 A. 
 
 
120
Unstimulated
B. 
Mo
ck
de
cti
n-1
 
CD
37
 
de
cti
n-1
 &
 C
D3
7 
CD
82
 
de
cti
n-1
 &
 C
D8
2
Ts
pa
n3
1
de
cti
n-1
 &
 Ts
pa
n3
1
0
20
40
60
80
100 Curdlan
* **
R
el
at
iv
e 
N
FA
T/
A
P-
1-
lu
ci
fe
ra
se
 a
ct
iv
ity
 
 
R
el
at
iv
e 
N
FA
T/
A
P-
1-
lu
ci
fe
ra
se
 a
ct
iv
ity
Mo
ck
de
cti
n-1
 
CD
37
 
de
cti
n-1
 &
 C
D3
7 
CD
82
 
de
cti
n-1
 &
 C
D8
2
Ts
pa
n3
1 
de
cti
n-1
 &
 Ts
pa
n3
1
0
100
200
300
400
500
600
700
800
Unstimulated
PMA/ionomycin
 
 86
  
 
 
 
 
C. 
                                                      
 
dectin-1 Mock 
dectin-1 & CD37  dectin-1 & CD82 dectin-1 & Tspan31 
TF=2 % 
MFI=167 
TF=4 % 
MFI=109 
 TF=3 % 
 MFI=206 
TF=3 % 
MFI=181 
Fo
rw
ar
d 
sc
at
te
r 
 
dectin-1  
 
 
 
 
Figure 3.4 CD37, CD82 and Tspan31 inhibit dectin-1 signalling in Jurkat T-cells 
 
Jurkat T-cells were transiently transfected with an NFAT/AP-1-luciferase reporter 
construct, β-galactosidase construct, pEF6-MYC-dectin-1 (10 μg) and pEF6-CD37, 
CD82, Tspan31 (20 μg each) or empty pEF6 vector (mock). Cells were stimulated 
with media alone (unstimulated), curdlan (250 μg/ml) (A) and PMA/ionomycin (B) 
for six hours as indicated. Luciferase activity was measured following stimulation and 
transfection efficiency was corrected to β-galactosidase activity in individual 
experiments. The dectin-1 with curdlan stimulation value was set to 100% and other 
conditions presented were calculated relative to this. An unpaired Student’s t-test 
indicated a statistically significant difference (P<0.05) between dectin-1 transfected 
alone compared to dectin-1 co-transfected with CD37, CD82 or Tspan31 as indicated 
*. Error bars represent the standard error of the mean. Experiments were performed 
three times. (C) Cells were stained with MYC primary antibody and then anti-mouse 
FITC-conjugated secondary antibody. Dead cells were gated out using propidium 
iodide. Antibody binding was visualized by flow cytometry. Dot plots were analysed 
and values indicate the average transfection efficiency (TF) and mean fluorescence 
intensity (MFI) of protein on the cell surface. Data is representative of three 
independent experiments.   
 87
 3.3.5 Dectin-1 signal inhibition by tetraspanin over-expression is not epitope tag-
dependent in Jurkat 
 
Although the FLAG tag is only eight amino acids long, it is possible that such tagging 
renders tetraspanins dysfunctional and that dectin-1 inhibition is an artefact. 
Therefore, Jurkat were transfected with dectin-1 and CD151 with or without a FLAG 
tag. CD151 was chosen because of the availability of non-tagged and tagged forms. In 
common with CD37, CD82 and Tspan31, CD151 inhibited dectin-1-induced 
NFAT/AP-1 activation, and this was independent of the presence of the tag (Figure 
3.5A). However, the degree of dectin-1-induced NFAT/AP-1 activation following 
curdlan stimulation was particulary weak, suggesting that the agonist preparation was 
not optimal in this case. In addition, all transfection conditions responded similarly to 
positive control stimulations (Figure 3.5B). Indeed, the PMA and ionomycin response 
with dectin-1 and CD151 transfectants was relatively higher than that of dectin-1 
transfectant. Cell surface expression of dectin-1 and CD151 was confirmed by flow 
cytometry and was similar between transfectants (Figure 3.5C-D). These data suggest 
that a tag on the tetraspanin is not the cause of dectin-1 signal inhibition by 
tetraspanin over-expression.       
 
3.3.6 Tetraspanins do not inhibit the signalling of the collagen receptor GPVI in 
Jurkat 
 
As all tetraspanins studied so far have had an inhibitory effect on dectin-1 signalling, 
it was important to determine whether tetraspanin over-expression was having a 
general inhibitory effect on receptor signalling. Consequently, the collagen receptor, 
GPVI/FcRγ, was studied to determine whether tetraspanins had an inhibitory effect on 
this receptor. GPVI and FcRγ (5 µg each) expression constructs were co-transfected 
with the tetraspanins CD37, CD81, CD82 and Tspan31 and stimulated with 5 μg/ml 
collagen. Expression of CD37, CD81, CD82 and Tspan31 had no significant effect on 
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 GPVI signalling as suggested by ANOVA (Figure 3.6A), although NFAT/AP-1 
activation in the presence of Tspan31 was only 50% of GPVI/FcRγ, for a reason that 
is not clear. All transfection conditions responded to positive control stimulations, 
albeit with some differences in magnitude (Figure 3.6B). The mock transfectant when 
stimulated with PMA and ionomcyin was relatively higher than all other transfectants. 
This data suggests that GPVI/FcRγ alone or when co-transfected with tetraspanins had 
a general inhibitory effect on the experiment. However, as the PMA and ionomycin 
response was similar, this does not detract from the conclusion presented that 
tetraspanins do not inhibit GPVI/FcRγ signalling following collagen stimulation. 
GPVI cell surface expression was determined by flow cytometry and was similar 
between transfectants (Figure 3.6C). These data demonstrate that tetraspanin over-
expression does not globally inhibit receptor signalling.     
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Figure 3.5 Dectin-1 signal inhibition by tetraspanin over-expression is not tag-
dependent 
 
Jurkat T-cells were transiently transfected with an NFAT/AP-1-luciferase reporter 
construct, β-galactosidase construct, pEF6-MYC-dectin-1 (10 μg) and pCDNA3-
FLAG-CD151 (20 μg) or pCDNA3-CD151 (20 μg) or empty pEF6/pCDNA3 vector 
(mock). Cells were stimulated with media alone (unstimulated), curdlan (250 μg/ml) 
(A) and PMA/ionomycin (B) for six hours as indicated. Luciferase activity was 
measured following stimulation and transfection efficiency was corrected to β-
galactosidase activity in individual experiments. The dectin-1 with curdlan 
stimulation value was set to 100% and other conditions presented were calculated 
relative to this. An unpaired Student’s t-test indicated a statistically significant 
difference (P<0.05) between dectin-1 transfected alone compared to dectin-1 co-
transfected with CD151-FLAG and CD151 as indicated *. Error bars represent the 
standard error of the mean. Experiments were performed twice. (C-D) Cells were 
stained with MYC or CD151 primary antibodies and then anti-mouse FITC-
conjugated secondary antibody. Dead cells were gated out using propidium iodide. 
Antibody binding was visualized by flow cytometry. Dot plots were analysed and 
values indicate the average transfection efficiency (TF) and mean fluorescence 
intensity (MFI) of protein on the cell surface. Data is representative of two 
independent experiments. 
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Figure 3.6 CD37, CD81, CD82 and Tspan31 do not inhibit GPVI/FcRγ signalling 
in Jurkat T-cells 
 
Jurkat T-cells were transiently transfected with an NFAT/AP-1-luciferase reporter 
construct, β-galactosidase construct, pCDNA3-MYC-GPVI/pEF6-FcRγ (5 μg each) 
and pEF6-CD37, CD81, CD82, Tspan31 (20 μg each) or empty pEF6 vector (mock). 
Cells were stimulated with media alone (unstimulated), collagen (5 μg/ml) (A) and 
PMA/ionomycin (B) for six hours as indicated. Luciferase activity was measured 
following stimulation and transfection efficiency was corrected to β-galactosidase 
activity in individual experiments. The GPVI/FcRγ with collagen stimulation value 
was set to 100% and other conditions presented were calculated relative to this. 
Analysis of variance (ANOVA) showed there was no significant difference between 
groups. Error bars represent the standard error of the mean. Experiments were 
performed three times. (C) Cells were stained with anti-human GPVI and then anti-
mouse FITC-conjugated secondary antibody. Dead cells were gated out using 
propidium iodide. Antibody binding was visualized by flow cytometry. Dot plots 
were analysed and values indicate the average transfection efficiency (TF) and mean 
fluorescence intensity (MFI) of protein on the cell surface. Data is representative of 
three independent experiments. 
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 3.3.7 The four-transmembrane L6 antigen does not inhibit dectin-1 signalling in 
Jurkat 
 
Since all tested tetraspanins inhibit dectin-1 signalling, it was important to investigate 
the possibility that any transmembrane protein has the ability to inhibit dectin-1 
signalling when over-expressed. Therefore, the L6 antigen was selected because it 
shares the four-transmembrane topology of the tetraspanin superfamily. Jurkat were 
transfected with dectin-1 and L6 expression constructs and NFAT/AP-1 activation 
was measured in response to 250 μg/ml curdlan. Unlike the previous data for 
tetraspanins, dectin-1 could still signal when co-transfected with L6 (Figure 3.7A). In 
addition, all transfection conditions responded similarily to positive control 
stimulations, apart from the mock transfectant which responsed weakly (Figure 3.7B). 
Dectin-1 and L6 cell surface expression was confirmed by flow cytometry (Figure 
3.7C-D). Together, these data suggest that over-expression of any four-
transmembrane protein does not inhibit dectin-1 signalling and that the inhibitory 
effect may be specific to tetraspanins.       
 
3.3.8 Evaluation of the level of tetraspanin over-expression and the role of 
palmitoylation in dectin-1 signal inhibition  
 
In the experiments conducted so far, it is not clear to what extent the tetraspanins were 
over-expressed compared to endogenous levels. Indeed, the previous experiments 
used mouse tetraspanins for which no antibodies were available. In order to determine 
the level of tetraspanin over-expression that is achieved in these experiments, human 
CD81 was selected because of the availability of antibodies and the strong 
endogenous expression on Jurkat, at about 10-fold over negative control staining as 
measured by flow cytometry (Figure 3.1).  
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 Cell surface expression of transfected CD81 was determined by flow cytometry 
(Figure 3.8A). Using mean fluorescence intensity (MFI) values it was possible to 
determine that there was approximately 10-fold over-expression of CD81 compared to 
mock-transfected cells. CD81 significantly inhibited dectin-1 signalling when 
stimulated with 250 μg/ml curdlan (Figure 3.8B). In addition, all transfection 
conditions responded similarly to positive control stimulations (Figure 3.8C) and 
dectin-1 was expressed at the cell surface as determined by flow cytomety (Figure 
3.8D). These data suggest 10-fold over-expression of a tetraspanin is sufficient to 
inhibit dectin-1 signalling.  
 
The role of palmitoylation was investigated, as it is thought palmitoylation is 
important for protein stability, localization, trafficking and protein-protein interactions 
(Berditchevski et al., 2002). Therefore, the utilisation of a CD81 palmitoylation 
mutant may affect dectin-1 signalling by tetraspanin over-expression. The CD81 
palmitoylation mutant was expressed at the cell surface as detemined by flow 
cytometry (Figure 3.8A). Despite this, dectin-1 signalling was still significantly 
inhibited by over-expression of the CD81 palmitoylation mutant (Figure 3.8B). These 
data suggest that palmitoylation is not required for dectin-1 signal inhibition by 
tetraspanin over-expression.        
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Figure 3.7 The L6 antigen does not affect dectin-1 signalling in Jurkat T-cells 
 
Jurkat T-cells were transiently transfected with an NFAT/AP-1-luciferase reporter 
construct, β-galactosidase construct, pEF6-MYC-dectin-1 (10 μg) and pCDNA3-L6 
(20 μg) or empty pEF6/pCDNA3 vector (mock). Cells were stimulated with media 
alone (unstimulated), curdlan (250 μg/ml) (A) and PMA/ionomycin (B) for six hours 
as indicated. Luciferase activity was measured following stimulation and transfection 
efficiency was corrected to β-galactosidase activity in individual experiments. The 
dectin-1 with curdlan stimulation value was set to 100% and other conditions 
presented were calculated relative to this. Analysis of variance (ANOVA) showed that 
there was no significant difference between groups. Error bars represent the standard 
error of the mean. Experiments were performed three times. (C-D) Cells were stained 
with either MYC or L6 antigen primary antibody and then anti-mouse FITC-
conjugated secondary antibody. Dead cells were gated out using propidium iodide. 
Antibody binding was visualized by flow cytometry. Dot plots were analysed and 
values indicate the average transfection efficiency (TF) and mean fluorescence 
intensity (MFI) of protein on the cell surface. Data is representative of three 
independent experiments. 
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Figure 3.8 Tetraspanin palmitoylation is not required for inhibition of dectin-1 
signalling 
 
Jurkat T-cells were transiently transfected with an NFAT/AP-1-luciferase reporter 
construct, β-galactosidase construct, pEF6-MYC-dectin-1 (10 μg) and pEF6-CD81 
(20 μg) or pEF6-CD81 palmitoylation mutant (P.M.) (20 μg) or empty pEF6 vector 
(mock). Cells were stimulated with media alone (unstimulated), curdlan (250 μg/ml) 
(B) and PMA/ionomycin (C) for six hours as indicated. Luciferase activity was 
measured following stimulation and transfection efficiency was corrected to β-
galactosidase activity in individual experiments. The dectin-1 with curdlan 
stimulation value was set to 100% and other conditions presented were calculated 
relative to this.  An unpaired Student’s t-test indicated a statistically significant 
difference (P<0.05) between dectin-1 transfected alone compared to dectin-1 co-
transfected with CD81 and CD81 P.M. as indicated *. Error bars represent the 
standard error of the mean. Experiments were performed three times. (A & D) Cells 
were stained with either MYC or CD81 primary antibody and then anti-mouse FITC-
conjugated secondary antibody. Dead cells were gated out using propidium iodide. 
Antibody binding was visualized by flow cytometry. Dot plots were analysed and 
values indicate the average transfection efficiency (TF) and mean fluorescence 
intensity (MFI) of protein on the cell surface. Data is representative of three 
independent experiments. 
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 3.3.9 Dectin-1 signalling is not inhibited by stable over-expression of the 
tetraspanin CD9 in Jurkat 
 
All experiments performed so far have used transient transfectants. It is possible that 
any tetraspanin that is transiently over-expressed might become the major component 
of tetraspanin microdomains on the cell, so disrupting microdomain function by 
displacing endogenous components. If this is true, one might predict that stable over-
expression of a tetraspanin would have less of an inhibitory effect because the cell 
might adapt to the presence of the stably over-expressed tetraspanin. However, this 
was not determined in this study, and full analysis of adaptation, possibly through 
upregulation of other tetraspanins, could be assessed when antibodies are available for 
all tetraspanins. In order to investigate whether a stably over-expressed tetraspanin 
could inhibit dectin-1-mediated signalling, CD9 was selected because of the 
availability of stably CD9-transfected Jurkat (generated by M.B. Protty). Firstly, to 
determine whether transiently over-expressed CD9, like other tetraspanins could 
inhibit dectin-1 signalling, dectin-1 and CD9 were transiently transfected into Jurkat. 
CD9 potently inhibited dectin-1 signalling by over 90% following stimulation with 
250 μg/ml curdlan (Figure 3.9A). All transfection conditions responded to control 
PMA and ionomycin stimulation, although a 4-fold decrease was observed upon 
dectin-1 and CD9 expression when compared to the mock-transfected cells, 
suggesting that the combination of dectin-1 and CD9 had a general inhibitory effect 
on this experiment (Figure 3.9B). However, even if data was expressed as a 
percentage of the PMA and ionomycin control, the data would still suggest that over-
expression of CD9 inhibits dectin-1 signalling. In addition, flow cytometry studies 
indicated expression of both dectin-1 and CD9 (Figure 3.9C-D).  
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 Dectin-1 signalling was next measured in stably CD9-expressing Jurkat cells. Stable 
CD9 over-expression in two transfected cell lines (AE9 & AE12) was first confirmed 
by flow cytometry, along with a human platelet control (Figure 3.9E); the latter is 
expressed at 49,000 copies per platelet (Higashihara et al., 1990; Protty et al., 2009). 
The CD9 expression levels were comparable to those in platelets and to those in the 
transient transfection experiment (Figure 3.9D & E). Dectin-1 was transiently 
transfected into Jurkat AE9 and AE12 and stimulated with 250 μg/ml curdlan. In 
contrast to the transient experiments, where dectin-1 signalling was inhibited by over 
90% (Figure 3.9A), dectin-1 signalling was only inhibited by about 40 to 50% in the 
two stable CD9 transfectants (Figure 3.9F). Moreover, ANOVA of the data suggested 
there was no significant difference between groups. As a control, all transfection 
conditions responded to PMA and ionomycin stimulation (Figure 3.9G). The PMA 
and ionomycin response for both mock transfected clones was a little higher than that 
of other transfectants. However, this does not detract from the conclusion of the 
experiment, as the PMA and ionomycin response for parental Jurkat transfected with 
dectin-1 compared to the stable CD9 clones following dectin-1 transfection was 
similar. Dectin-1 cell surface expression was not affected by the presence of CD9 
(Figure 3.9H). In summary, these data suggest that dectin-1 signalling is almost 
completely inhibited by transient tetraspanin over-expression, but is not significantly 
inhibited by stable over-expression.          
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Figure 3.9 Transiently, but not stably, over-expressed CD9 significantly inhibits 
dectin-1 signalling in Jurkat T-cells 
 
Jurkat T-cells were transiently transfected with an NFAT/AP-1-luciferase reporter 
construct, β-galactosidase construct, pEF6-MYC-dectin-1 (10 μg) and pEF6-CD9 (20 
μg) or empty pEF6 vector (mock). Cells were stimulated with media alone 
(unstimulated), curdlan (250 μg/ml) (A) and PMA/ionomycin (B) for six hours as 
indicated. Luciferase activity was measured following stimulation and transfection 
efficiency was corrected to β-galactosidase activity in individual experiments. The 
dectin-1 with curdlan stimulation value was set to 100% and other conditions 
presented were calculated relative to this. An unpaired Student’s t-test indicated a 
statistically significant difference (P<0.05) between dectin-1 transfected alone 
compared to dectin-1 co-transfected with CD9 as indicated *. Error bars represent the 
standard error of the mean. Experiments were performed three times. (C & D) Cells 
were stained with either MYC or CD9 primary antibody and then anti-mouse FITC-
conjugated secondary antibody. Dead cells were gated out using propidium iodide. 
Antibody binding was visualized by flow cytometry. Dot plots were analysed and 
values indicate the average transfection efficiency (TF) and mean fluorescence 
intensity (MFI) of protein on the cell surface. Data is representative of three 
independent experiments. (E) Jurkat T-cells, those stably-expressing CD9 (AE9 & 
AE12) and human platelets were stained with either mouse negative (closed 
histograms) or CD9 (open histograms) primary antibody and then anti-mouse FITC-
conjugated secondary antibody. Dead cells were gated out using propidium iodide. 
Antibody binding was visualized by flow cytometry. Data is representative of three 
independent experiments. Jurkat T-cells stably over-expressing CD9 were transiently 
transfected with an NFAT/AP-1-luciferase reporter construct, β-galactosidase 
construct, pEF6-MYC-dectin-1 (10 μg) or empty pEF6 vector (mock). Cells were 
stimulated with media alone (unstimulated), curdlan (250 μg/ml) (F) and 
PMA/ionomycin (G) for six hours as indicated. Luciferase activity was measured 
following stimulation and transfection efficiency was corrected to β-galactosidase 
activity in individual experiments. The dectin-1 (parental) with curdlan stimulation 
value was set to 100% and other conditions presented were calculated relative to this. 
Analysis of variance (ANOVA) showed that there was no significant difference 
between groups. Experiments were performed three times. (H) Cells were stained 
with MYC primary antibody and then anti-mouse FITC-conjugated secondary 
antibody. Dead cells were gated out using propidium iodide. Antibody binding was 
visualized by flow cytometry. Dot plots were analysed and values indicate the average 
transfection efficiency (TF) and mean fluorescence intensity (MFI) of protein on the 
cell surface. Data is representative of three independent experiments. 
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 3.4 DISCUSSION 
 
In this Chapter we have shown that over-expression of CD37, and the other 
tetraspanins CD9, CD81, CD82 and Tspan31 potently inhibit dectin-1-induced 
NFAT/AP-1 by over 90% in the Jurkat T-cell line. The observation was not dependent 
upon the tag attached to the tetraspanin, which has been suggested to interfere with 
certain types of protein-protein interaction (Wahl, Zoller & Claas; 2nd European Mini-
Symposium on Tetraspanins, Madrid, 2007). The data in this Chapter suggests that 
more than one tetraspanin has the ability to negatively regulate dectin-1 signalling in 
Jurkat, and in particular that dectin-1 regulation is not unique to CD37, as suggested 
previously (Meyer-Wentrup et al., 2007).  
 
In order to determine specificity, over-expression of the L6 antigen, which shares the 
four-transmembrane topology of the tetraspanin superfamily, did not inhibit dectin-1 
signalling, despite its potential for recruitment into tetraspanin-enriched 
microdomains (Lekishvili et al., 2008). This suggests that the effects observed may be 
specific to the tetraspanins, and that over-expression of any four-transmembrane 
protein will not inhibit dectin-1 signalling. Moreover, it was imperative to determine 
if tetraspanin over-expression would inhibit the signalling of any receptor that signals 
via a tyrosine kinase-linked mechanism in a similar manner to dectin-1. Therefore, the 
major platelet collagen receptor, GPVI, that signals in conjunction with the FcRγ 
chain via an ITAM was utilised. In contrast to dectin-1, over-expression of CD37, 
CD81, CD82 and Tspan31 did not significantly inhibit the signalling of GPVI.  
 
In addition, the role of palmitoylation in dectin-1 signal inhibition by tetraspanin 
over-expression was investigated by utilising a CD81 palmitoylation mutant. It is 
thought that palmitoylation is important for protein stability, localization, trafficking 
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 and protein-protein interactions (Berditchevski et al., 2002). However, data in this 
Chapter suggests that palmitoylation is not required for the inhibitory effect. 
 
The present results show that tetraspanin over-expression inhibits dectin-1 signalling 
in the Jurkat T-cell line. All initial experiments were transient in nature, and so Jurkat 
T-cells stably over-expressing CD9 were generated. In line with previous data, 
transient over-expression of CD9 inhibited dectin-1 signalling by over 90%. However, 
those Jurkat stably over-expressing CD9 did not exhibit significantly reduced dectin-1 
signalling, although interpretation of this data is complicated by the partial (40-50%) 
inhibition that was observed. One possibility is that transient over-expression of 
tetraspanins may disrupt the normal tetraspanin-enriched microdomain organisation, 
possibly by displacing endogenous proteins normally present within the 
microdomains, which may be essential for dectin-1-mediated signalling. The stable 
transfectants may have partially adapted to the presence of CD9, perhaps by 
modulating the expression of other tetraspanins or associated proteins, hence the 
partial reduction in dectin-1 signalling. 
 
The PMA and ionomycin stimulation used in this Chapter, and elsewhere in this 
thesis, is an important control that complements the transfection control that is 
included in each experiment, namely the transfection of a constitutively-expressed β-
galactosidase construct followed by a β-galactosidase assay, to which all data are 
normalised. The primary aim of PMA and ionomycin is to induce a relatively strong 
MAPK activation and calcium influx, respectively, that bypasses receptor-proximal 
events. This therefore determines whether the cells are still responsive to stimulation 
and have not become signalling incompetent following transfection. This is 
particulary important as tetraspanin over-expression has been shown to almost 
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 completely inhibit dectin-1 signalling in this Chapter. Interestingly, although a 
number of studies that have used NFAT/AP-1 luciferase reporter assays have 
presented their data in an identical manner to this thesis (Fuller et al., 2007; 
Tomlinson et al., 2004), most others have not. For example, many studies have not 
utilised the β-galactosidase control, instead presenting their data as a percentage of the 
PMA and ionomycin response (Seet et al., 2007; Tomlinson et al., 2007; Yablonski et 
al., 2001). Other studies have used β-galactosidase to normalise for transfection 
efficiency but have not shown PMA and ionomycin responses (Shan et al., 2000; 
Williams et al., 1997). The best way to normalise such data is thus debatable and 
different investigators clearly have their own preferences. However, if the product of 
transfection were to affect β-galactosidase expression or activity, this method of 
normalisation would be misleading. Similarly, if the transfection product affected 
signalling downstream of PMA and ionomycin, this would not be an ideal 
normalisation method. For these reasons, both β-galactosidase normalisation and 
PMA and ionomycin were presented in this thesis. 
 
There is clearly some variability in the degree of PMA and ionomycin response 
between transfections in this and subsequent Chapters. In this Chapter, between two- 
and five-fold variation in PMA and ionomycin responses were observed in four of the 
eight figures that contained luciferase data (3.4B, 3.6B, 3.7B and 3.9B & G). The 
reasons for these differences are not clear, but could be due to an effect of the 
transfection product on PMA and ionomycin signalling. For example, if over-
expression of the functionally uncharacterised tetraspanin Tspan31 could inhibit PMA 
and/or ionomycin responses, this could explain the 60% reductions observed in 
Figures 3.4B and 3.6B. Importantly, however, even if all of the data were expressed 
as ‘percentage of the PMA and ionomycin response,’ all conclusions drawn would 
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 have been entirely unchanged. Similar unexplained variations in PMA and ionomycin 
responses have been observed previously (Tomlinson et al., 2004). For example, 
constutively active Tec kinase constructs resulted in a dose dependent reduction in 
PMA and ionomycin signalling, perhaps due to the prior activation of negative 
feedback responses (Tomlinson et al., 2004). Mutant Tec constructs also caused up to 
a 60% reduction in PMA and ionomycin signalling, although in this case it did not 
correlate with constitutive signalling (Tomlinson et al., 2004). Finally, a fifteen-fold 
variation in PMA and ionomycin signalling was observed between wild-type and five 
different DT40 mutant cell lines, each mutation of which was upstream of PMA and 
ionomycin signalling (Tomlinson et al., 2004). In conclusion, PMA and ionomycin 
signalling, though relatively well understood, is likely to be affected by positive and 
negative feedback pathways that we do not understand. It is therefore important not to 
rely on PMA and ionomycin for normalisation of NFAT/AP-1 reporter assay data, but 
to include additional controls such as the β-galactosidase assay used throughout this 
thesis.    
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 3.5 SUMMARY 
In this Chapter it has been shown that transient over-expression of CD37 and other 
tetraspanins potently inhibit dectin-1-mediated signalling in an NFAT/AP-1-luciferase 
reporter assay in Jurkat. This model system will be useful for future mechanistic 
studies and to test for an inhibitory effect of tetraspanins on other family members 
such as CLEC-2. 
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CHAPTER 4 – 
 
INVESTIGATION OF THE MECHANISM BY WHICH 
TETRASPANINS INHIBIT DECTIN-1 SIGNALLING 
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 4.1 INTRODUCTION 
4.1.1 The mechanism of dectin-1 signal regulation by tetraspanins 
The tetraspanin CD37 has been shown to interact with and to negatively regulate 
dectin-1 signalling by an as yet unknown mechanism (Meyer-Wentrup et al., 2007). 
The authors hypothesise that CD37 may associate with a molecule that may 
dephosphorylate or sequester a key molecule involved in dectin-1 signalling. Indeed, 
the tetraspanin CD53 has been shown to associate with an unknown phosphatase 
(Carmo and Wright, 1995). As discussed in Chapter Three, the van Spriel group focus 
on primary cells, and as they are not readily transfected and thus not amenable to 
genetic manipulation, the mechanism of dectin-1 signal regulation by CD37 is not 
explored. In addition to CD37, the tetraspanin CD63 has been shown to co-
immunoprecipiate with dectin-1 in dendritic cells, using the relatively mild detergent 
CHAPS, suggesting that dectin-1 may be regulated within tetraspanin microdomains 
(Mantegazza et al., 2004).  
 
In Chapter Three, it has been shown that over-expression of multiple tetraspanins can 
inhibit dectin-1 signalling in the Jurkat T-cell line using an NFAT/AP-1-luciferase 
reporter assay. Therefore, the aim of this Chapter was to explore the mechanism of 
dectin-1 signal inhibition by tetraspanin over-expression by utilising several methods. 
These include using different leukocyte cell lines to determine whether the effects 
observed in Jurkat are specific to this cell type, RNAi-knockdown of tetraspanins and 
co-immunoprecipitation studies to determine whether tetraspanins interact with 
dectin-1.      
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 4.2 AIMS 
• To determine whether tetraspanins inhibit the capacity of dectin-1 to activate 
the AP-1 promoter.   
• To determine whether tetraspanins inhibit dectin-1 signalling in other 
leukocyte cell lines. 
• To determine the effect of Syk/Zap-70 family tyrosine kinases upon dectin-1 
signalling by tetraspanins. 
• To investigate the effect of tetraspanin knockdown on dectin-1 signalling.   
• To determine whether tetraspanins co-immunoprecipitate with dectin-1.  
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 4.3 RESULTS 
4.3.1 CD37 inhibits AP-1 activation by dectin-1 in Jurkat 
 
The data in Chapter Three showed that tetraspanins inhibit dectin-1-induced 
NFAT/AP-1 activation in Jurkat, which requires both calcium and MAPK signalling 
respectively. Therefore, there are three distinct mechanisms by which tetraspanins 
might inhibit the NFAT/AP-1 response: firstly by inhibiting dectin-1 from sending 
any signal; secondly by specifically inhibiting the calcium arm of the pathway; or 
thirdly by specifically inhibiting the MAPK pathway. To begin to address this issue, a 
MAPK-responsive reporter construct was used in which luciferase is driven by the 
AP-1 promoter only. 
 
Jurkat were transfected with NFAT/AP-1 or AP-1 luciferase reporters, dectin-1 and/or 
CD37 and stimulated with 250 μg/ml curdlan. Dectin-1 signalling was inhibited by 
over 90% when co-transfected with CD37 when either NFAT/AP-1 or AP-1 elements 
were used (Figure 4.1A). However, the degree of NFAT/AP-1 activation was 
relatively lower compared to AP-1. Consistent with this, NFAT/AP-1 activation 
following PMA and ionomycin stimulation was lower than that of AP-1 (Figure 
4.1B). Cell surface expression of dectin-1 was determined by flow cytometry and was 
similar between transfectants (Figure 4.1C). This data suggests that tetraspanins either 
specifically inhibit dectin-1-induced MAPK activation or inhibit dectin-1 signalling at 
a more receptor-proximal level. 
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Figure 4.1 CD37 inhibits AP-1 and NFAT/AP-1 activation by dectin-1 in Jurkat 
T-cells 
 
Jurkat T-cells were transiently transfected with an NFAT/AP-1- or AP-1-luciferase 
reporter construct, β-galactosidase construct, pEF6-MYC-dectin-1 (10 μg) and pEF6-
CD37 (20 μg) or empty pEF6 vector (mock). Cells were stimulated with media alone 
(unstimulated), curdlan (250 μg/ml) (A) and PMA or PMA plus ionomcyin (B) for six 
hours as indicated. Luciferase activity was measured following stimulation and 
transfection efficiency was corrected to β-galactosidase activity in individual 
experiments. The dectin-1 (NFAT/AP-1) with curdlan stimulation value was set to 
100% and other conditions presented were calculated relative to this.   An unpaired 
Student’s t-test indicated a statistically significant difference (P<0.05) between 
dectin-1 transfected alone compared to dectin-1 co-transfected with CD37 as 
indicated *. Error bars represent the standard error of the mean. Experiments were 
performed twice. (C) Cells were stained with MYC primary antibody and then anti-
mouse FITC-conjugated secondary antibody. Dead cells were gated out using 
propidium iodide. Antibody binding was visualized by flow cytometry. Dot plots 
were analysed and values indicate the average transfection efficiency (TF) and mean 
fluorescence intensity (MFI) of protein on the cell surface. Data is representative of 
two independent experiments.  
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 4.3.2 The tetraspanins CD9 and CD37 do not inhibit dectin-1 signalling in DT40 
B- and RBL-2H3 cells 
 
In order to determine whether the capacity of tetraspanins to inhibit dectin-1-induced  
NFAT/AP-1 activation is cell type dependent, chicken DT40 B- and rat RBL-2H3 
mast-cell lines were utilised to investigate the effect of tetraspanin over-expression 
upon dectin-1 signalling. In contrast to the Jurkat data, dectin-1 signalling in DT40 
cells was not inhibited in response to curdlan when co-transfected with CD9 and 
CD37 as determined by an NFAT/AP-1 reporter assay (Figure 4.2A). Antibodies were 
not available for mouse CD37, so human CD9 was selected for study, as antibodies 
are available to determine cell surface expression. All transfection conditions 
responded to the PMA and ionomycin control stimulation, although the combination 
of dectin-1 and CD37 transfection substantially increased NFAT/AP-1 activation 
(Figure 4.2B). Nevertheless, even if the data was expressed as a percentage of the 
PMA and ionomycin control, it would still suggest that CD37 over-expression does 
not inhibit dectin-1 signalling in DT40. Cell surface expression of both dectin-1 and 
CD9 was determined by flow cytometry and was similar between transfectants 
(Figures 4.2C & D). Similar data was gathered using the RBL-2H3 mast-cell line 
(Figure 4.3A-C), although in this experiment only CD37 was used and its expression 
was not confirmed because of the relatively low numbers of RBL-2H3 cells that were 
harvested following transfection. This demonstrates that the inhibition of dectin-1 
signalling by tetraspanin over-expression is dependent on the cell type in which these 
proteins are expressed. 
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Figure 4.2 Dectin-1 signalling is not inhibited when co-transfected with CD9 and  
CD37 in DT40 B-cells 
 
DT40 B-cells were transiently transfected with an NFAT/AP-1-luciferase reporter 
construct, β-galactosidase construct, pEF6-MYC-dectin-1 (5 μg), pEF6-CD9, CD37 
(2.5 μg) or empty pEF6 vector (mock). Cells were stimulated with media alone 
(unstimulated), curdlan (100 μg/ml) (A) and PMA/ionomycin (B) for six hours as 
indicated. Luciferase activity was measured following stimulation and transfection 
efficiency was corrected to β-galactosidase activity in individual experiments. The 
dectin-1 with curdlan stimulation value was set to 100% and other conditions 
presented were calculated relative to this.  Analysis of variance (ANOVA) of the data 
showed that there was no significant difference between dectin-1 and dectin-1 co-
transfected with either CD9 or CD37. Error bars represent the standard error of the 
mean. Experiments were performed twice. (C & D) DT40 B-cells were stained with 
MYC or CD9 primary antibody and then anti-mouse-FITC conjugated secondary 
antibody. Dead cells were gated out using propidium iodide. Antibody binding was 
visualized by flow cytometry. Dot plots were analysed and values indicate the average 
transfection efficiency (TF) and mean fluorescence intensity (MFI) of protein on the 
cell surface. Data is representative of two independent experiments. 
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 4.3.3 CD37 does not inhibit AP-1 activation by dectin-1 in DT40 
he failure of tetraspanins to inhibit dectin-1-induced NFAT/AP-1 activation in DT40 
the subtle difference between these cells and Jurkat in their response 
d with 100 μg/ml 
 
 
 
 
 
T
might be due to 
to ionomycin. For a reason that is not clear, ionomycin alone can induce weak 
NFAT/AP-1 activation in DT40 but not in Jurkat (Figure 4.4A & B). Therefore, if 
tetraspanins specifically inhibit dectin-1-induced MAPK activation, leaving the 
calcium arm of the pathway intact, this could partially explain why NFAT/AP-1 is not 
inhibited in DT40, as these cells have less of a requirement for AP-1 activation. If 
true, one would predict that tetraspanins would inhibit dectin-1-induced AP-1 
activation in DT40.  
 
To address this hypothesis, DT40 were transfected with the AP-1 luciferase reporter, 
or NFAT/AP-1 as a control, plus dectin-1 and/or CD37 and stimulate
curdlan. As found previously for NFAT/AP-1, dectin-1-induced AP-1 activation was 
not inhibited by CD37 in DT40 cells (Figure 4.5A). In positive control stimulations, 
all transfection conditions responded in a similar manner (Figure 4.5B) and cell 
surface expression of dectin-1 was similar between transfectants (Figure 4.5C). These 
data show that dectin-1 signalling, as detected by either AP-1 or NFAT/AP-1 
reporters, is not inhibited by tetraspanins in DT40. Moreover, the striking inhibitory 
effect of tetraspanins in Jurkat cannot be explained by a specific effect on the MAPK-
driven AP-1 pathway. 
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stimulated with media alone (unstimulated), PMA, ionomycin or PMA plus 
ionomycin for six hours as indicated. Luciferase activity was measured following 
stimulation and transfection efficiency was corrected to β-galactosidase activity in 
individual experiments. Error bars represent the standard error of the mean. Data is 
representative of three independent experiments.  
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Figure 4.5 CD37 does not inhibit AP-1 activation by dectin-1 in DT40 B-cells 
DT40 B-cells were transiently transfected with an NFAT/AP-1- or AP-1-luciferase 
reporter construct, β-galactosidase construct, pEF6-MYC-dectin-1 (5 μg) and pEF6-
CD37 (2.5 μg) or empty pEF6 vector (mock). Cells were stimulated with media alone 
(unstimulated), curdlan (100 μg/ml) (A) and PMA or PMA plus ionomycin (B) for six 
hours as indicated. Luciferase activity was measured following stimulation and 
transfection efficiency was corrected to β-galactosidase activity in individual 
experiments. The dectin-1 with curdlan stimulation value was set to 100% and other 
conditions presented were calculated relative to this. Analysis of variance (ANOVA) 
of the data suggests no difference between dectin-1 and dectin-1 co-transfected with 
CD37. Error bars represent the standard error of the mean. Experiments were 
performed twice. (C) Cells were stained with MYC primary antibody and then anti-
mouse FITC-conjugated secondary antibody. Dead cells were gated out using 
ropidium iodide. An  binding was flow cytometry. Dot plots 
ere analysed and values indicate the average transfection efficiency (TF) and mean 
uorescence intensity (MFI) of protein on the cell surface. Data is representative of 
o independent experiments.  
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 4.3.4 Tetraspanins inhibit dectin-1 signalling in Zap-70+/Syk- and Zap-70+/Syk+ 
urkat cell lines 
he p  in this t tet
regulate a component of the dectin-1 signalling pathway that is present in Jurkat but 
not in DT40 or RBL-2H3 cells. The list of po ies includes the tyro ases 
Lck, Itk and Zap-70, the adapter SLP-76 and the phospholipase PLCγ1. This is 
because for each of these proteins, a different family member is expressed in DT40 
and  
particularly promising candidate is Zap-70, since dectin-1 is known to signal by 
interacting with and activating Syk/Zap-70 fa rosine kinases. Could anin 
over-expression result in inhibition of Zap-70 but not Syk? Interestingly, there are two 
major Jurkat clones that are commonly used, the E6.1 clone, used in earlier sections, 
hich expresses Zap-70 but not Syk, and the DNAX Jurkat clone that expresses both 
ap-70 and Syk (Fargnoli et al., 1995)
ap-70 but not Syk, the latter would be expected to compensate Zap-70 and abrogate 
e inhibitory effect of tetraspanin over-expression, thus similar to the lack of 
duced NFAT/AP-1 activation in all cases, with some 
J
 
T revious sections Chapter suggest tha raspanins may negatively 
ssibilit sine kin
RBL-2H3 cells, namely Lyn, Btk, Syk, BLNK and PLCγ2 (Figure 1.11). A 
mily ty  tetrasp
w
Z . If tetraspanin over-expression does inhibit 
Z
th
inhibition observed previously in Syk-expressing DT40 and RBL-2H3 cells. 
 
An NFAT/AP-1-luciferase reporter assay was therefore performed to compare the 
effect of CD9 on dectin-1-induced NFAT/AP-1 activation in Zap-70+/Syk- (E6.1 
Jurkat clone) versus Zap-70+/Syk+ (DNAX Jurkat clone). CD9 was selected due to the 
availability of antibodies to determine cell surface expression. In both Jurkat clones, 
dectin-1 signalling was inhibited by over 90% when co-transfected with CD9 
following stimulation with curdlan (Figure 4.6A). This strongly suggests that 
tetraspanin over-expression does not inhibit Zap-70 while leaving Syk function intact. 
Positive control stimulations in
 131
 variation observed between transfections (Figure 4.6B). However, in the Jurkat E6.1 
clone, the PMA and ionomycin response in both the dectin-1 and dectin-1/CD9 
transfectants were almost identical, although 50% that of the mock. Moreover, in the 
DNAX Jurkat clone the PMA and ionomycin response, following transfection of 
dectin-1, alone was two- to three-fold higher than mock and dectin-1/CD9 transfected 
cells (Figure 4.6B). This suggests a partial (three-fold) inhibitory effect of CD9 over-
expression on maximal NFAT/AP-1 activation. But this cannot explain the almost 
complete inhibition of dectin-1-induced NFAT/AP-1 activation, as seen by comparing 
the similar ‘mock curdlan’ with ‘dectin-1 & CD9 curdlan’ data (Figure 4.6A). In 
addition, expression of both dectin-1 and CD9 was similar between the two Jurkat 
clones (Figure 4.6C & D). Together these data suggest that tetraspanin over-
expression does not inhibit dectin-1 signalling by a mechanism which involves 
specific inhibition of Zap-70, with Syk function remaining intact. 
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Figure 4.6 CD9 significantly inhibits dectin-1 signalling in E6.1 or DNAX Jurkat 
T-cell clones 
 
Jurkat T-cells, either E6.1 or DNAX clones, were transiently transfected with an 
NFAT/AP-1-luciferase reporter construct, β-galactosidase construct, pEF6-MYC-
dectin-1 (10 μg), pEF6-CD9 (20 μg) or empty pEF6 vector (mock). Cells were 
stimulated with media alone (unstimulated), curdlan (250 μg/ml) (A) and 
rs as indicated. Luciferase activity was easured 
imulation and transfection efficiency was corrected to β-galactosidase 
ctivity in individual experiments. The de with curdlan stimulation value (E6.1 
 DNAX Jurkat) was set to 100% and other conditions presented were calculated 
lative to this.  An unpaired Student’s t-test indicated a statistically significant 
ifference (P<0.05) between dectin-1 transfected alone compared to dectin-1 co-
ansfected with CD9 as indicated *. Error bars represent the standard error of the 
ean. Experiments were performed twice. (C & D) Jurkat T-cells, either E6.1 or 
NAX clones, were stained with either MYC or CD9 primary antibody, followed by 
nti-mouse-FITC-conjugated secondary antibody. Dead cells were gated out using 
ropidium iodide. Antibody binding was visualized by flow cytometry. Dot plots 
ere analysed and values indicate the average transfection efficiency (TF) and mean 
uorescence intensity (MFI) of protein on the cell surface. Data is representative of 
o independent experiments. 
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 4.3.5 CD81 knockdown does not affect dectin-1-induced NFAT/AP-1 
n RNAi approach was performed on CD81 to determine the effect of knockdown of 
is protein upon dectin-1 signalling, as previous experiments have primarily involved 
traspanin over-expression. Moreover, the CD37 knockout was previously shown to 
sult in hyper-responsive dectin-1 on primary mouse macrophages (Meyer-Wentrup 
t al., 2007). CD81 was selected due to its high expression on Jurkat (Figure 3.1) and 
e availability of CD81 siRNA duplexes, previously shown to cause 100% 
nockdown of CD81 on human umbilical cord endothelial cells (M.G. Tomlinson, 
npublished data). Control or CD81 siRNA duplexes were transfected into Jurkat in 
e presence or absence of dectin-1, and two days post transfection the cells were 
imulated with curdlan. Dectin-1-induced NFAT/AP-1 activation was not affected by 
D81 knockdown (Figure 4.7A & B). Flow cytometry demonstrated substantial 
D81 knockdown in greater than 50% of the cells and no knockdown in the 
mainder (Figure 4.7C). The latter probably represent non-transfected cells that also 
iled to take up the expression constructs and the NFAT/AP-1 reporter, and thus did 
 to the assay. Similar dectin-1 surface expression between control and 
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CD81 siRNA transfectants was also confirmed by flow cytometry (Figure 4.7D). 
Therefore, this data suggests that knockdown of CD81, unlike tetraspanin over-
expression, does not affect the ability of dectin-1 to signal.     
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Figure 4.7 CD81 knockdown does not affect dectin-1 signalling in Jurkat T-cells 
rkat T-cells were transiently transfected with an NFAT/AP-1-luciferase reporter 
construct, β se, pE p
either CD81 or contr
nstimulated), curdlan (250 μg/ml) (A) and PMA/ionomycin (B) for six hours as 
dicated. Luciferase activity was measured following stimulation and transfection 
ficiency was corrected to β-galactosidase ac n individual experim he 
ctin-1 and control RNAi with curdlan stimulation value was set to 100% and other 
nditions presented were calculated relative to this. Error bars represent the standard 
ror of the mean. Analysis of variance (ANOVA) of the data suggested no significant 
fference between groups. Experiments were performed twice. (C & D) Cells were 
ed with either negative (closed histograms), CD81 (open histograms) or MYC
primary antibody and then anti-mouse FITC-conjugated secondary antibody. Dead 
lls were gated out using propidium io ts/histograms were analysed and 
alues indicate the average transfection e d/or mean fluorescence 
intensity (MFI) of protein on the cell surface. Data is representative of two 
dependent experiments.    
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 4.3.6 Tetraspanins do not co-immunoprecipitate with dectin-1 in Jurkat 
 is possible that tetraspanins inhibit dectin-1 signalling through a direct interaction, 
iven that the van Spriel group has shown an interaction between dectin-1 and CD37 
in HEK293T cells (Meyer-Wentrup et al., 2007). To test for such an interaction in 
Jurkat, cells were transiently transfected with MYC-tagged dectin-1 and the FLAG-
tagged tetraspanins CD37 and CD151, both of which inhibit dectin-1 signalling 
(Figures 3.3A & 3.5A). Cells were lysed in the relatively mild detergent Brij97 that is 
thought to maintain tetraspanin-tetraspanin interactions (Hemler, 2005), 
immunoprecipitated for tetraspanins (FLAG) and blotted for dectin-1 (MYC). Neither 
CD37 nor CD151 co-immunoprecipitated with dectin-1 (Figure 4.8A). However, 
dectin-1 was detected in whole cell lysate samples (Figure 4.8B) and both tetraspanins 
were detected in the immunoprecipitates, although CD37 appeared to be expressed at 
a lower level than CD151 (Figure 4.8C). This data suggests that tetraspanins do not 
interact with dectin-1 in Jurkat, although it is possible that there is a relatively low 
affinity interaction that is lost during cell lysis and immunoprecipitation. However, as 
this experiment was performed once and no positive control was used, it may be 
necessary to repeat with a suitable control for studies in the future.     
traspanin-tetraspanin interactions but maintain some stronger tetraspanin-partner 
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4.3.7 Tetraspanins co-immunoprecipitate with dectin-1 in HEK293T-cells 
 
The failure to detect a dectin-1 interaction with CD37 was surprising since the 
proteins were previously shown to co-immunoprecipitate from transfected HEK293T 
cells (Meyer-Wentrup et al., 2007). In an attempt to repeat this and to determine 
whether the interaction is specific to CD37, HEK293T cells were transiently 
transfected with MYC-tagged dectin-1 and a panel of 18 FLAG-tagged tetraspanins. 
Cells were lysed in the stringent detergent Triton X-100 that is thought to disrupt 
te
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 interactions (Hemler, 2005). Transfected HEK293T cell lysates were 
precipitation of 
ndogenous levels from platelet lysates failed to identify an interaction (Protty et al., 
009). Together these data reinforce the widely-held belief that co-
immunoprecipitation studies of highly over-expressed proteins are prone to artefacts, 
and provide no definitive evidence that dectin-1 interacts with tetraspanins.    
 
 
 
 
immunoprecipitated for tetraspanins with FLAG antibody and blotted for dectin-1 
with MYC. Consistent with Meyer-Wentrup et al. (2007), dectin-1 was readily 
detected following CD37 immunoprecipitation (Figure 4.9A), the positive control in 
this experiment. However, all other tetraspanins, with the exception of Tspan31, were 
also readily detected. As a negative control, dectin-1 was not detected in FLAG 
immunoprecipitations from control cells that lacked tetraspanin transfection (Figure 
4.9A). The efficiency of dectin-1 co-immunoprecipitation differed between 
tetraspanins, but interpretation is complicated by different levels of transfected dectin-
1, as detected by MYC blotting of whole cell lysates (Figure 4.9B), and tetraspanins, 
as detected by FLAG blotting of immunoprecipitates (Figure 4.9C). Nevertheless, this 
data raises the possibility that dectin-1 has a general affinity for tetraspanins that 
might only be revealed when the proteins are co-expressed at relatively high levels in 
a cell such as HEK293T. However, this HEK293T data may be an artefact of the high 
levels of over-expression. Consistent with this idea, multiple tetraspanin interactions 
have also been observed between tetraspanins and the major platelet integrin αIIbβ3 in 
HEK293T cells (Figure 4.10), under conditions in which co-immuno
e
2
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igure 4.8 Tetraspanins do not co-immunoprecipitate with dectin-1 in Jurkat 
rkat cells were lysed in 1% Brij97 after transient transfection with dectin-1 (20 μg) 
nd tetraspanins (20 μg) and immunoprecipitated (IP) for tetraspanins (FLAG) for 1.5 
ours. Proteins were visualised by SDS-PAGE and western blotting with indicated 
ntibodies. In panel A, only the light chain from the immunoprecipitating antibody is 
etectable. This experiment was performed once. 
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igure 4.9 Tetraspanins co-immunoprecipitate with dectin-1 in HEK293T cells F
 
HEK293T cells were lysed in 1% Triton X-100 two days after transient transfection 
with dectin-1 (5 μg) and tetraspanins (5 μg) and immunoprecipitated (IP) for 
tetraspanins (FLAG) for 1.5 hours. Proteins were visualised by SDS-PAGE and 
western blotting with indicated antibodies. CD37 has previously been shown to co-
immunoprecipitate with dectin-1 in HEK293T cells (Meyer-Wentrup et al., 2007) 
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igure 4.10 Tetraspanins co-immunoprecipitate with α β  in HEK293T cells 
 
 
 
 
 αIIbβ3  
 
- C
D
9 
 
Ts
pa
n3
1 
Ts
pa
n3
3  
C
D
37
C
D
63
 
C
D
81
 
C
D
82
 
C
D
15
1 
Ts
pa
n3
Ts
pa
n3
 2 
Ts
pa
n1
4 
Ts
pa
n1
5 
Ts
pa
n1
7 
Ts
pa
n1
8 
Ts
pa
n4
 
Ts
pa
n5
 
Ts
pa
n6
 
Ts
pa
n9
 
 
IP: tetraspa
(FLAG
nin 
) 
β3 
) 
WCL 
β3 
) 
in 
B spanin 
(FLAG) 
 
 
 
 
 
 
 
 
 
 
 
F IIb 3
 
HEK293T cells were lysed in 1% Brij97 two days after transient transfection with 
αIIbβ3 (5 μg) and tetraspanins (5 μg) and immunoprecipitated (IP) for tetraspanins 
(FLAG) for 1.5 hours. Proteins were visualised by SDS-PAGE and western blotting 
with indicated antibodies. 
175 αIIb 
Blot: αIIb
(MYC
β3 
83 
αIIb 175 
Blot: αIIb
(MYCβ  3 83 
175 
33 
25 
17 
48 
83 
62 
IP: tetraspan
lot: tetra
 146
 4.4 DISCUSSION 
 this Chapter a number of methods have been utilised to investigate the mechanism 
f dectin-1 signal inhibition by tetraspanin over-expression in the Jurkat T-cell line. 
everal hypotheses have been tested and further work is necessary to fully elucidate 
ossible mechanisms.  
he data in Chapter Three showe hat tetraspanin over-expression inhibits dectin-1-
duced NFA at ires both 
alcium, to activate NFAT, and MAPK, to activate AP-1, it is possible th
nhibits either calcium or MAPK signalling. This was 
vestigated using an AP-1 reporter construct because of the unavailability of a go
milar to the NFAT/AP-1 data, CD37 was 
found to almost completely inhibit dectin-1-induced AP-1 activation. This suggests 
that either tetraspanins specifically inhibit signalling at a more receptor-proxim
level, before the pathway bifurcates at the level of PLCγ, or that tetraspan
specifically inhibit the calcium arm of the pathway. This calcium possibility could
investigated further using calcium imaging experiments. However, it seems mo
likely that there is a specific inhibition of the proximal events in dectin-1 si nalli
his is due to the fact that tetraspanins do not inhibit GPVI signalling, as shown in 
hapter Three: it is difficult to imagine how tetraspanins could inhibit calcium 
gnalling downstream of dectin-1 but not GPVI, because both utilise a similar 
rosine kinase/PLCγ/calcium pathway. 
by 
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NFAT reporter (Shapiro et al., 1996). Si
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A key question was to determine whether inhibition of dectin-1 signalling 
tetraspanin over-expression was specific to the Jurkat T-cell line. Therefore, the DT40 
B- and RBL-2H3 mast cell lines, both of which are established models to study 
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 tyrosine kinase-linked receptor signalling (Fuller et al., 2007; Tomlinson et al., 2007), 
 different cell lines, because flow cytometry proved them to be 
milar. Instead, the contrasting findings may be attributed to the different signalling 
ng tetraspanin over-expression in Jurkat. 
were selected to answer the question. However, unlike in Jurkat, tetraspanin over-
expression did not inhibit dectin-1 signalling in DT40 B- and RBL-2H3 cell lines. 
Such a striking difference did not appear to be due to different tetraspanin or dectin-1 
expression levels in the
si
proteins in these cell lines. One potential candidate is the tyrosine kinase Syk, which 
appears to be central to dectin-1 signalling through interaction with the YXXL motif 
in the cytoplasmic tail of the receptor. Interestingly, Syk is expressed in DT40 and 
RBL-2H3 but not in the Jurkat clone used in this thesis, clone E6.1, which instead 
expresses Zap-70 (Fargnoli et al., 1995). This was explored further by comparing 
dectin-1 signalling in Jurkat that express Zap-70 (clone E6.1), versus those that 
express both Zap-70 and Syk (so-called ‘DNAX Jurkat’). However, no difference 
between the two clones was observed in dectin-1 signal inhibition by tetraspanin over-
expression. This line of enquiry could be explored further by using Jurkat deficient in 
both Zap-70 and Syk. In addition, in Jurkat the dectin-1 signal is thought to be 
initiated by the Src family kinase Lck (Fuller et al., 2007), whereas Lyn and Fyn are 
the main players in DT40 and RBL-2H3 cells. The possibility of a specific tetraspanin 
effect on Lck has been suggested previously, since the hyperproliferative phenotype 
observed in CD37-deficient T-cells was found to be accompanied by elevated Lck 
kinase activity (van Spriel et al., 2004). It would be interesting to test whether dectin-
1-induced Lck activity is impaired followi
Moreover, it would be useful to generate stable Lck transfectants of Lyn-deficient 
DT40, to test whether tetraspanins could now inhibit dectin-1 signalling in this cell 
line. 
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In antigen-presenting cells from the CD37-deficient mouse, the observed increase in 
dectin-1 signalling might be due to an indirect effect caused by disruption of 
tetraspanin microdomains, rather than the proposed specific CD37-dectin-1 
interaction (Meyer-Wentrup et al., 2007). To perform a somewhat analogous 
experiment in Jurkat, which express minimal CD37 but substantial levels of CD81, 
the latter was knocked down using RNAi. However, despite a substantial proportion 
of cells exhibiting almost complete CD81-knockdown, which presumably reflects 
those 
If tetraspanin over-expression inhibits receptor-proximal signalling, a substantial 
decrease in tyrosine phosphorylation should in theory be observed. In an attempt to 
perform this experiment, Jurkat were transiently transfected with dectin-1, in the 
presence or absence of a tetraspanin, to study tyrosine phosphorylation over a time 
course following stimulation with curdlan. However, no inducible phosphorylation 
was observed, even in the absence of tetraspanin over-expression (data not shown). 
This may have been due to the relatively low transfection efficiencies achieved in 
Jurkat (approximately 5-6% dectin-1-positive cells), combined with the fact that 
dectin-1 and related receptors induce only relatively weak tyrosine phosphorylation in 
cell lines (J. Mori, personal communication). To attempt to address this issue in 
future, large-scale transfections could be followed by flow cytometry-based sorting of 
transfected cells. Alternatively, cells could be co-transfected with an epitope-tagged 
form of a signalling protein such as PLCγ1. Following cell stimulation, this ‘reporter 
protein’ could be immunoprecipitated with an anti-tag antibody and tyrosine 
phosphorylation detected by western blotting. This is an approach that has previously 
proved successful in Jurkat co-transfection experiments (Tomlinson et al., 2004).  
 
that were successfully transfected, no effect on dectin-1 signalling was 
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 observed. There are a number of interpretations of this experiment. Firstly, it is 
possible that knockdown of CD81 does not disrupt tetraspanin microdomains in 
Jurkat to the same extent as over-expression of tetraspanins does. Secondly, it is 
possible that endogenous CD81 plays no role in dectin-1 signalling. These 
possibilities could be further investigated by knocking down other Jurkat tetraspanins, 
either alone or in combination.    
 
ctly 
ffect other proteins is not without precedent. Indeed, studies of the urokinase 
receptor, which is involved in plasminogen activation and proteolytic activity, 
indicate that its activity is reduced in the presence of CD82 over-expression, despite 
the authors finding no association between this receptor and tetraspanins at the cell 
surface and by co-immunoprecipitation studies (Bass et al., 2005). Despite the failure 
in this Chapter to detect dectin-1 co-immunoprecipitation with tetraspanins in Jurkat, 
studies were extended to determine whether a panel of 18 tetraspanins could interact 
with dectin-1 in HEK293T cells using the relatively stringent detergent Triton X-100. 
This particular cell line was utilised by the van Spriel group to show that dectin-1 and 
Finally, co-immunoprecipitation studies in Jurkat suggest that dectin-1 is not a 
component of tetraspanin microdomains, as no interaction was observed between 
dectin-1 and the tetraspanins CD37 and CD151 in the relatively weak detergent 
Brij97, which is thought to maintain the integrity of tetraspanin microdomains by 
preserving tetraspanin-tetraspanin interactions (Hemler, 2005). Therefore, tetraspanin 
over-expression appears to somehow inhibit dectin-1 signalling without actually 
interacting with the receptor. It is possible that tetraspanin over-expression might 
indirectly affect dectin-1 signalling by disrupting tetraspanin microdomains, leading 
to the release of factors which inhibit dectin-1 signalling. This speculative idea will be 
expanded upon in Chapter Seven. However, the idea that tetraspanins can indire
a
 150
 CD37 interact (Meyer-Wentrup et al., 2007). However, data in this Chapter suggests 
that multiple tetraspanins may have the ability to interact with dectin-1 in HEK293T 
cells, which is difficult to envisage unless the receptor has a general tetraspanin-
binding pocket. It is more likely that the interaction in HEK293T cells is an artefact of 
the very high expression levels that can be achieved in this cell line. Consistent with 
this, all tetraspanins were similarly able to co-immunoprecipitate an unrelated protein, 
tegrin αIIbβ3, in these cells. This data suggests that co-immunoprecipitation studies 
in HEK293T cells may not be suitable to identify potential tetraspanin-partner protein 
interactions, and that they should be interpreted with some caution, as any interactions 
may be an over-expression artefact.        
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 4.5 SUMMARY 
In this Chapter a number of methods have been employed to investigate how 
tetraspanin over-expression inhibits dectin-1 signalling in Jurkat. These studies have 
demonstrated that tetraspanins inhibit both NFAT/AP-1 and AP-1 reporter activation 
by dectin-1. However, no such inhibition was observed in two other model cell lines, 
the DT40 B- and the RBL-2H3 mast-cell lines, suggesting that tetraspanins regulate a 
Jurkat-specific signalling protein. In addition, knockdown of CD81 did not affect 
dectin-1 signalling in Jurkat. Finally, co-immunoprecipitation experiments failed to 
definitively determine whether dectin-1 interacts with tetraspanins. No interaction was 
observed in transfected Jurkat using the detergent Brij97, but an interaction was 
etected between dectin-1 and many tested tetraspanins in transfected HEK293T cells 
using the detergent Triton X-100. The latter may be an artefact of the relatively high 
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expression levels than can be achieved.   
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TETRASPANIN OVER-EXPRESSION INHIBITS CLEC-2 
SIGNALLING 
 
 
 
CHAPTER 5 – 
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 5.1 INTRODUCTION 
LEC-2 signals via a single YXXL motif that undergoes tyrosine phosphorylation to 
duce platelet aggregation with a distinct lag phase when stimulated with its ligand, 
the snake venom toxin rhodocy ., 2006). As well as studies in 
DT40 B- and Jurkat T-cell mut ignalling pathway downstream 
f this receptor (Fuller et al., 2007). Together these studies have generated a model in 
nd 
PLCγ, but is only partially dependent on the SLP-76/BLNK family of adaptor 
proteins (Fuller et al., 2007). 
 
In the previous Chapters, tetraspanin over-expression was shown to inhibit signalling 
by dectin-1. Since CLEC-2 is a member of the dectin-1 family sharing the CTLD and 
cytoplasmic YXXL signalling motif, it is possible that tetraspanins also negatively 
regulate CLEC-2. At present, there has been no published literature regarding the 
ability of tetraspanins to regulate CLEC-2 signalling. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C
in
tin (Suzuk Inoue et ali-
platelets from mutant mice, the NFAT/AP-1-luciferase reporter assay has been used in 
ant lines to study the s
o
which CLEC-2 signalling requires Src, Syk and Tec family tyrosine kinases a
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 5.2 AIM 
 
• To determine whether tetraspanin over-expression inhibits CLEC-2 signalling 
in a model cell line. 
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 5.3 RESULTS 
 
onstrated that, in Jurkat cells, transfected CLEC-2 
duces NFAT/AP-1 activation in response to its ligand rhodocytin (Fuller et al., 
007). To establish dose response data and to ultimately determine whether 
traspanins affect the signalling of CLEC-2, Jurkat cells were initially transfected 
ith four different amounts of a CLEC-2 expression construct. The degree of 
FAT/AP-1 activation was measured in response to 50 nM rhodocytin, a 
ncentration used previously in this assay (Fuller et al., 2007). Rhodocytin-induced 
FAT/AP-1 activation was maximal at 10 μg of the CLEC-2 expression construct 
igure 5.1A). As a positive control, all transfection conditions responded to PMA 
d ionomycin, although there is an unexplainable downwards trend in the degree of 
sponse (Figure 5.1B). Despite this, there was still a robust response even when 20 
g of CLEC-2 was stimulated with PMA and ionomycin. Consistent with the 
FAT/AP-1 data, the percentage of cells expressing CLEC-2 at the surface increased 
ith increasing amounts of transfected CLEC-2, to a maximal level with 10 μg of the 
pression construct (Figure 5.1C). As a result of the data gathered, 10 μg CLEC-2 
as used in all subsequent experiments to investigate whether tetraspanins inhibit the 
gnalling of this receptor. 
3.2 Tetraspanins inhibit CLEC-2 signalling in Jurkat 
o determine whether CD37 and the platelet-expressed tetraspanins CD9, CD63, 
D151 and Tspan32 could inhibit CLEC-2 signalling, Jurkat cells were co-transfected 
ith the NFAT/AP-1-luciferase construct and CLEC-2 in the presence or absence of 
ch tetraspanin. In each case, the tetraspanin abolished CLEC-2-induced NFAT/AP-
 
5.3.1 Rhodocytin induces NFAT/AP-1 activation in CLEC-2-transfected Jurkat 
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 1 activation (Figure 5.2A). Moreover, all transfection conditions responded robustly 
 
 
 
 
 
 
 
 
 
 
 
to positive control stimulations, with some variability in the magnitude of the
response (Figure 5.2B). The degree of PMA and ionomycin stimulation between 
mock, CLEC-2, CLEC-2-CD9 and CLEC-2-CD63 was robust and similar in response. 
However, the degree of PMA and ionomcyin response between CLEC-2-CD151, 
CLEC-2-Tspan32 and CLEC-2-CD37 was relatively weak in comparison. Despite 
this, the PMA and ionomycin data does not retract from the fact that over-expression 
of all tetraspanins tested inhibit CLEC-2 signalling following rhodocytin stimulation. 
In addition, CLEC-2 cell surface expression was not affected by tetraspanin 
expression (Figure 5.2C). This suggests that signal inhibition was not due to reduced 
cell surface expression of CLEC-2 when co-transfected with tetraspanins compared to 
receptor alone. This data shows that a number of tetraspanins inhibit the signalling of 
CLEC-2.  
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Figure 5.1 Rhodocytin induces NFAT/AP-1 activation in a CLEC-2 dose-
dependent manner in Jurkat T-cells 
 
Jurkat T-cells were transiently transfected with an NFAT/AP-1-luciferase reporter 
construct, β-galactosidase construct, pEF6-MYC-CLEC-2 or empty pEF6 vector 
(mock). Cells were stimulated with media alone (unstimulated), rhodocytin (50 nM) 
(A) and PMA/ionomycin (B) for six hours as indicated. Luciferase activity was 
measured following stimulation and transfection efficiency was corrected to β-
galactosidase activity in individual experiments. The CLEC-2 (10 μg) with rhodocytin 
stimulation value was set to 100% and other conditions presented were calculated 
relative to this. Error bars represent standard error of the mean. Experiments were 
performed three times. (C) Cells were stained with MYC primary antibody and then 
anti-mouse FITC-conjugated secondary antibody. Dead cells were gated out using 
ropidium iodide. Dot plots were analysed and values indicate the average 
ansfection efficiency (TF) and mean fluorescence intensity (MFI) of protein on the 
 three independent experiments.   
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Figure 5.2 Tetraspanin over-expression inhibits CLEC-2 signalling in Jurkat T-
cells 
 
Jurkat T-cells were transiently transfected with an NFAT/AP-1-luciferase reporter 
construct, β-galactosida C-CLE F6-CD37, 
CD9, CD63, CD151, Tspan32 (20 pty pEF6 vector (m
stimulated with media alone (unstimulated), rhodocytin (50 nM) (A) and 
PMA/ionomycin (B) for six hours as indicated. Luciferase activity was measured 
following stimulation and transfe ficiency was correcte -galactosidase 
activity in individual experiments. The CLEC-2 with rhodocytin stimulation value 
was set to 100% and other conditions presented were calculated relative to this. An 
unpaired Student’s t-test indicated a statistically significant difference (P<0.05) 
between CLEC-2 transfected alone compared to CLEC-2 co-transfected with the 
traspanins as indicated *. Error bars represent standard error of the mean. 
xperiments were performed twice. (C)  stained with MYC primary 
tibody and then anti-mouse FITC-conjug dary antibody and analysed by 
ow cytometry. Dead cells were gated out using propidium iodide. Dot plots were 
alysed and values indicate the average transfection efficiency (TF) and mean 
uorescence intensity (MFI) of protein on the cell surface. Data is representative of 
o independent experiments.  
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 5.4 DISCUSSION 
 this Chapter, over-expression of CD37 or the platelet-expressed tetraspanins CD9, 
D63, CD151 and Tspan32 was shown to potently inhibit CLEC-2-induced 
FAT/AP-1 in the Jurkat T-cell line. Such data is remarkably similar to that of 
ectin-1 signal inhibition by tetraspanin over-expression in Jurkat cells, as described 
 Chapter Three.  
he data in this Chapter suggests that tetraspanins may have the ability to regulate the 
gnalling of CLEC-2 and dectin-1, compared to other receptors that signal via a 
milar tyrosine kinase-linked mechanism, for example, the platelet collagen receptor, 
PVI. Unlike some of the data for dectin-1 and tetraspanins, the level of tetraspanin 
ver-expression required to inhibit CLEC-2 signalling was not determined. However, 
e powerful inhibition of CLEC-2 signalling would suggest that the tetraspanins were 
xpressed in this assay. It is tempting to speculate that tetraspanins may be the global 
gulators of this family as a result of the data gathered in respect of both dectin-1 and 
ine whether tetraspanins regulate this receptor, as it signals via a single YXXL 
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CLEC-2. The recently identified CLEC9A would be an ideal candidate to study to 
etermd
motif contained within the cytoplasmic tail (Huysamen et al., 2008).  
 
There is the possibility that tetraspanins may regulate CLEC-2 on platelets. Indeed, 
there are differences between CLEC-2 and GPVI signalling on the platelet, and an 
association with a tetraspanin may be a possible explanation. For example, CLEC-2 
signals as a dimer via two single YXXL motifs whereas GPVI signals via an ITAM; 
upon CLEC-2 stimulation with its ligand rhodocytin there is a distinct lag phase 
before the onset of shape change and aggregation compared to GPVI stimulation; and 
there is a partial dependence on the SLP-76/BLNK family of adaptor proteins in 
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 respect of CLEC-2 compared to GPVI (Fuller et al., 2007; Suzuki-Inoue et al., 2006; 
 
 
 
 
 
 
 
 
 
 
Watson et al., 2001). Therefore, data gathered in this Chapter paves the way for 
CLEC-2-induced platelet aggregation in response to rhodocytin stimulation to be 
investigated using mice deficient in a tetraspanin.    
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 5.5 SUMMARY 
 
In this Chapter it has been shown that tetraspanins completely inhibit CLEC-2 
signalling. These data suggest that the dectin-1/CLEC-2/CLEC9A family might be 
regulated by tetraspanins and that CLEC-2 signalling might be abnormal in 
traspanin-deficient platelets.  
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CLEC-2 SIGNALLING IS NORMAL IN CD9-DEFICIENT 
PLATELETS 
 
          
 
 
CHAPTER 6 – 
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 6.1 INTRODUCTION 
6.1.1 CLEC-2 and platelets 
human haematopoietic cells, including 
monocytes, granulocytes, dendr Colonna et al., 2000; Kerrigan 
et al., 2009; Suzuki-Inoue et al., 2006). C
mouse platelets as a receptor for in rhodocytin by Suzuki-Inoue 
et al. (2006) using rhodocytin affinity chromatography and mass spectrometry. 
dy 
ads to a specific loss of CLEC-2 in circulating platelets for several days resulting in 
efective aggregate formation in vivo and in vitro, and as a consequence increased 
leeding times and impaired occlusive thrombus formation (May et al., 2009). In 
addition, the transmembrane glycoprotein podoplanin was found to be a ligand for 
LEC-2 (Suzuki-Inoue et al., 2007). Podoplanin is expressed on tumour cells, 
mphatic endothelial cells and renal cells (podocytes), and the physiological 
th podoplanin has yet to be determined 
(Christou et al., 2008; Ozaki et al., 2009; Wicki and Christofori, 2007). 
6.1.2 The role of tetraspanins on platelets 
ication that tetraspanins play a role in platelet function was the ability of 
oth CD9 and CD151 antibodies to induce platelet activation (Roberts et al., 1995; 
u et al., 2000). Moreover, it was established that CD9 is expressed at approximately 
49,000 copies per platelet, which has recently been confirmed (Higashihara et al., 
. In addition, several groups have performed co-
munoprecipitation studies in relatively weak detergents suggesting an interaction 
etween tetraspanins and integrin αIIbβ3 (Israels et al., 2001). However, our group 
CLEC-2 is expressed on a number of 
itic cells and platelets (
LEC-2 was identified on both human and 
 the snake venom tox
Indeed, it has recently been shown that treatment of mice with a CLEC-2 antibo
le
d
b
C
ly
significance of the CLEC-2 interaction wi
 
The first ind
b
W
1990; Protty et al., 2009)
im
b
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 were unable to detect such an association suggesting the possibility of a relatively 
vertheless, studies suggested a role for 
atelets had not been thoroughly investigated until relatively 
latively high expression level of 49,000 
weak interaction (Protty et al., 2009). Ne
tetraspanins on platelets. To date, at least five tetraspanins are known to be expressed 
on the platelet: CD9, CD63, CD151, Tspan32 and Tspan9 (Goschnick and Jackson, 
2007; Protty et al., 2009; Tomlinson, 2009). In addition, recent proteomic studies 
suggest the additional expression of several other tetraspanins in human platelets 
(Lewandrowski et al., 2009). However, these cannot be confirmed to be platelet-
expressed until antibodies are used due to the possibility of contamination from other 
blood cells (Tomlinson, 2009). 
 
Mice deficient in CD151 or Tspan32 have a mild bleeding phenotype (Goschnick et 
al., 2006; Lau et al., 2004). In particular, the authors observe defective platelet 
spreading on fibrinogen, delayed clot retraction and a tendency to re-bleed in tail-
bleeding assays, and attribute these observations to defective “outside-in” signalling 
of integrin αIIbβ3 (Goschnick and Jackson, 2007). In addition, an in vivo thrombus 
defect is observed in the Tspan32 knockout (Goschnick et al., 2006). 
 
The role of CD9 on pl
recently (Mangin et al., 2009). CD9 has a re
copies per human platelet, second only to the major platelet integrin αIIbβ3 at 80,000 
copies per cell (Higashihara et al., 1990; Protty et al., 2009; Wagner et al., 1996), and 
it was of great interest to determine its role on platelets. However, Mangin et al. found 
a minor phenotype in CD9-deficient platelets, including a shorter bleeding time in tail 
bleeding assays, a reduced overall blood loss, increased in vivo thrombosis and 
increased αIIbβ3 activation, as determined by fibrinogen binding, compared to wild-
type controls (Mangin et al., 2009). This data was surprising given the relatively high 
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 expression level of CD9, and is in contrast to CD151- and Tspan-32-deficient 
platelets, and suggests that in wild-type mice CD9 may prevent excessive thrombus 
growth by acting as a negative regulator of platelet recruitment (Mangin et al., 2009).    
 
 
Recently, mice deficient in the tetraspanin CD63, which is localized to dense granules 
and lysosomes, have been reported with only very minor differences in platelet 
function (Schroder et al., 2009). The only difference between wild-type and CD63-
deficient platelets are slightly stronger aggregation responses in the knockout in vitro 
(Schroder et al., 2009). In addition, CD63 has been shown to associate with integrin 
αIIbβ3, with the authors hypothesising that it may regulate platelet spreading and 
Lastly, Tspan9, a previously uncharacterised tetraspanin, has recently been identified 
as a novel platelet tetraspanin (Protty et al., 2009). Expression of Tspan9 is relatively 
specific to platelets and megakaryocytes (Protty et al., 2009), suggesting an important 
role for this tetraspanin in common with other platelet/megakaryocyte-specific cell 
6.1.3 The role of tetraspanins in CLEC-2 signalling on platelets 
In Chapter Five, tetraspanin over-expression potently inhibited CLEC-2-induced 
NFAT/AP-1 luciferase activity following stimulation with rhodocytin in the Jurkat T-
cell line. Therefore, the basis of this Chapter was to investigate CLEC-2-induced 
platelet aggregation following stimulation with rhodocytin in CD9-deficient platelets. 
CD9 was selected due to its relatively high expression of 49,000 copies per cell 
(Protty et al., 2009).  
 
signalling on fibrinogen, but any functional significance of this interaction has yet to 
be determined (Israels and McMillan-Ward, 2005).  
 
surface proteins such as integrin αIIbβ3, GPIb-IX-V and GPVI. 
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 6.2 AIMS 
• To investigate CLEC-2-induced platelet aggregation following rhodocytin 
stimulation from mice deficient in the tetraspanin CD9.  
 
 
 
 
 
• To determine whether tetraspanins co-immunoprecipitate with CLEC-2 in 
human platelets. 
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 6.3 RESULTS 
 
d CD9-/- platelets by 
rface expression was similar in CD9+/+ and CD9-/- platelets 
igure 6.1A). A Student’s t-test indicated that there was no significant difference 
etween CD9+/+ and CD9-/- when data was expressed as the geometric mean of 
LEC-2 cell surface expression from three mice (Figure 6.1B).   
6.3.2 CLEC-2-induced aggregation is normal in CD9-/- mouse platelets 
It was pertinent to investigate CLEC-2 signalling in the platelet utilising mice 
deficient in CD9 to determine whether platelets would exhibit altered aggregation 
following stimulation of the receptor with rhodocytin. Platelets were stimulated with a 
high (100 nM), intermediate (15 nM) and a sub-threshold (5 nM) dose of rhodocytin 
and aggregation responses were measured. CD9-/- platelet aggregation was not altered 
compared to CD9+/+ at 100 nM and 15 nM rhodocytin (Figure 6.2A-B). Control and 
CD9-deficient platelets stimulated with 5 nM rhodocytin did not respond (Figure 
6.2C), even after 20 minutes (data not shown). As a control, aggregation responses 
were then measured to the platelet agonists ADP and collagen, which act upon the 
GPCRs P2Y1 and P2Y12, and the collagen receptors GPVI and integrin α2β1, 
respectively. CD9+/+ and CD9-/- platelets were similar in their aggregation response to 
 μg/ml collagen and 2 μM ADP (Figure 6.2D-E). Together these data demonstrate 
at CLEC-2-induced platelet aggregation is not dependent on CD9.   
 
6.3.1 CLEC-2 cell surface expression is normal in the absence of CD9 
CLEC-2 cell surface expression was determined on CD9+/+ an
incubating with a rabbit anti-mouse CLEC-2 antibody or with a relevant negative 
control. CLEC-2 cell su
(F
b
C
 
 
5
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platelets 
(A) CD9+/+ and CD9-/- washed mouse platelets were stained with either rabbit anti-
antibody (open histograms) and then anti-mouse FITC-conjug
 
 
Figure 6.1 Normal CLEC-2 cell surface expression on CD9+/+ and CD9-/- mouse 
 
mouse negative (filled histograms) or rabbit anti-mouse CLEC-2 polyclonal primary 
ated secondary 
antibody. Antibody binding was visualized by flow cytometry. (B) Data is also 
presented as the geometric mean cell surface expression level from three 
dependent experiments. An unpaired Student’s t-test indicated no statistically 
gnificant difference between CD9+/+ and CD9-/- . Experiments were performed three 
mes.  
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esentative of 2-3 independent experiments. 
 
 
 
 
 
 
 
Figure 6.2 CD9-/- mouse platelets aggregate normally following stimulation of 
CLEC-2 with rhodocytin 
 
Washed mouse platelets were pre-incubated with human fibrinogen (0.32 mg/ml) for 
30 seconds and aggregation was measured for 3 minutes following stimulation with 
either 100 nM rhodocytin (A), 15 nM rhodocytin (B), 5 nM rhodocytin (C), 5 μg/ml 
collagen (D) or 2 μm ADP (E). The arrow indicates the addition of the agonist. Data 
are repr
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 6.3.3 CLEC-2-induced tyrosine phosphorylation is normal in the absence of CD9 
ysates in 1% NP-40 were prepared following aggregation to investigate the 
ossibility of a phosphorylation defect in CD9-/- platelets. Samples were resolved on 
radient 4-12% reducing SDS-PAGE and incubated with anti-phosphotyrosine 
(4G10) antibodies. There were no major differences in the phosphorylation profiles 
between CD9+/+ and CD9-/- platelets following rhodocytin stimulation, although some 
phospho-proteins appeared to be slightly enhanced in the absence of CD9 (Figure 
6.3A). As this experiment was performed once, it is worthy of further investigation, 
for example, repeating the experiment using a ours blotting hosp
specific antibodies to identify the up-regulated phospho-proteins. Indeed, if such 
s changes are reproducible, it is possible that aggregation is insufficiently 
sensitive to detect such small changes in reactivity, which nevertheless would be 
consistent with a role for tetraspanins in the negative regulation of CLEC-2 signalling. 
As a control, lysates were blotted with an anti-CD9 antibody (Figure 6.3B) to confirm 
the absence of CD9 in the CD9-/- platelets.         
 
6.3.4 Other tetraspanins are not up-regulated in CD9-deficient megakaryocytes 
One possibility for the lack of phenotype in CD9-/- mouse platelets is that other 
traspanins may be up-regulated thereby compensating for the lack of CD9. A 
hylogenetic analysis of mammalian tetraspanins (www.ebi.ac.uk/clustalw/) revealed 
at Tspan2 and CD81 are highly related to CD9 (48% and 45% respectively) 
ccording to amino-acid identity (Figure 1.1). Other candidates that might be up-
atelet tetraspanins CD63, CD151, Tspan9 and Tspan32. 
ed because the anulceate platelet 
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regulated are the known pl
However, antibodies are not available to most of these mouse tetraspanins, therefore 
mRNA levels were determined using semi-quantitative RT-PCR for megakaryocytes, 
the platelet progenitors. Megakaryocytes were us
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 contains low levels of mRNA (Gnatenko et al., 2003) such that RT-PCR is technically 
difficult due to the potential for contamination with mRNA from other blood cells. 
Tetraspanins were amplified using cDNA from CD9+/+ and CD9-/- megakaryocytes 
(Figure 6.4). A positive control RT-PCR was performed using primers against 
GAPDH. It was apparent that no tetraspanins were up-regulated in the CD9-/- 
megakaryocytes when compared to CD9+/+. Slightly increased CD81 levels were 
apparent in the two lanes containing the highest concentration of target 
megakaryocyte cDNA (Figure 6.4). However, it is difficult to interpret this because 
these concentrations both appear to give a saturating signal. Indeed, the lack of any 
substantial CD81 upregulation was supported by a second, independent experiment, in 
which CD81 PCR bands were of identical intensity between the wild-type and 
knockout (M.G. Tomlinson, Appendix Figure I.I). 
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igure 6.3 CD9+/+ and CD9-/- mouse platelets phosphorylation profiles 
ouse platelets were lysed with 1% NP-40 following aggregation with the indicated 
gonists for 3 minutes. Proteins in whole cell lysates were visualised by SDS-PAGE 
nd western blotting with indicated antibodies. This experiment was performed once.  
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igure 6.4 RT-PCR of CD9-/- megakaryocytes suggest that other tetraspanins are 
ot up-regulated 
T-PCR was performed on CD9+/+ (WT) and CD9-/- (KO) megakaryocytes using 
CD9 
WT KO WT KO
 
 
 
F
n
 
R
primers against particular tetraspanins as indicated, and cDNA templates at 10-fold 
dilutions. In addition, dH20 and GAPDH were used as negative and positive controls 
respectively. Data is representative of two independent experiments.  
- 
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 6.3.5 Tetraspanins do not co-immunoprecipitate with CLEC-2 in rhodocytin-
imulated human platelets 
o determine whether tetraspanins interact with CLEC-2 in platelets, a co-
munoprecipitation approach in rhodocytin-stimulated human platelets was 
ed. Washed human platelets were stimulated with either 300 nM rhodocytin 
or left unstimulated, and lysed in the relatively mild detergent Brij97, thought to 
aintain tetraspanin-tetraspanin interactions (Hemler, 2005). Aggregations were 
perf d t sure tha  rh cytin st lati ad work data  shown). 
S ples were immunoprecipitated for CLEC-2, CD9 or ADAM-10, the latter serving 
as a positive control as it is known to be a tetraspanin-associated protein (Arduise et 
al., 2008). Both CD9 and ADAM-10 did not co-immunoprecipitate with CLEC-2 in 
Brij97 lysis conditions in either unstimulated or rhodocytin-s late nditions 
(Figure 6.5A). However, CLEC-2 was detected in the whole cell lysate and CLEC-2 
immunoprecipitations (F -immun ed with the 
ADAM-10 positive control (Figure 6.5B). Together, these data suggest that 
tetraspanins either do not interact with CLEC-2 or that the interaction is weak and not 
detectable by co-immunoprecipitation.   
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igure 6.5 Tetraspanins do not co-immunoprecipitate with CLEC-2 in 
hodocytin-stimulated human platelets  
ashed human platelets were stimulated with 300 nM rhodocytin or left 
nstimulated, lysed with 1% Brij97 and immunoprecipitated for 1.5 hours with the 
dicated antibodies. Proteins were visualised by SDS-PAGE and western blotting 
ith the indicated antibodies. Note that CD9 was only weakly detected in the whole 
ell lysate (wcl) at this level of exposure. Data was kindly provided by Dr. M.G. 
omlinson.  
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 6.4 DISCUSSION 
 this Chapter, it has been shown that mice deficient in the tetraspanin CD9 do not 
ave a platelet aggregation or signalling phenotype following stimulation of CLEC-2 
sing high, intermediate or low doses of the snake venom toxin rhodocytin. In 
ddition, no in ion obs  between CD9 and CLEC-2 in rhodocytin-
im ed hum tele ing latively weak detergent Brij97, which is not 
icrodomains.  
ot i  with tetraspanins or that if it does interact, but the interaction is not stable 
during co-immunoprecipitation in Brij97 lysis conditions.  
 
One possibility for the lack of a platelet phenotype was the up-regulation of
tetraspanins to compensate for the lack of CD9. Functional redundancy has been 
suggested to account for the subtle phenotypes observed in mouse platelets deficient 
in either CD151 or Tspan32 (Goschnick et al., 2006; Lau et al., 2004). O
e les of compensation include the phenotype observed in CD9-/- oocy
jection of CD81 mRNA restores the fertilization rate to approximately 50% of wild-
pe levels (Kaji et al., 2002). Therefore, a semi-quantitative RT-PCR approach was 
erformed using the progenitor of the platelet, the megakaryocyte, to determine 
hether other tetraspanins are up-regulated in CD9-deficient megakaryocytes. RT-
CR is difficult to perform in platelets due to the potential for contamination as 
latelets express relatively low levels of mRNA (Gnatenko et al., 2003). No such 
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mRNA upregulation was observed for the CD9-related tetraspanins Tspan2 and 
CD81, or the platelet-expressed tetraspanins CD63, CD151, Tspan9 and Tspan32. The 
RT-PCR approach used was not fully quantitative and therefore future experiments in 
the platelet would be necessary, as this does not prove that tetraspanins are not up-
 180
 regulated at the protein level. For example, a mouse CD81 antibody exists (Maecker 
 CD63 knockouts, thus 
et al., 2000), and so it is possible to determine whether CD81 is up-regulated in the 
platelet. However, this question will not be able to be addressed fully until antibodies 
have been generated for all tetraspanins.      
 
Multiple tetraspanins may be expressed in platelets, in addition to CD9, CD63, 
CD151, Tspan32 and Tspan9 (Goschnick and Jackson, 2007; Protty et al., 2009; 
Tomlinson, 2009), and it is possible that CD9 is not the tetraspanin that regulates 
CLEC-2. Indeed, platelet phenotypes are observed in CD151 and Tspan32 knockouts, 
but mild phenotypes are only observed in CD9 and
highlighting the differences in tetraspanin-deficient mice (Goschnick et al., 2006; Lau 
et al., 2004; Mangin et al., 2009; Schroder et al., 2009). There is the possibility that 
CD151, Tspan32, CD63, Tspan9, or another platelet tetraspanin may specifically 
regulate the signalling of CLEC-2 on platelets, perhaps by binding directly to the 
receptor to regulate its clustering or downstream signalling. Further work to address 
these questions would include utilising mice deficient in CD151, Tspan32 and CD63, 
or indeed any tetraspanin-deficient mice that are generated in the future. 
 
A final point is to question whether rhodocytin is the ideal agonist to activate CLEC-
2. Podoplanin has been identified as the natural endogenous ligand for CLEC-2 
(Suzuki-Inoue et al., 2007) and a potential second ligand has been proposed in plasma 
or on the surface of platelets (May et al., 2009). It is possible that a tetraspanin 
association with CLEC-2 is more important for activation by these endogenous 
agonists.   
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 6.5 SUMMARY 
In this Chapter it has been shown that mice deficient in the tetraspanin CD9 do not 
have a platelet aggregation or signalling phenotype following stimulation of CLEC-2 
with rhodocytin. Moreover, CLEC-2 cell surface expression is similar between 
 
 
 
 
 
 
 
 
 
 
 
CD9+/+ and CD9-/- platelets. In addition, it appears that other tetraspanins are not up-
regulated in megakaryocytes. Finally, tetraspanins do not co-immunoprecipitate with 
CLEC-2 in rhodocytin-stimulated human platelets. 
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 7.1 Summary of findings 
he main objective of this thesis was to investigate the role tetraspanins and their 
ability to regulate the signalling of dectin  CLEC-2 in model cell lines using a 
anscriptional reporter assay. A secondary aim
platelet aggregation in mice deficient in th major platelet tetraspanin CD9. The work 
l group that suggests that 
r-
Wentrup et al., 2007). However, the role of other tetraspanins in both dectin-1 and 
CLEC-2 signal regulation had not been investigated until now. The work done in this 
esis suggests that transient over-expression of multiple tetraspanins can negatively 
gulate dectin-1 and CLEC-2 signalling in a model cell line, suggesting that 
traspanins play a general role in regulating C-type lectin signalling. Specifically, 
is thesis demonstrates that: (a) over-expression of multiple tetraspanins can potently 
hibit dectin-1 signalling; (b) multiple tetraspanins similarly regulate CLEC-2 
gnalling; and (c) CLEC-2-induced platelet aggregation is, however, normal in the 
bsence of the major platelet tetraspanin CD9. The mechanism behind tetraspanin 
hibition of dectin-1 and CLEC-2 signalling in the cell line is not clear. Nevertheless, 
e hypothesise that tetraspanins play an important role in the regulation of dectin-1 
nd CLEC-2 in the endogenous setting. This could be via a direct mechanism, by 
cruitment of the two receptors into tetraspanin microdomains. Alternatively the 
echanism could be indirect, if a protein that regulates dectin-1 and CLEC-2 is itself 
gulated by tetraspanins.   
 
T
-1 and
tr  was to investigate CLEC-2-induced 
e 
in this thesis was stimulated by a publication of the van Sprie
the tetraspanin CD37 negatively regulates dectin-1-mediated signalling (Meye
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 7.2 Direct and indirect models for tetraspanin regulation of C-type lectin-like 
eceptors 
This thesis has attempted to establish a conclusive mechanism as to how tetraspanins 
can regulate both dectin-1 and CLEC-2 signalling, but a number of questions still 
remain. In particular, how can many different tetraspanins, in fact all that were tested, 
each almost completely inhibit dectin-1 and CLEC-2 signalling when over-expressed 
in Jurkat T-cells? It seems improbable that this could be achieved by a direct 
interaction between all these over-expressed tetraspanins and dectin-1 and CLEC-2. 
Therefore it would appear that transiently over-expressed tetraspanins perturb the cell 
in some way so as to largely prevent signalling by these receptors. Since the most 
well-characterised feature of tetraspanins is their capacity to interact with other 
tetraspanins, it is likely that tetraspanin over-expression perturbs the cell by 
associating with endogenous tetraspanins and disrupting the architecture and function 
of tetraspanin microdomains. 
 
f tetraspanin-associated signalling machinery and the 
pairment of lipid raft localization, both of which are discussed in more detail 
elow.   
 
r
 
7.2.1 Direct models for tetraspanin regulation of C-type lectin-like receptors 
There are a number of potential direct models for the negative regulation of C-type 
lectin-like receptor signalling by tetraspanins. Such models, which assume a direct 
interaction between one specific tetraspanin and the lectin-like receptor, and 
regulation of the receptor within tetraspanin microdomains, are based on the 
hypothesis that over-expression of any single tetraspanin can disrupt the normal 
make-up and function of tetraspanin microdomains. These microdomain disruption 
models include a loss o
im
b
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 7.2.1.1 Loss of tetraspanin-associated signalling machinery 
This is a simple model by which tetraspanin over-expression might negatively 
regulate both dectin-1 and CLEC-2 (Figure 7.1). Recent studies have shown that the 
plasma membrane contains several hundred punctate tetraspanin microdomains, with 
an average size of 0.2 μm  (Espenel et al., 2008; Nydegger et al., 2006). In the 
endogenous setting, dectin-1 or CLEC-2 may be recruited into tetraspanin 
microdomains enabling the receptor to signal, perhaps because essential downstream 
signalling molecules are also recruited to these microdomains via interactions with 
specific tetraspanins. However, following transient tetraspanin over-expression, the 
normal microdomain organisation may become disrupted and dysfunctional due to 
domination of the microdomain by a single tetraspanin. Consequently, the lectin-like 
receptor may be unable to couple to the relevant signalling machinery resulting in 
signal inhibition. An argument against this model is the fact that CLEC-2 was not co-
immunoprecipitated with tetraspanins in platelets, even in relatively low stringency 
rity 
7.2.1.2 Lipid raft localization 
The lipid raft localization model is another possible direct mechanism of C-type 
lectin-like receptor regulation that is dependent on microdomain disruption by 
tetraspanin over-expression (Figure 7.2). In the endogenous setting, the lectin-like 
receptor may associate with an as yet unidentified tetraspanin. Following receptor 
ross-linking upon stimulation, it becomes activated and may localize to lipid rafts, 
2
lysis conditions (1% Brij97) that are thought to preserve microdomain integ
(Hemler, 2005). Moreover, there is no evidence that any of the signalling molecules 
utilised by lectin-like receptors are present in tetraspanin microdomains. Indeed, it has 
recently been shown that CLEC-2 translocates to lipid rafts upon ligand engagement 
(Pollitt et al., 2010).       
 
c
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 which are rich in C-type lectin-like-activating signalling molecules such as Src family 
it is possible that a potential tetraspanin-CLEC-2/dectin-1 
teraction might involve a tetraspanin that has yet to be tested, because of a current 
lack of antibodies to most tetraspanins.  
 
 
tyrosine kinases. This hypothesis is supported by data which shows that CLEC-2 
translocates to lipid rafts following stimulation with rhodocytin in platelets (Pollitt et 
al., 2010), and by very recent similar data for dectin-1 (Xu et al., 2009a). The putative 
C-type lectin-like receptor-associated tetraspanin might then become palmitoylated by 
a lipid raft-resident palmitate transferase, resulting in sustained localization to lipid 
rafts and sustained signalling. Such a mechanism would be analogous to the 
regulation of the B-cell receptor/CD19/CD21 complex by the tetraspanin CD81, 
where inducible palmitoylation of CD81 is required for sustained localization of the 
B-cell receptor-CD19/CD21/CD81 complex to lipid rafts, thus allowing productive 
signalling (Cherukuri et al., 2004a; Cherukuri et al., 2004b). If this is true, over-
expression of any tetraspanin might out-compete the lectin-like receptor for binding to 
its specific tetraspanin partner, sequestering the tetraspanin away from the receptor. 
The latter would then fail to exhibit sustained raft localization and sustained 
signalling, resulting in a failure to activate NFAT/AP-1. This hypothesis could be 
easily tested by fractionation in a sucrose gradient of stimulated and unstimulated 
cells. In common with the previously described direct model, this model is not 
compatible with the failure to co-immunoprecipitate platelet CLEC-2 with 
tetraspanins. However, 
in
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Loss of tetraspanin-associated signalling machinery 
1) Normal physiological conditions  2) Tetraspanin over-expression 
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igure 7.1 Loss of tetraspanin-associated signalling machinery 
he loss of tetraspanin-associated signalling machinery is a simple model which 
ssumes that the C-type lectin-like receptor and its signalling machinery is a 
component of tetraspanin microdomains (1). Tetraspanin over-expression (shown in 
d) could displace endogenous tetraspanins (three different tetraspanins shown in 
black) and associated signalling machinery, resulting in a failure of the receptor to 
gnal (2).    
F
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ation 
 raft localization model is one model by which tetraspanins may regulate C-
t dectin-1/CLEC-2 
otes lipid raft 
gnal normally (3). 
Figure 7.2 Lipid raft localiz
The lipid
type lectin-like receptor signalling. This model hypothesises tha
associate with a specific tetraspanin, shown in black (1), which prom
localisation upon receptor cross-linking (2) in a manner that is similar to that shown in 
regard to the B-cell receptor and the tetraspanin CD81 (Cherukuri et al., 2004a; 
Cherukuri et al., 2004b). Lipid raft-specific lipids are shown in green and the over-
expressed tetraspanin in red. The latter could disrupt normal microdomain 
architecture, sequester away the specific dectin-1/CLEC-2-interacting tetraspanin, and 
so lead to a failure of dectin-1/CLEC-2 to be sustained in lipid rafts and consequently 
a failure to si
L
X
X
Y
1. C-type lectin-like receptor 
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 7.2.2 Indirect models for tetraspanin regulation of C-type lectin-like receptors 
 
If dectin-1 and CLEC-2 do not interact with tetraspanins, which would be consistent 
with the failure to co-immunoprecipitate the latter with platelet tetraspanins, then an 
i e 
expression. Indeed, an unidentified protein may 
itself is regulated by tetraspanins and is dysregulated by tetraspanin over-expression. 
Putative tetraspanin-regulated candidates include transmembrane proteinases and 
signal-promoting molecules which are discussed in more detail below.   
 
7.2.2.1 Dysfunction of a tetraspanin-associated transmembrane proteinase 
Since the transmembrane proteinases ADAM-10 and MT1-MMP are thought to be 
regulated by tetraspanin microdomains (Arduise et al., 2008; Lafleur et al., 2009; 
Yanez-Mo et al., 2008), it is poss tetraspanin might 
disrupt the microdomains leading teinase (Figure 7.3). The 
proteinase might cleave its targets, which could release soluble proteins that inhibit 
dectin-1/CLEC-2 signalling; dectin-1/CLEC-2 is unlikely to be the direct proteinase 
target because the experiments in this thesis found no evidence for dectin-1/CLEC-2 
cleavage using flow cytometry and western blotting. If the proteinase or its dectin-
1/CLEC-2-regulating target is present on Jurkat but not DT40 or RBL-2H3 cells, this 
could explain the failure to observe inhibition in the latter two lines. Such a model 
ting whether conditioned media from tetraspanin-
ndirect mechanism must be responsible for th inhibitory effect of tetraspanin over-
regulate dectin-1 or CLEC-2, which 
ible that over-expression of any 
 to activation of the pro
could readily be investigated by tes
transfected Jurkat cells could inhibit dectin-1 and CLEC-2 signalling.       
 
7.2.2.2 Sequestration of an inhibitory protein within tetraspanin microdomains 
Another possible indirect model could involve an inhibitory signalling protein that is 
normally tetraspanin-associated, and so sequestered away from the lectin-like receptor 
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 (Figure 7.4). However, upon tetraspanin over-expression, the microdomain could 
 
 
 
become disrupted, so releasing the inhibitory protein that can subsequently inhibit 
dectin-1 and CLEC-2 signalling. The putative tetraspanin-associated inhibitory 
protein could be a phosphatase that dephosphorylates a molecule involved in C-type 
lectin-like signalling. Indeed, the van Spriel group allude to this model as a 
mechanism of dectin-1 signal regulation by the tetraspanin CD37 (Meyer-Wentrup et 
al., 2007). Moreover, the tetraspanin CD53 has been shown to associate with as yet, 
an unidentified phosphatase (Carmo and Wright, 1995).      
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igure 7.3 Dysfunction of a tetraspanin-associated transmembrane proteinase 
 proteinase and its target are hypothesized to be negatively regulated within 
tetraspanin microdomains (1). Tetraspanin over-expression (shown in red) causes mis-
calization and dysfunction of the proteinase, which can cleave its targets to release 
soluble proteins that inhibit C-type lectin-like receptor signalling (2). 
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 able to inhibit 
ectin-1 and CLEC-2 signalling (2).     
Sequestration of an inhibitory protein within tetraspanin microdomains 
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    Signalling 
Figure 7.4 Sequestration of an inhibitory protein by tetraspanin microdomains
A membrane protein or an intracellular signalling protein, that can negatively regulate 
dectin-1 and CLEC-2 signalling, is normally compartmentalised into tetraspanin 
microdomains (1). However, upon tetraspanin over-expression (shown in red), the 
microdomain becomes disrupted releasing the protein, which is now
d
1) Under normal physiological 
conditions, a protein that can 
inhibit C-type lectin-like receptor 
signalling is compartmentalised 
within tetraspanin microdomains 
X
X
L
X
X
YPhosphatase? 
    No signalling 
2) Over-expression of any tetraspanin 
disrupts the microdomain, releases 
the inhibitory protein, which is now 
able to inhibit C-type lectin-like 
receptor signalling  
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 7.3 Future directions 
 
his thesis has focussed on the regulation of the C-type lectin-like receptors dectin-1 
nd CLEC-2 by tetraspanins in model cell lines. However, the ultimate aim is to focus 
n the platelet-expressed CLEC-2 for the following reasons: the Nieswandt group 
ave established an important role for CLEC-2 as a platelet activating receptor in 
ggests tetraspanins regulate CLEC-2 signalling; and our group’s focus is on 
platelets.  
 
7.3.1 Does tetraspanin over-expression disrupt tetraspanin microdomains? 
As discussed previously, tetraspanin over-expression is likely to inhibit CLEC-2 
signalling by interacting with endogenous tetraspanins and so disrupting the normal 
make-up and function of tetraspanin microdom s. There are a number of 
biochemical and microscopy-based experiments that could address the hypothesis that 
tetraspanin over-expression anin mic ssed below.  
 
T panin ov
m cell surf
immunoprecipitation of an endogenous tetraspanin, under low stringency lysis 
conditions, and streptavidin blotting to detect interacting proteins. This could be done 
in Jurkat using the endogenous tetraspanin CD81 and transfected CD9, and the 
transfected cells would need to be first purified by flow cytometry sorting. 
Comparisons of banding patterns between CD9-transfected and control cells might 
reveal loss or reduced intensity of some bands following CD9 over-expression, 
T
a
o
h
thrombosis and haemostasis (May et al., 2009); there is no published data that 
su
ain
 disrupts tetrasp rodomains, as discu
o biochemically test whether tetras
icrodomains, one could use 
er-expression disrupts tetraspanin 
ace biotinylation followed by 
indicating disruption of tetraspanin microdomains.  
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 Another method to determine whether tetraspanin over-expression disrupts tetraspanin 
s in the plasma membrane. 
Chemical cross-linking studies in cell lines have previously been used in the 
Any potential direct interaction can also be studied by bioluminescence resonance 
energy transfer (BRET), a method our group has used to study GPVI dimerisation 
microdomains is to employ microscopy-based methods. One possibility is use 
confocal total internal reflection fluorescence (TIRF) microscopy to determine surface 
localization of endogenous tetraspanins, for example CD81, in the presence or 
absence of transiently over-expressed CD9. In addition, single molecule tracking of 
an endogenous tetraspanin, as used by others (Espenel et al., 2008), could be utilised 
to determine whether tetraspanin over-expression affects the mobility of endogenous 
tetraspanin
 
7.3.2 Does CLEC-2 interact with tetraspanins? 
Both direct and indirect models are proposed for tetraspanin regulation of C-type 
lectin-like receptors. Therefore, a further avenue to pursue is to perform more 
experiments to determine whether CLEC-2 interacts with tetraspanins or whether it is 
localised exclusively outside of tetraspanin microdomains.  
 
tetraspanin field to demonstrate direct interactions between tetraspanins and their 
partner proteins, for example, CD151 and integrin α3β1, and CD81 and EWI-2 
(Charrin et al., 2001; Yauch et al., 2000). Cells co-transfected with CLEC-2 and 
tetraspanins could be chemically cross-linked and co-immunoprecipitated with a view 
to identify interacting proteins. In addition, these experiments could be done in 
platelets to determine whether the endogenous proteins interact. An advantage of 
using chemical cross-linkers is their capacity to capture direct but relatively weak 
interactions that are lost during immunoprecipitation. 
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 (Tomlinson et al., 2007). BRET involves first generating expression constructs 
encoding luciferase- and GFP-tagged forms of potentially interacting proteins. Upon 
transfection of these constructs into a cell line and addition of a luciferase substrate, a 
transfer of energy between the luminescent donor and fluorescent acceptor can be 
detected if the proteins are within 10 nm of each other (Pfleger and Eidne, 2006). A 
similar method, fluorescence resonance energy transfer (FRET), could also be 
employed and has previously been used to study tetraspanins and their associated 
partner proteins (Harris et al., 2008; Yanez-Mo et al., 2008).  
 mice 
Higashihara et al., 1990; 
rotty et al., 2009), only a minor role has been reported, where tail bleeding assays 
reveal a shorter bleeding time and reduced blood loss compared to wild-type controls, 
along with increased αIIbβ3 activation (Mangin et al., 2009). In addition, increased 
thrombi are observed in CD9-deficient platelets, suggesting a model whereby CD9 
negatively regulates platelet recruitment to prevent excessive thrombus growth 
(Mangin et al., 2009). Therefore, in light of this data, there are a number of other 
possible candidates for tetraspanin regulation of CLEC-2 signalling.   
 
enotypes are observed in the 
D151- and Tspan32-knockout mice as both have a mild bleeding phenotype 
(Goschnick et al., 2006; Lau et al., 2004), and one may hypothesise that either CD151 
 
7.3.3 CLEC-2 signalling in tetraspanin deficient
CLEC-2 signalling was investigated using mice deficient in the major platelet 
tetraspanin CD9. However, as no CLEC-2 phenotype was observed, it is possible that 
the wrong tetraspanin-deficient mouse was selected for study. Even though CD9 is 
relatively highly expressed at 49,000 copies per platelet (
P
CD151 and Tspan32 are two such candidates for study to determine whether such 
tetraspanins regulate CLEC-2 signalling. Indeed, ph
C
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 or Tspan32 may regulate CLEC-2. The Jackson group observe defective platelet 
spreading on fibrinogen, delayed clot retraction and a tendency to re-bleed in tail-
bleeding assays, and attribute these observations to defective “outside-in” signalling 
of αIIbβ3 (Goschnick and Jackson, 2007). Moreover, an in vivo thrombus defect is 
observed in the Tspan32 knockout (Goschnick et al., 2006). Further to the study of 
CLEC-2 signalling in these mice, there should be some consideration to generate mice 
deficient in both CD151 and Tspan32 to determine whether a more pronounced 
phenotype is observed. However, as both CD151 and Tspan32 are located on the 
me chromosome (Table 7.1), this is relatively difficult.  
 
If the above tetraspanins are not the regulators of CLEC-2 as revealed by knockout 
mouse studies, there are a number of other potential candidates, for example the 
recently identified Tspan9 (Protty et al., 2009). In addition, recent proteomic studies 
suggest the additional expression of several other tetraspanins in human platelets 
sa
The dense granule- and lysosome-localised tetraspanin CD63 has been shown to play 
a minor role in platelet function, where slightly stronger aggregation responses are 
observed in the knockout (Schroder et al., 2009). Therefore, the possibility of 
identifying a CLEC-2 phenotype in CD63-deficient platelets is relatively slim 
compared to other candidates such as CD151 and Tspan32. Nevertheless, if such mice 
were readily available, preliminary platelet studies could be conducted to identify a 
CLEC-2 phenotype.     
 
(Lewandrowski et al., 2009) (Figure 7.1). However, as discussed previously, this 
cannot be confirmed until specific antibodies to these tetraspanins are generated. Of 
particular interest given that CLEC-2 is expressed on the megakaryocyte/platelet 
lineage but not on most other cell types, our group has shown that Tspan9 is relatively 
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 platelet- and megakaryocyte-specific (Protty et al., 2009), and Tspan9-deficient mice 
have now been generated. Moreover, our group have recently acquired the Tspan33 
knockout mouse from the Tsai group (Heikens et al., 2007). The study of CLEC-2 
signalling in these mice might establish a role for tetraspanins in the regulation of 
CLEC-2 on platelets.  
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 Table 7.1 - Potential platelet tetraspanins as revealed by proteomics 
 
Tetraspanin 
 
Mouse 
chromosomal 
 
Comments Platelet phenotype in knockout 
mice 
(Lewandrowski et al., 2009)  
localization 
CD9 6qF3 - Minor role in the negative regulation of 
αIIbβ3 activation & thrombus formation 
(Mangin et al., 2009). 
 
Tspan9 6qF3 - 
 
Knockout mouse not analysed (our 
group). 
  
Tspan33 6qA3.3 - 
 
Not reported (Heikens et al., 2007). 
CD151 7qF5 - 
 
Positive role in the regulation of αIIbβ3 
signalling, thrombus formation & 
stability (Lau et al., 2004).  
 
CD63 10qD3 - Minor role in the negative regulation of 
platelet aggregation in vitro, but no 
effect on thrombus formation in vivo 
(Schroder et al., 2009). 
 
CD82 2qE1 Potential contamination 
from other blood cells as 
unable to detect on platelets 
by flow cytometry.  
 
No knockout mouse. 
 
Tspan14 14qB - No knockout mouse. 
Tspan32 7qF5.7 - Positive role in the regulation of αIIbβ3 
signalling, thrombus formation & 
stability (Goschnick et al., 2006). 
 
Tspan15 10qB4 - No knockout mouse. 
Tspan4 7qF5 Potential contamination 
from other blood cells as 
unable to detect on platelets 
by flow cytometry. 
 
No knockout mouse. 
CD81 7qF5 Potential contamination 
from other blood cells as 
unable to detect on platelets 
by flow cytometry. 
 
Not reported (Cherukuri et al., 2004b) 
.  
CD37 7qB4 Potential contamination 
from other blood cells as 
unable to detect on platelets 
by flow cytometry. 
 
Not reported (Knobeloch et al., 2000). 
  
Tspan2 3qF3 - No knockout mouse. 
Tspan18 2qE1 - No knockout mouse. 
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 7.3.4 Does tetraspanin over-expression affect CLEC-2 localization or 
dimerisation? 
 
A further avenue to pursue is to dete her tetra ts 
CLEC-2 localization or dimerisation. In spread platelets, CLEC-2 has recently been 
shown to exhibit a punctuate localisation pattern  
m P., unpublish
experiments could be extended to Jurkat cells transfected with CLEC-2, which could 
be stained for this protein in the presence or absence s. 
Additional recent experiments have shown that CLE mer at the 
platelet surface, as detected using chemical cross-linki  
(Hughes et al., 2010; Watson et al., 2009). Indeed, Hughes et al. have shown that 
dimerisation allows the tande Syk to effectively engage the two 
YXXL motifs of a CLEC-2 dimer. The dimerisation methodology could also be 
extended to transfe rkat cells, to d rmine whether tetraspanin over-expression 
affects CLEC-2 dimerisation. 
 
7 e recently ified eceptor CL
 
The novel C-type lectin-like re  was recently identified, and signals in 
a r way to de 1 and L ). 
Therefore, the next logical ste ine whether tetraspanins regulate this 
receptor. Preliminary studies of tetraspanins in LEC9A signal 
regulation were conducted a thesis project (data not shown). An 
NFAT/AP-1 reporter assay in Jurkat cells was performed following co-transfection of 
. However, CLEC9A was not activated 
thus the role of tetraspanins upon 
gnalling was not determined (data not shown). Moreover, flow cytometry studies in 
rmine whet spanin over-expression affec
, as detected using confocal
icroscopy (Pollitt, A.L. & Watson S. ed data). Such imaging 
of a co-transfected tetraspanin
C-2 can exist as a di
ng followed by western blotting
m SH2 domains of  
cted Ju ete
.3.5 Th ident C-type lectin-like r
ceptor CLEC9A
EC9A 
 simila ctin-  CLEC-2 via a YXX
p was to determ
motif (Huysam n et al., 2008e
regarding the role 
 part of this 
C
s
HA epitope-tagged CLEC9A and tetraspanins
when cross-linked with the HA antibody, and 
si
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 human platelets suggested that CLEC9A is not expressed, even following activation 
of the platelet (data not shown). Nevertheless, the future study of the role of 
tetraspanins in CLEC9A signalling on antigen-presenting cells is an exciting prospect.     
 
ternalisation and degradation, similar to what they have 
bserved for GPVI (Rabie et al., 2007). In vitro studies showed that CLEC-2-deficient 
latelets failed to respond to rhodocytin. Under flow conditions, the CLEC-2-deficient 
platelets adhered normally to collagen, but then failed to form stable aggregates. 
Similarly, in vivo, CLEC-2-deficient platelets adhered to the site of ferric chloride-
injury in arterioles, but were unable to form thrombi that block the vessel. In tail bleed 
assays in these mice, about two thirds of CLEC-2-deficient mice bled for twice as 
long, while one third failed to stop bleeding during the 20 minute experiment. 
Together, these data suggest that CLEC-2 is necessary for normal thrombus growth 
and stability, and lead the authors to hypothesize that CLEC-2 has a novel ligand on 
platelets (May et al., 2009). However, one argument against this idea is that tyrosine 
phosphorylation of CLEC-2 is not detected when platelets are aggregated using 
7.4 The role of CLEC-2 on platelets 
The role of CLEC-2 on platelets and the literature regarding this activation receptor 
has grown rapidly since its discovery (Suzuki-Inoue et al., 2006). Indeed, its ability to 
signal in a novel manner via a single YXXL motif through interaction with the Syk 
kinase has fuelled the study of this receptor (Fuller et al., 2007; Ozaki et al., 2009). 
The Nieswandt group have recently shown that CLEC-2 is essential in haemostasis 
and thrombosis (May et al., 2009). For these experiments, CLEC-2-deficient platelets 
were generated by treatment of mice with a CLEC-2 antibody, which lead to the loss 
of CLEC-2 at the surface of platelets. The reason for this loss of CLEC-2 is not clear, 
but the authors propose that it may involve ectodomain shedding by a 
metalloprotease, or receptor in
o
p
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 agonists such as thrombin, which should in theory result in CLEC-2 activation by 
engagement with its putative ligand on other platelets (Pollitt et al., 2010). The 
generation of CLEC-2-deficient mice is now essential to firmly establish a role for 
CLEC-2 on the platelet and to determine whether this receptor has any other functions 
in the adult mouse or during development. In light of this exciting data from the 
Nieswandt group, it is tempting to speculate that CLEC-2 might be an ideal drug 
target for the treatment of thrombotic disease. It is also possible that tetraspanins 
could regulate thrombosis through regulation of CLEC-2 function, particularly since 
CD151 and Tspan32, are like CLEC-2, essential for normal thrombus formation and 
stability (Tomlinson, 2009). 
 
A role for CLEC-2 in cancer cell metastasis has also been proposed, since the 
identification of a tumour cell ligand, podoplanin, for this receptor (Ozaki et al., 2009; 
Suzuki-Inoue et al., 2007). Podoplanin is a protein that has been implicated in both 
tumour cell-induced platelet aggregation and tumour metastasis (Wicki and 
Christofori, 2007). Indeed, it is tempting to speculate that tumour cells that have 
disengaged from the solid tumour mass and entered the blood stream, might bind to 
circulating platelets via a podoplanin/CLEC-2 interaction. This might benefit the 
tumour in several ways. For example, a tumour cell that is coated with platelets might 
more easily avoid detection by immune cells, and might more easily become lodged at 
a site in the microvasculature where it can develop into a metastic tumour. In addition, 
since platelets contain several growth factors, these may promote tumour growth once 
the tumour has come to rest. Tetraspanins have recently been implicated in the 
regulation of this podoplanin/CLEC-2 interaction. Indeed, the tetraspanin CD9, when 
over-expressed on tumour cells, appears to interact with podoplanin and to inhibit 
podoplanin-induced platelet aggregation and pulmonary metastasis (Nakazawa et al., 
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 2008). Although one important aspect of the study that the Fujita group did not 
address, was whether CD9 affected podoplanin expression (Nakazawa et al., 2008). 
Nevertheless, the data suggests that CD9 may act as a metastasis suppressor, a 
proposal that has been suggested by other groups previously (Takeda et al., 2007a), 
and indicates how tetraspanins might regulate CLEC-2 function at the level of its 
ligand, podoplanin. Moreover, CLEC-2 might be a promising drug target in the 
treatment of cancer.      
 
Finally, CLEC-2 may have a role in facilitating HIV infection, as platelets can engulf 
a significant amount of the virus. In both CLEC-2-transfected cells and platelets, 
CLEC-2 has the ability to capture HIV-1, irrespective of the viral envelope protein 
7.5 The role of tetraspanins 
Tetraspanins are an intriguing family of proteins that have been shown to associate 
with, and in some cases, regulate a plethora of partner proteins within tetraspanin-
enriched microdomains. These microdomains are thought to regulate fundamental 
cellular functions such as adhesion, signalling, intracellular trafficking and cell-cell 
fusion (Charrin et al., 2009; Hemler, 2008). 
 
(Chaipan et al., 2006). Moreover, treatment with CLEC-2 antibodies potently reduced 
the association of HIV-1 with platelets, implicating CLEC-2 in HIV-1 spread in the 
bloodstream of infected individuals. However, the related lectin DC-SIGN also 
facilitated HIV-1 binding to platelets, suggesting that CLEC-2 is not indispensable in 
this process (Chaipan et al., 2006). Despite this, CLEC-2 may be a drug target in the 
treatment of HIV-1.        
 
In contrast to early suggestions that tetraspanin microdomains might form a ‘web’ 
across the entire plasma membrane (Maecker et al., 1997), recent evidence suggests 
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 that tetraspanin microdomains form several hundred distinct clusters across the 
membrane, with an individual size of 0.2 μm2 (Nydegger et al., 2006). Further 
evidence using single molecule tracking suggests that tetraspanin microdomains are 
highly dynamic and can readily move across the plasma membrane (Espenel et al., 
2008). It has also become apparent that most cell surface proteins do not appear to 
localize to tetraspanin microdomains (Charrin et al., 2009; Hemler, 2008). The full 
complement of tetraspanin microdomains on different cell types awaits proteomic 
vestigation.    
 
dectin-1 following over-expression in HEK293T cells, and 
ultiple tetraspanins could inhibit dectin-1 signalling when over-expressed in Jurkat 
T-cells.  
 
t with some compensatory roles, as CD81 
ver-expression in CD9-deficient oocytes partially restores sperm-egg fusion 
(Higginbottom et al., 2003). A second problem arises from the fact that tetraspanins 
in
Despite much research on this family of proteins, few definitive functions have been 
assigned to individual family members. A good example is the proposed role for 
CD37 in the negative regulation of dectin-1 signalling (Meyer-Wentrup et al., 2007). 
In this study, it was not proven that CD37 and dectin-1 form a direct interaction. 
Moreover, other tetraspanins were not tested for an ability to regulate dectin-1 
(Meyer-Wentrup et al., 2007). Indeed, the data in this thesis does not support the 
theory that CD37 specifically regulates dectin-1: multiple tetraspanins could co-
immunoprecipitate with 
m
One problem with assigning functions to tetraspanins is that 33 members have been 
identified in mammals. This allows considerable scope for functional redundancy 
between family members. For example, CD9 and CD81 share approximately 45% 
protein sequence identity, which is consisten
o
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 cluster together in tetraspanin-enriched microdomains. This would suggest that 
deletion of different tetraspanins in the same microdomain might similarly disrupt 
microdomain function and yield similar phenotypes. This is certainly possible in 
CD151- and Tspan32-deficient platelets, which are defective in spreading and clot 
retraction leading to a mild bleeding phenotype (Goschnick et al., 2006; Lau et al., 
2004), and in CD37-, CD81-, CD151- and Tspan32-deficient T-cells, which are 
hyperproliferative in response to T-cell receptor triggering (Knobeloch et al., 2000; 
Miyazaki et al., 1997; Tarrant et al., 2002; van Spriel et al., 2004; Wright et al., 2004). 
hilst such studies have revealed some interesting tetraspanin-regulated functions, 
the precise mechanisms behind the observations have yet to be elucidated, and in 
particular the role of individual tetraspanins is not clear. A final problem is that the 
tetraspanin field is dominated by a select few tetraspanins. These were discovered at 
the beginning of the field due to the relative ease by which monoclonal antibodies 
could be generated to these proteins. This has left some of the more recently identified 
members unstudied and has left a void in tetraspanin research. In particular it is 
dangerous to draw general conclusions from the functional analyses of a small subset 
of the tetraspanin family. Our ideas on tetraspanin function may change considerably 
when all members have been studied.    
 
s discussed previously, one of the best studied examples of a strong, highly 
stoichiometric, direct interaction is in regard to CD151 and the laminin-binding 
integrins, such as α3β1. Indeed, it has been shown that CD151 recruits these integrins 
to tetraspanin microdomains and in the absence of CD151, association with 
microdomains is lost and integrin adhesion strength, signalling, trafficking and 
glycosylation is impaired (Serru et al., 1999; Winterwood et al., 2006; Yang et al., 
2008; Yauch and Hemler, 2000). Consistent with these findings in cell lines, knockout 
W
A
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 mouse studies have shown decreased pathologic angiogenesis both in vivo and in vitro 
by impaired integrin signalling and failure to associate with tetraspanin-enriched 
microdomains (Takeda et al., 2007b). In addition, mice deficient in CD151 exhibit 
kidney failure (Baleato et al., 2008; Sachs et al., 2006). However, there are few 
similar examples of such a direct interaction being assigned a specific function. This 
prompts the question as to whether CD151-α3β1 functional interaction is the norm for 
other tetraspanins. Do all tetraspanins have one or more specific partners that they 
recruit into tetraspanin microdomains? Or do some only bind other tetraspanins and 
play an anchoring role or organising role at the core of the microdomain? Or do some 
tetraspanins fail to interact with other tetraspanins, perhaps regulating a partner 
protein in a non-microdomain environment? These questions will only be answered 
when good antibody reagents exist to all tetraspanins, allowing an integrated study 
using biochemical and imaging studies in wild-type and tetraspanin-knockdown cells.  
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igure I.I RT-PCR of CD9-/- megakaryocytes suggest that other tetraspanins are 
ot up-regulated 
T-PCR was performed on CD9+/+ (WT) and CD9-/- (KO) megakaryocytes using 
rimers against particular tetraspanins as indicated, and cDNA templates at 10-fold 
ilutions. Data was kindly provided by Dr. M.G. Tomlinson.  
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